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Summary 
 
Patients with a significant bleeding history and normal routine laboratory tests are labelled as 
having unclassified bleeding disorder (UBD).  Approximately one third of patients with acute 
deep vein thrombosis (DVT) have no risk factor identified and are labelled idiopathic.  The 
experiments conducted herein investigate whether the phospholipid composition of the 
platelet membrane is contributory to the clinical phenotype.   
The ability of platelets and microvesicles to support thrombin generation was investigated 
using a thrombin generation assay tailored to be sensitive to the phospholipid membrane.  
Peak thrombin generation supported by washed platelets and microvesicles was reduced in 
UBD patients compared with healthy controls.  Peak thrombin and velocity index were 
increased in patients with DVT.    
To determine whether changes in thrombin generation could be attributed to native 
aminophospholipids in the platelet membrane, Phosphatidylserine (PS) and 
Phosphatidylethanolamine (PE) were measured by mass spectrometry following thrombin-
activation of platelets.  The thrombin generation assays were sensitive to externalised PE/PS as 
demonstrated by the minimal amount of thrombin generated by the platelets of a Scott 
syndrome patient.  Externalised PE/PS species were similar in disease cohorts and healthy 
controls.   
Previous studies demonstrate that enzymatically oxidised phospholipids produced rapidly on 
platelet activation support thrombin generation in vitro.  Overall, trends of lower quantities of 
procoagulant 12-HETE-PE and 12-HETE-PC species were measured in UBDs compared with 
healthy controls whereas 12-HETE-PE species were higher in DVT patients.  Lastly, in UBD 
patients receiving desmopressin for invasive procedures there was increased externalisation of 
PS and a trend towards increased peak thrombin generation supported by washed platelets.   
The observed changes in procoagulant oxidised phospholipids suggest the phospholipid 
composition of the platelet membrane may be implicated in haemostatic disorders.  
Desmopressin may be effective in UBD because it increases externalised PS and supports 
thrombin generation.  Further studies are required to confirm these findings.        
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Chapter 1 - General Introduction 
1.1. Normal haemostasis 
Haemostasis is a rapid and localised process involving a tightly regulated balance of 
procoagulant and anticoagulant mechanisms.  Excessive bleeding or unwanted thrombosis occur 
when certain elements involved in these processes are dysfunctional or absent.  Common 
manifestations of clotting dysregulation in the clinical setting include venous thromboembolism 
and acute coronary syndrome or abnormal bleeding following a haemostatic challenge such as 
surgery.  
The combined processes of haemostasis result in the production of a haemostatic plug and the 
formation of an occlusive thrombus at the site of vascular injury.  Platelets are essential for 
maintaining normal haemostasis. The initial interaction of circulating platelets with the 
disrupted vessel wall mediates the formation of a platelet plug at the injury site in a process 
referred to as primary haemostasis.  Additionally, the platelet surface is critical for the control 
of coagulation reactions that lead to thrombin generation and fibrin clot formation called 
secondary haemostasis [1]. To date, studies investigating the role of platelets in the 
pathophysiology of haemorrhagic or thrombotic disorders have focused mainly on platelet 
number and tests of platelet aggregation [2-6].  This investigative approach has identified many 
disorders associated with abnormal bleeding. For example, inherited defects in platelet 
aggregation or adhesion such as Glanzmann’s thrombasthenia and Bernard Soulier syndrome 
are associated with moderate to severe haemorrhage.  A deficiency in platelet number or 
function may be associated with haemostatic failure in acquired conditions such as liver and 
renal disease.  Thrombocytopenia encountered in the clinical setting has many underlying 
causes including bone marrow failure and immune mediated as well as inherited pathologies.  
In some hereditary platelet and bleeding disorders, the cause of impaired haemostasis has 
remained undefined with current available coagulation assays and platelet function tests and 
these are usually termed unclassified bleeding disorders.  In recent years, large scale projects 
including the BRIDGE-BPD study have focused on the use of gene panels and genome sequencing 
in order to identify causal gene variants associated with uncharacterised platelet and bleeding 
disorders [7].  This approach has led to the discovery of novel mutations [8, 9] and has increased 
the number of genes implicated in bleeding and platelet disorders to a total of 76 [10].  However, 
a large proportion of cases of unclassified bleeding disorders in this study had no identifiable 
mechanism to account for the clinical bleeding phenotype.   
Whilst it is well known that platelets are important for providing a membrane surface for the 
interaction of coagulation factors, the contribution of the platelet procoagulant membrane in 
the pathophysiology of coagulation disorders is an unexplored area.  In this study, the role of 
the platelet membrane is investigated in both unexplained bleeding and venous thrombosis.   
   
1.2 Platelets  
Platelets are small, cell fragments without a nucleus typically measuring 2-3µm in diameter.  
They are derived from megakaryocytes which are large haematopoietic cells sparsely distributed 
in the bone marrow [11].  Following DNA expansion during maturation, megakaryocytes enlarge 
and develop thick cytoplasmic pseudopods leading to the formation of pro-platelets.  The pro-
platelets are shed into bone marrow sinusoids in a process of cytoplasmic fragmentation.  
Individual platelets are subsequently released from the end of the pro-platelet [12, 13].  This 
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process is regulated by thrombopoietin (TPO) and its cell receptor c-mpl [14].  It is estimated 
that about 3000 platelets are generated from each megakaryocyte [15].  Platelets have a life-
span of 7-10 days, and circulate with a normal count of 150-400 x 10 9/L in humans [16].  They 
are ultimately sequestered in the spleen and by Kupffer cells in the liver [17].   
In the resting state, platelets have a disc-like shape due to a complex cytoskeleton composed of 
spectrin, actin filaments and microtubules [18].  Despite the absence of a nucleus, platelets 
conserve messenger RNA (mRNA) transferred from the megakaryocyte and are able to 
synthesise proteins within their endoplasmic reticulum [12].  The main organelles include 
lysosomes, mitochondria and α and dense storage granules, both of which are released upon 
platelet activation [12].  The more abundant α granules (40-80 per platelet) contain proteins 
involved in platelet adhesion and aggregation (e.g. VWF, fibrinogen) as well as several 
membrane integrins (e.g. GPIIbIIIa, P-selectin) [19].  Other constituents include growth factors 
and chemokines which play a role in vessel wall repair, inflammation and host defence.  Dense 
granules (3-8 per platelet) contain ATP, ADP, serotonin (5HT), calcium and polyphosphates [20, 
21].    
The platelet surface membrane contains five types of integrin receptors, each composed of α 
and β subunit, which mediate adhesive interactions and aggregation [22] [23, 24].  Following 
exposure to specific agonists, transmembrane G-protein coupled receptors (GCPR) initiate the 
amplification stage of platelet activation through intracellular signalling pathways.  The main 
soluble agonists and their membrane receptors include thrombin (PAR1, PAR4), ADP (P2Y1, 
P2Y12), epinephrine (α2-adrenergic receptors) and thromboxane A2 (TPα and β) [25].     
The open canicular system (OCS) is a widespread network of channels which extends into 
invaginations of the platelet membrane. This serves to increase the surface area of the 
membrane during platelet spreading and facilitates the release of storage granule contents [26].  
Within the cytoplasm, a closed channel network known as the dense tubular system (DTS) forms 
part of the endoplasmic reticulum where calcium is stored and released on activation [27].   
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Figure 1.1 Ultrastructure of a platelet (cross-sectional plane).  The surface membrane extends 
into channels of the open canalicular system (OCS), which provides a pathway for the transport 
of granule contents.  The cytoskeleton is maintained by circumferential microtubules and the 
organelles are contained within the cytosol.  Used with permission from White JG, Gerrard JM.  
Ultrastructural features of abnormal platelets.  A review.  The American Journal of Pathology, 
1976. 83: 590 [28] 
 
1.3 Haemostasis 
1.3.1 Primary haemostasis 
Platelets play a central role in the generation of a haemostatic plug which prevents blood loss 
at the site of vessel injury.  The undisrupted vascular endothelium releases metabolites such as 
nitric oxide (NO) and prostaglandin (PGI2) which promote vasodilation but also have inhibitory 
actions on circulating platelets[29].  Following injury to the vessel wall, the initial step in 
haemostasis involves the tethering of platelets to the site of injury which occurs through the 
interaction of platelet complex GPIb-V-IX and extravascular VWF bound to collagen.  In 
addition, other subendothelium matrix proteins including fibronectin and laminin are exposed 
which enable the platelets to adhere [30] [31].  The damaged endothelium responds by 
exhibiting vasoconstriction through secretion of mediators such as endothelin-1 (ET-1), which 
also induces smooth muscle growth and the synthesis of growth factors such as platelet-
derived growth factor (PDGF) [32].      
VWF is a large multimeric glycoprotein which is produced in vascular endothelial cells and 
megakaryocytes.  It is stored in endothelial Weibel-Palade bodies prior to release whilst some 
undergoes abluminal secretion from the endothelial cell and thus is directly exposed to 
subendothelial collagen [33, 34].  Plasma VWF is mainly derived from endothelial cells, 
although a small proportion is released from the α granules of activated platelets [35].  Above 
a shear rate of 500-800/sec, VWF undergoes a structural change which facilitates interactions 
with platelet GPIb and collagen via its A1 and A3 domain respectively [36].    
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Figure 1.2 Schematic diagram of initial platelet-vessel wall interaction.  Circulating platelets 
contact exposed components of the extracellular matrix at the site of vascular injury, and slow 
down sufficiently to adhere through the binding of GPIb-V-IX to VWF deposited on the 
subendothelium.  Stable adhesion of the rolling platelet involves the interaction of platelet 
integrins with their ligands.  Both the GPVI receptor and integrin α2β1 bind collagen.  
 
 
The ligand action of VWF enables platelets at the vessel wall to bind collagen via the GPVI 
receptor so that a firm adherence is formed.  GPVI, the main collagen receptor belongs to the 
immunoglobulin superfamily and has two IgG domains with an associated FcR adaptor protein 
(FcRϒ).  The binding of collagen to FcRϒ initiates a tyrosine kinase pathway characterised by 
activation of phospholipase Cγ2 (PLCγ2) [37, 38].  This leads to downstream signalling events 
which involve the hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-
bisphosphonate (PIP2) to form diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3).  IP3 
binds to specific receptors of the dense tubular system to initiate calcium mobilisation, which 
triggers the release of platelet storage granule contents (e.g. ADP, thromboxane A2, adhesion 
molecules)[39, 40] [41].  Through secondary mechanisms, platelet receptors α2β1 and αIIbβ3 
are converted to a high-affinity state which promotes their respective binding to collagen and 
fibrinogen [42].  Both αIIbβ3 and VWF via its C1 domain can bind fibrinogen which is required 
for the aggregation of platelets.  It is reported that up to 80,000 copies of the αIIbβ3 integrin are 
present on the platelet surface [43].  
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Figure 1.3. Signalling events following platelet adhesion.  The binding of collagen to GPVI leads 
to platelet activation through a tyrosine kinase signalling pathway that involves the kinases Syk 
and phospholipase Cγ2 (PLC γ2) [37].  PLCγ2 hydrolyses phosphatidylinositol 4,5-bisphosphonate 
(PIP2) to form secondary messengers diacylglcerol (DAG) and inositol 1,4,5-triphosphate (IP3).  
IP3 triggers calcium release from storage in the dense tubular system which leads to granule 
release, synthesis of thromboxane (TXA2) and shape change.  Calcium and DAG-related guanine 
nucleotide exchange factor 1 (CalDAG-GEF1), a member of the Ras GRP family is a signalling 
molecule which triggers integrin activation and enhances collagen-dependent TXA production 
[44, 45].  Image adapted from Mackman et al and Mosawy [46, 47]              
 
The activation of αIIbβ3 involves a conformational change, termed ‘inside-out signalling’ which 
increases the affinity of the integrin for fibrinogen [43].  This mechanism is triggered by the 
soluble agonists ADP, thromboxane A2 and thrombin in addition to collagen [48].  The platelet 
agonists mediate their effects via activation of G-protein coupled receptors.  Through G protein 
mediated signalling, thromboxane A2, thrombin and ADP induce platelet shape-change which 
involves polymerisation of the actin-based cytoskeleton, loss of discoid shape and the 
development of filopodia to promote platelet spreading.  These contractile actions are regulated 
by two main pathways.  Firstly, Gq signalling activates phospholipase β (PLC β), and via IP3 
formation mobilises calcium from intracellular stores.  Calcium is required for myosin light chain 
kinase (MLCK) activity which induces the phosphorylation of myosin light chain required for the 
contraction of actin filaments.  Secondly, G12/13 signalling activates the Rho/Rho-kinase 
pathway which is involved in regulating myosin light chain phosphorylation [25, 49].  
Additionally, the platelet agonists act as positive feedback regulators by promoting their own 
production and release thus amplifying the activation process which leads to recruitment of 
additional platelets in order to increase thrombus growth [25].  
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Specifically, ADP acts on P2Y1 and P2Y12 receptors [25].  Thromboxane A2, is a short-lived 
platelet agonist which is synthesised from arachidonic acid stored in the plasma membrane.  It 
exerts its action via the TPα receptor, although both TPα and TPβ isoforms are expressed on 
platelets [50].  Following hydrolysis by cytosolic phospholipase A2, arachidonic acid is 
metabolised by cyclo-oxygenase 1 (COX-1) and thromboxane synthase to generate the end-
product.  Thrombin generated from secondary haemostasis is the most potent of the agonists 
and activates platelets via PAR1 and PAR4 [25]. 
 
 
 
 
Figure 1.4 Platelet agonists and G protein signalling.  ADP, thromboxane (TXA2) and thrombin 
mediate platelet shape change through Gq signalling which activates phospholipase C (PLC β) 
and results in calcium mobilisation.  Calcium regulates myosin light chain kinase (MLCK) activity 
which induces the phosphorylation of myosin light chain required for platelet contraction.  
Thrombin and thromboxane also mediate Gq12/13 signalling which activates the Rho/Rho 
kinase pathway which regulates actin-myosin interactions.  P2Y12 linked to Gi inhibits adenyl 
cyclase (AC) enhancing platelet aggregation and additionally activates PI3K.  Figure adapted from 
Stegner et al [49]         
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A sub-population of platelets dually activated by collagen and thrombin - (COAT) platelets – 
expose serotonin (5HT) and retain several α granule proteins on their negative phospholipid 
surface and are considered the most procoagulant forms within the platelet plug [51].  Other 
studies report the additional clustering of coagulation factors on the surface of COAT platelets, 
thus forming a procoagulant “cap” [52].  Polyphosphate (PolyP) released from the dense 
granules during platelet activation is recognised to have an important role in promoting 
coagulation through its interaction with nearby coagulation factors.  Short-chain polymers of 
polyP facilitate the activation of Factor V and Factor XI by acting as a co-factor for thrombin.  
Long-chain polyphosphates more so than their shorter counterparts, bind the fibrin clot 
subsequently formed thereby increasing its stability [53, 54].    
1.3.2. Secondary haemostasis     
This procoagulant system is initiated when tissue factor (TF) is exposed following vascular injury 
[55].  TF is a 47-kDa integral transmembrane protein [56] which is expressed by vessel wall cells 
such as smooth muscle cells and fibroblasts where they have been described as forming a 
‘haemostatic envelope’or barrier [57].  It is also expressed by tumour cells, foam cells in 
atherosclerotic plaques and peripheral blood monocytes in response to inflammation [58, 59].  
Currently, it is proposed that TF exists in a ‘cryptic’ or inactive state.  The interaction of TF with 
anionic phospholipids, specifically phosphatidylserine (PS) is recognised to be of importance in 
the ‘decryption’ or activation of TF, although the precise mechanisms for decryption is still under 
debate [60].             
Historically, the system initiated by the exposure of FVII to cells expressing TF following vascular 
injury has been referred to as the extrinsic pathway.  The binding of TF to the serine protease 
Factor VIIa triggers the enzymatic conversion of a cascade of coagulation factors (zymogens) into 
their active serine forms.  Plasma FVIIa, despite circulating at low concentrations (0.005 µg/ml) 
can form a potent enzymatic complex with TF (TF-VIIa).  Alternatively, the more abundant 
zymogen FVII can be converted to FVIIa either by ‘auto-activation’ or by downstream serine 
proteases in a process significantly accelerated by TF [61, 62].  The TF-VIIa complex converts 
Factor IX to FIXa and Factor X to Xa.  The initiation stage produces a trace amount of thrombin 
which is sufficient to activate Factor XI and cofactors Factor VIIIa and Factor Va.  In the 
amplification phase, Factor XIa cleaves Factor IX to IXa.  The newly generated Factor IXa forms a 
complex with VIIIa and subsequently activates Factor X which binds to FVa.  The tenase (FVIIIa-
FIXa) and prothrombinase (FXa-FVa) complexes are both dependent on an influx of calcium ions 
in platelets leading to exposure of anionic phospholipid surface provided by the activated 
platelet for catalytic efficiency.  The propagation phase culminates in the rapid conversion of 
prothrombin to thrombin by the prothrombinase complex[55, 62] [63].  Thrombin cleaves 
fibrinogen to fibrin and activates Factor XIII to enable cross-linkage of the insoluble fibrin clot.   
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Figure 1.5 Tissue factor driven haemostasis network.  Following vessel wall injury, FVII is 
exposed to tissue factor (TF) -expressing cells.  TF-FVIIa complex activates a sequential series of 
coagulation reactions which initially yields a minimal amount of thrombin.  Thrombin back-
activates FXI and co-factors FVIII and FV.  The tenase (FVIIIa-IXa) and prothrombinase (Xa-Va) 
complexes assemble in the presence of calcium and membrane phospholipid.  This culminates 
in the ‘thrombin burst’ that leads to production of a fibrin clot.         
 
The contact or intrinsic pathway is triggered when Factor XII undergoes spontaneous activation 
upon contact with an artificial surface such as glass or ellagic acid and historically was considered 
of relevance to haemostasis occurring in vitro.  The generation of FXIIa converts prekallikrein 
into kallikrein and Factor XI into FXIa.  This interaction is mediated by the cofactor high molecular 
weight kininogen (HMWK).  FXIa then propagates the formation of the tenase complex with 
subsequent downstream events.  Whilst a natural deficiency of FXII, HMWK or kallikrein does 
not result in a bleeding disorder, contact activation in the clinical setting is associated with the 
use of cardiopulmonary bypass circuits and extracorporeal membrane oxygenation [63] [64].  In 
murine studies, FXII deficiency has been associated with protection against thrombus formation.  
In a thromboembolism model induced by ADP and collagen, defective thrombus formation was 
observed in FXII-deficient mice at the site of arterial injury [65].  Similarly, mice lacking FXII were 
reported to be protected from thrombosis in ischaemic brain injury [66].  It is widely recognised 
that polyphosphates secreted from activated platelets can directly trigger FXII activation [67].   
Other components of coagulation that have been reported as contact pathway activators 
include PS-liposomes and matrix proteins such as collagen although their roles in this regard are 
not well defined[68, 69] [70]. 
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The haemostatic process is regulated by the action of several natural anticoagulants.  The initial 
TF-VIIa complex is inhibited by tissue factor pathway inhibitor (TFPI), a serine protease inhibitor 
composed of three kunitz domains (K1-3).  Kunitz domains 1 and 2 binds FVIIa and FXa 
respectively.  Kunitz domain 3 binds Protein S, which promotes the interaction of TFPI with FXa.  
Thus, TFPI is critical for the inactivation of the extrinsic tenase complex [71]. Factor Xa can also 
be inhibited by Protein Z-dependent protease inhibitor, requiring co-factor Protein Z [72].      
The protein C pathway is another important mechanism for inhibiting the coagulation response 
to injury and is initiated by the binding of thrombin to thrombomodulin on endothelial cells.  
Protein C, a vitamin K- dependent zymogen, is activated by the thrombin-thrombomodulin 
complex and this interaction is enhanced by endothelial protein C receptors (EPCR).  Once 
formed, activated PC together with co-factor Protein S proteolytically cleaves and inactivates 
factors Va and VIIIa [73, 74].   
Finally, the inactivation of thrombin and Factor IXa, Xa and XIa is mediated by antithrombin, a 
58kDa serine protease inhibitor produced in the liver [75].  The active serine site of the 
coagulation protease cleaves the arginine-serine bond in the active region of antithrombin 
which induces a conformational change in antithrombin resulting in inactivation of the serine 
protease [76, 77].  Vessel wall glycosaminoglycans such as heparan sulphate or the anticoagulant 
heparin, significantly increase the rate of inactivation (>1000 fold) [78].  Other inhibitors of 
thrombin include heparin co-factor II and α2-macroglobulin [79]. 
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Figure 1.6 Regulators of the haemostasis network.  Tissue factor pathway inhibitor (TFPI) 
inhibits the activity of the TF-VIIa complex.  Antithrombin (AT) inhibits thrombin and Xa in 
addition to serine proteases IXa and XIa.  Thrombin bound to thrombomodulin (TM) on the 
endothelium surface activates Protein C associated with its receptor EPCR.  Activated Protein C 
(APC) and its co-factor Protein S inhibit FVa and FVIIIa.   
 
1.3.3 Fibrinolysis 
Fibrinolysis involves the break-down of the fibrin clot formed following injury to a blood vessel.  
A key component of the pathway is the glycoprotein zymogen plasminogen, the precursor of the 
active serine protease, plasmin.  The conversion of plasminogen to plasmin occurs through 
cleavage of a single peptide bond (Arg561-Val562) forming Glu-plasmin, which undergoes auto-
catalytic degradation to the more active Lys-plasmin.  The main plasminogen activator is t-PA 
which is synthesised and secreted from vascular endothelial cells [80] [81].  
Briefly, plasmin degrades the clot by cleaving fibrinogen and fibrin into small, soluble fragments 
referred to as fibrin degradation peptides (FDP’s).  The cross-linking of fibrin by thrombin-
activated factor XIII, however results in a different fragmentation pattern after plasmin-induced 
cleavage due to transamidation of the fibrin chains induced by Factor XIIIa [82, 83].  One of the 
characteristic fragments (D-dimer) can be measured in blood and is of clinical use in determining 
the likelihood of venous thromboembolism.  
Each fibrinolytic step is inhibited by a specific protease.  PAI-1 is the main inhibitor of tPA whilst 
plasmin is inhibited by α-2 antiplasmin.  Thrombin activatable fibrinolysis inhibitor (TAFI), an 
enzyme derived from carboxypeptidase B removes the C-terminal lysines from fibrin that has 
been partially lysed by plasmin, thereby preventing the binding of plasminogen and tPA.  The 
activation of TAFI occurs following the interaction of thrombin with thrombomodulin [84].     
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Figure 1.7 The fibrinolytic system.  Plasminogen (PLG) and tPA bind to the fibrin clot.  The 
plasminogen is cleaved by tPA to plasmin which then converts fibrin into soluble fibrin 
degradation products (FDP’s).  PAI-1 inhibits tPA and α2-antiplasmin inhibits plasmin.  TAFIa 
removes C terminal lysines from partially degraded fibrin thereby preventing the binding of 
plasminogen and tPA. Adapted from http://themedicalbiochemistrypage.org/blood-
coagulation.html.   
 
1.4 Phospholipids 
1.4.1. Platelet phospholipid structure  
The ‘fluid mosaic model’ describes the structure of the plasma membrane as a ‘mosaic’ of  
membrane proteins embedded in a fluid lipid-rich phase [85].  Phospholipids are the main 
constituents of the membrane and due to their amphipathic nature, are organised in a bilayer 
with the polar heads facing outwardly and the nonpolar fatty acid tails orientated inwardly thus 
forming a hydrophobic barrier.  Other membrane components include sphingomyelin, 
cholesterol and transmembrane glycoproteins [86].  Diacyl phospholipids are a common 
subclass of lipids within the membrane and are composed of two hydrophobic fatty acids which 
are each attached to the Sn1 and Sn2 positions of a glycerol backbone by an acyl bond.  The 
polar phosphate-containing headgroup is esterified to the Sn3 position [87].  Their classification 
is based on the nature of the head-group and the length and saturation of the fatty acid chains.  
Whilst the head-group dictates the charge of the membrane, the fatty acid chains influence the 
curvature, thickness and fluidity [88-90].    
 12 
 
 
 
Figure 1.8. Example of a diacyl phospholipid.  The structural components include the glycerol 
backbone, the phosphate group and the organic head group.  Fatty acid chains occupy the Sn1 
and Sn2 position of the glycerol backbone.  The presence of a double bond indicates an 
unsaturated fatty acid chain.  Adapted from Hanna et al[91] 
 
 
In platelets, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are the most 
abundant species accounting for 35-38% and 27-35% of total phospholipids respectively.  
Phosphatidlyserine (PS) contributes approximately 10-15% and phosphatidylinositol (PI) is the 
least abundant representing only 5% of the total [92].  The fatty acid chains are diverse with 
regards to their carbon chain length and degree of saturation, referring to the presence of 
carbon double bonds (unsaturated) or their absence (saturated) [90].  The Sn2 position is 
generally occupied by polyunsaturated fatty acids whilst saturated fatty acids occupy the Sn1 
position [93].  Arachidonic acid (20:4, 20 carbon and 4 double bonds) is one of the most 
abundant fatty acid in platelet phospholipids.  Others include oleic acid (18:1), linoleic acid 
(18:2), stearic acid (18:0) and palmitic acid (16:0) [94].  Recently, the composition of the fatty 
acid chain has been reported to influence coagulation with longer unsaturated fatty acid chains 
supporting thrombin generation somewhat better than shorter fatty acid chains [95]. 
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Figure 1.9 Structure of the main diacyl phospholipid species.  The 4 main species of 
phospholipid in the platelet membrane is shown.  Images constructed using LIPIDMAPS 
resources. www.lipidmaps.org/resources/tools/index.php 
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Figure 1.10 Structures of the more common Sn1 fatty acids and Sn2 fatty acids in platelets.  
The first number within the bracket denotes the number of carbon atoms and the second 
number indicates the total number of double bonds in the fatty acid.  Images constructed 
using LIPIDMAPS resources. www.lipidmaps.org/resources/tools/index.php   
 
 
More structural variety is introduced by the type of bond (vinyl ether or acyl) present at the Sn1 
position of the glycerol backbone.  The plasmalogen subclass of phospholipids has a 
characteristic structure where the Sn2 fatty acid is linked via an acyl bond, whilst the Sn1 fatty 
acid is attached by a vinyl ether bond [96].  In platelets, plasmalogens with an ethanolamine 
linked head-group are abundant and are reported to represent approximately 12% of total 
membrane phospholipids [97] [98].  The vinyl ether bond is particularly vulnerable to reactive 
oxygen species, thus implicating a protective role for plasmalogens in limiting oxidative damage 
to other lipid species and cells [98] [99].  It is hypothesised that oxygen free radicals generated 
from platelets or other blood cells may induce platelet aggregation and contribute to thrombus 
formation for example in atherosclerotic plaques [100] [101].  Whether the antioxidant 
properties of plasmalogens are of significance in this disease process remains to be elucidated.   
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1.4.2. Role of the phospholipid platelet membrane in coagulation 
The phospholipid composition of the membrane plays an essential role in coagulation.  In the 
resting state, the phospholipid membrane is maintained in an asymmetrical configuration.  The 
outer leaflet is mainly composed of phosphatidylcholine (PC) and sphingomyelin, whereas 
phosphatidylethanolamine (PE) and phosphatidylserine (PS) are located in the inner surface of 
the membrane [102].  The distribution of mostly neutral phospholipids in the outer membrane 
and negatively charged lipids in the inner membrane creates an electrical gradient which is 
regulated by transmembrane lipid transporters.  ATP-dependent translocase or flippase 
facilitates the transport of PS and PE from the outer to the inner membrane.  A second ATP-
dependent mechanism due to floppase activity, regulates the movement of predominantly PC 
to the outer membrane [103].  The export of lipids in the manner described is associated with 
the ABC transporter superfamily.  Of those members characterised, ABCB4 is identified as having 
specificity for the outward translocation of PC [104] [105].   
 
 
 
 
Figure 1.11 Regulation of phospholipid membrane asymmetry.  The action of the three 
transporters involved in the movement of phospholipids between the inner and outer 
membrane is shown. Flippase and floppase both require ATP to move phospholipids in a 
unidirectional manner.  Scramblase activity is bidirectional and is calcium dependent.  The 
activated platelet membrane externalises PS and PE.    
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Upon platelet activation or apoptosis, membrane lipid asymmetry is disrupted due to the rapid 
passage of negatively charged PE and PS to the outer surface.  This is induced by calcium-
dependent scramblase activity which mediates the bidirectional movement of phospholipids.  
At the same time, the increased intracellular calcium renders both flippase and floppase 
inactive [102, 103].  The net effect of these processes is the surface exposure of PS and PE.  At 
the surface, they are available to interact with the negatively - charged Gla domains of the 
Vitamin K dependent coagulation factors (II, VII, IX, X).  It is currently thought that the binding 
of calcium ions to the Gla domain exposes a hydrophobic region within the omega loop which 
can then penetrate the anionic phospholipid membrane [106].  Each Gla domain has a single 
binding site specific for the PS head-group in addition to binding sites for interactions with the 
phosphates on any phospholipid apart from PC.  Nuclear magnetic resonance (NMR) analysis 
has shown that the PL head-group must bend to enable its phosphate to associate with 
calcium bound within the Gla domain.  Whilst PE can engage in phosphate-specific interactions 
and thus enhance the function of PS, it is hypothesised that PC may impede these interactions 
due to the bulky nature of the choline head-group [106] [107].  The phospholipid-binding 
properties of the non-vitamin K dependent co-factors (FVIII and FV) resides within the C 
domain.  Specifically, binding sites have been identified in the C2 domain which contains a ‘β2 
barrel framework’ with hydrophobic residues [108] although additional sites have been 
identified in the C1 domain [109] [110].    
 
 
 
 
Figure 1.12a Gla domains binding to the phospholipid membrane.  The omega loop of the Gla 
domain of prothrombin (blue) is shown interacting with the external leaflet of the membrane.  
The hydrophobic residues of the omega loop (yellow) are exposed and calcium (purple) is 
tightly bound within the Gla domain.  Figure used with permission from Morrissey JH, 
Tajkhorshid E and Rienstra CM.  Nanoscale studies of protein- membrane interactions in blood 
clotting.  Journal of Thrombosis and Haemostasis, 2011.  9:163 [111]. 
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Figure 1.12b Membrane interactions of the Gla domain of FVIIa.  (A) The residues of the Gla 
domain (yellow) of FVIIa is shown interacting with exposed PS on the membrane surface. (B) 
The TF-FVIIa complex is membrane associated (C) Binding of PS (green stick representation) to 
the Gla domain (dark purple) with its head-group in contact with calcium (pink/purple). (D-E) 
Interaction of calcium bound within the Gla domain and the phosphate groups (red) of PS.  
Figure used with permission from Morrissey JH, Tajkhorshid E and Rienstra CM.  Nanoscale 
studies of protein- membrane interactions in blood clotting.  Journal of Thrombosis and 
Haemostasis, 2011.  9:164 [111] 
 
Activated platelets undergo blebbing and shedding of the plasma membrane forming 
microvesicles.  This process is dependent upon an increase in intracellular calcium which also 
induces scramblase activity and is associated with degradation of cytoskeleton proteins 
mediated by calpain [112] [113].  Microvesicles are small lipid particles (100 nm- 1 µM) which 
have been demonstrated to express externalised PS/PE by Annexin V binding and thus possess 
procoagulant properties[114].  Their accumulation at the site of clot formation facilitates the 
assembly of coagulation complexes on their surface thus promoting the generation of thrombin 
[115].  The presence of active TF-bearing microvesicles derived from cells such as monocytes in 
response to lipopolysaccharide (LPS) is well established [116], however the role of platelets as a 
source of TF, and thus as a source of TF-positive microvesicles has been debated.  Whilst some 
studies have reported the presence of platelets expressing TF in response to stimulation with an 
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agonist [117, 118], others have failed to demonstrate these findings [119, 120].  Currently, the 
most widely held concept involves the integration of TF into the platelet membrane from TF-
bearing microvesicles derived from cells such as monocytes and endothelial cells[121].  
Alternative mechanisms that have been proposed include the transfer of TF mRNA from the 
megakaryocyte to a subset of platelets during their production [122].    
 
1.4.3. Arachidonic acid metabolism in platelets 
Arachidonic acid metabolism is of importance in platelets as this lipid is a precursor for the 
generation of several lipid mediators.  Following platelet activation, arachidonic acid from 
membrane PL is hydrolysed from the Sn2 position by phospholipase A2 (PLA2).  Of the several 
isoforms, cytosolic group IV PLA2 (cPLA2) shows specificity for phospholipids containing 
arachidonic acid at the Sn2 position [123] and is regulated by calcium and kinases including 
mitogen-activated protein kinase (MAPK) [124].  Free arachidonic acid can be utilised in the 
cyclooxygenase (COX) pathway leading to the production of prostaglandin G2 (PGG2) and then 
prostaglandin H2 (PGH2).  The COX enzyme family consists of two isoforms, COX-1 and COX-2.  
COX-1 is constitutively expressed in human platelets in contrast to COX-2, an inducible isoform 
which is activated in response to inflammatory stimuli [125].  PGG2 and PGH2 compounds are 
converted by thromboxane synthetase into thromboxane A2 which in addition to its function as 
a platelet activator also mediates smooth muscle contraction [126].  Other arachidonic acid 
derived oxylipins (PGE2, PGD2) which regulate the response to inflammation and hypersensitivity 
are also generated by platelets, but in far less amounts [127].  
The second pathway of arachidonic acid metabolism in platelets involves lipoxygenases (LOX), 
a group of non-heme iron-containing enzymes [128].  LOX enzymes oxidize arachidonic acid 
forming hydroxyperoxyeicosotetranoeic acids (HPETEs) which are rapidly reduced by 
glutathione peroxidases to form hydroxyeicosotetranoeic acids (HETEs).  The oxidation 
reaction catalysed by LOX involves hydrogen abstraction followed by radical migration and 
subsequently the stereospecific addition of oxygen at a particular carbon, dictated by the LOX 
isoform [129].  LOX isoforms are numbered in accordance with the carbon position at which 
arachidonic acid is oxygenated [130].  In human platelets, the formation of 12-HETE results 
from the enzymatic oxidation of arachidonic acid by 12-LOX [131-133].  12-HETE can either be 
released by activated platelets or be esterified generating oxidised phospholipids (OxPLs) 
[134].     
5-LOX in human leucocytes (neutrophils/monocytes) and its products are used for the 
downstream production of leukotrienes which have potent inflammatory actions [130].  Two 
different subtypes of 15-LOX have been described in humans, 15-LOX-1 (leukocyte-type) and 
15-LOX-2 (epidermis-type)[131] [132].  Of these isoforms, 15-LOX-1 has the wider distribution 
of the two and is expressed in reticulocytes, eosinophils, bronchial airway epithelial cells and 
skin [135].  Peripheral blood monocytes, however express 15-LOX-1 when exposed to anti-
inflammatory cytokines such as IL-4 and IL-13 [136] [129].    
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Figure 1.13a Mechanism of the lipoxygenase reaction.  (1) - removal of hydrogen from the 
unsaturated fatty acid (hydrogen abstraction) (2) – radical rearrangement (3) addition of oxygen 
at the site of lipoxygenase specificity and (4) reduction of the peroxyl radical to form the 
hydroperoxyeicosotetranoeic acid (HPETE) within the enzyme active site.  Figure used with 
permission from http://www.lipidhome.co.uk/lipids/fa-eic/eic-hete/index.htm   
 
 
Figure 1.13b Examples of LOX specificity at different positions of arachidonic acid.  The 
carbon number is denoted in red.  The initial position of the removal of hydrogen (abstraction) 
is arrowed in green and differs to the carbon position at which arachidonic acid is oxygenated 
by LOX.  Figure used with permission from http://www.lipidhome.co.uk/lipids/fa-eic/eic-
hete/index.htm 
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1.4.4 Enzymatic and non- enzymatic formation of oxidised phospholipids  
The oxidation of a polyunsaturated fatty acid (PUFA) such as arachidonic acid can occur by 
enzymatic or non-enzymatic mechanisms either when they are free or attached to PLs [137].  
The non-enzymatic oxidation of PL can be initiated by free radicals or reactive oxygen species 
generated during inflammation for example.  The initial reactions involved in non-enzymatic PL 
oxidation produce peroxyl radicals which can react with the methylene group in other PUFA 
molecules to form hydroperoxides and other carbon centred radicals.  Further secondary 
peroxidation reactions can then occur in an enzyme-independent manner leading to the 
generation of a wide variety of oxPL products [137].  The biological effects of non-
enzymatically formed oxPL have been associated with the development of human 
atherosclerotic plaques due to their influence on vascular endothelial cells and macrophages 
[138-140].      
Despite being derived from the same initial set of chemical reactions (Figure 1.13a), a clear 
distinction is made with enzymatically formed OxPLs regulated by COX and LOX enzymes.  The 
stereospecific activity governed by a particular LOX isoform results in the generation of a less 
diverse number of molecular species [141].  Over the last two decades, a number of HETE-PL 
species generated by LOX enzymes have been identified following the cellular activation of 
human monocytes, neutrophils and platelets [134, 142, 143].  Although their role has not fully 
elucidated in health or disease, there is increasing evidence that the families of eoxPL 
generated in this manner are important in mediating the inflammatory response and 
promoting coagulation [141].       
It is well established that large amounts of 12-HETE are generated and released from platelets 
upon agonist activation [134, 142].  For example, collagen and collagen related peptide (CRP) 
activate 12-LOX via GPVI signalling inducing the production of 12-HETE [144].  More recently it 
has been observed that other platelet agonists including thrombin, convulxin and ionophore 
rapidly generate free 12-HETE [134].  Stable isotope labelling demonstrated that of the total 12-
HETE synthesised, approximately 30% is esterified to PLs and remains cell-associated whilst the 
remaining free 12-HETE is secreted from the platelet [134].  The mechanisms involved in agonist-
activation of 12-LOX include intracellular signalling through PI3 kinase activation and calcium 
mobilisation [144].  The six molecular species of 12-HETE-PLs produced by activated platelets 
include four molecular species of 12-HETE-PE (PE(18:0a_12-HETE), PE(18:0p_12-HETE), 
PE(18:1p_12-HETE), PE(16:0p_12-HETE)) and two species of 12-HETE-PC (PC(18:0a_12-HETE), 
PC(16:0a_12-HETE)).  Their identification has been observed within minutes and is sustained for 
up to 3 hours [134].   
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Figure 1.14 Structure of 12-HETE-PEs and 12-HETE-PCs generated by activated human 
platelets.  Images constructed using LIPIDMAPS. 
www.lipidmaps.org/resources/tools/index.php 
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1.4.5. eoxPL and coagulation  
There is an increasing body of evidence to support the idea that 12-HETE-PLs have thrombotic 
effects [145].  In thrombin generation experiments activated by TF-containing liposomes in 
platelet poor plasma, the rate and amount of thrombin produced was increased by incremental 
amounts of 12-HETE-PE (ranging from 1-10% of total lipid composition) when compared to 
unoxidized PE (30% of total lipid composition).  Interestingly, similar findings were observed 
when 12-HETE-PC (ranging from 1-10%) was substituted for the native form (65% of total lipid 
composition) [146].  This is in contrast to native unoxidized PC which does not support 
coagulation [102, 107].  In a reconstituted coagulation system of physiological concentrations of 
coagulation factors (II, V, VII, IX, X), 12-HETE PE and 12-HETE-PC both enhanced the formation 
of the tenase and prothrombinase complexes which were triggered in TF-dependent manner 
[146].  As native PC is generally found on the outside of membranes, it is proposed that 12-HETE-
PCs are also located on the external leaflet where they can exert procoagulant activity.  The 
incorporation of the HETE hydroxyl-group (OH) into arachidonate facilitates a change in 
configuration of the PL to a bent form which enables its interaction with calcium and the 
phosphate groups of other lipids or the carboxylate on the PS head-group [134, 146].  It has been 
shown by molecular modelling that due to the increased polarity introduced by the -OH group, 
12-HETE-PCs can associate with the outer part of the membrane where they can contribute to 
the electronegative charge in addition to generating space between head-groups for calcium to 
bind [146].    
 
Figure 1.15a Mechanism of 12-HETE- PE and 12-HETE-PC formation in platelets.  Following 
thrombin activation of the PAR receptor, synthesis of 12-HETE occurs via signalling pathways 
involving Src tyrosine kinase, phospholipase C and calcium.  The formation of 12-HETE-PL 
involves hydrolysis of arachidonate by cPLA2, oxidation by 12-LOX and then re-esterification by 
fatty acyl- CoA ligase.  Some 12-HETE-PE moves to the outside membrane where it can promote 
coagulation.  12-HETE-PC is located on the external membrane leaflet.  Figure adapted from 
O’Donnell et al[147] [148]. 
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Figure 1.15b Molecular dynamics simulation image showing the association of the -OH group 
of 12-HETE-PC with the outer polar membrane.   The bent-up configuration of 12-HETE-PC is 
shown where the -OH group is close to the polar membrane where it can interact with the 
phosphate groups of other lipids and the nearby phosphatidylserine (PS) head-group.  From 
Lauder SN et al.  Networks of enzymatically oxidised membrane lipids support calcium- 
dependent coagulation factor binding to maintain haemostasis.  Science Signalling, 2017, 
10(507).  Reprinted with permission from AAAS [146].  
 
In addition to the above findings, in vivo murine experiments using a tail bleeding model 
demonstrated that mice deficient in 12/15 LOX or 12-LOX had increased bleeding times 
compared to their wild-type counterparts.  Importantly, injection of 12-HETE-PE liposomes 
significantly shortened the bleeding time compared to unoxidized PE.  Subsequently, platelets 
from patients with antiphospholipid syndrome (n=12) generated increased levels of 12-HETE-PE 
compared to healthy controls (n=18) both basally and after thrombin stimulation (P < 0.05) 
[146].  Finally, it was demonstrated that measured levels of 12-HETE -PE and 12-HETE-PC were 
lower in the platelets of patients post cardio-pulmonary bypass surgery compared to pre-
operatively [149].  Such patients are recognised to be susceptible to bleeding in this clinical 
scenario for many reasons including contact activation, acquired platelet defect or from 
anticoagulation, and it was hypothesised that decreased levels of oxPL may be contributory.  
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1.4.6. Native aminophospholipids (APL) 
The externalisation of PE and PS that occurs during agonist activation, apoptosis or ageing has 
traditionally been measured using flow cytometry techniques using annexin V or lactadherin 
[150-152].  Whilst these techniques have been useful in establishing the presence of APL, they 
are unable to distinguish different species or their specific quantities.  Following the 
development of a new lipodomics method using a cell impermeable reagent, it was 
demonstrated that human platelets undergoing activation, ageing or energy depletion could 
externalise 5 species of PE and 3 species of PS [95, 153].  The importance of calcium dependent 
scramblase activity in PE/PS exposure has previously been shown in the rare bleeding disorder, 
Scott syndrome where this mechanism is impaired due to a causative TMEM16F mutation [154].  
The platelets of such patients externalise significantly reduced quantities of PE and PS, which is 
recognised to account for the bleeding phenotype [134, 155].  
It has been suggested, however that whilst TMEM16F is required for scramblase activity 
triggered by platelet agonists such as collagen and thrombin, other independent mechanisms 
may account for PS exposure due to apoptosis [155].  It has been shown that platelets contain 
proteins including members of the BCL-2 family which regulate apoptosis and caspases (caspase 
3 and 9), which mediate programmed cell death [156] [157, 158].  Subsequently, inhibition of 
the anti-apoptotic protein Bcl-XL in platelets, was reported to result in mitochondrial damage, 
activation of caspase and exposure of PS [159-161].  Whether there is an association between 
the apoptotic pathway and agonist-activated mechanisms for PS exposure is currently 
undetermined [158, 159].  Apart from Scott syndrome, there have been no investigations into 
potential variations in externalised PE and PS in bleeding or thrombotic disorders.   
Recently, it was reported that increased PE exposure was observed on the surface of platelets 
and eosinophils of Alox12- or Alox15- deficient mice.  In a murine model of Angiotensin-II driven 
aortic abdominal aneurysm (AAA), both 12- and 12/15- LOX deficient mice demonstrated 
evidence of a consumptive coagulopathy as confirmed by increased prothrombin time and 
higher thrombin-antithrombin complexes (TAT’s) compared to wild type.  Whilst these mice 
generate less procoagulant oxPL compared to wild - type, increased basal quantities of 
externalised PE were measured in platelets and in eosinophils following activation with ADP.  
This was hypothesised to be a compensatory mechanism for the underlying coagulation defect 
[162].     
 
1.4.7. Phospholipid remodelling 
The main remodelling pathway of phospholipids is known as the Lands cycle which was initially 
described in 1958 [163].  This process is initiated when the fatty acid chain at the Sn2 position is 
hydrolysed by phospholipase A2 generating a PUFA such as arachidonic acid, and a lyso-
phospholipid for example lyso-PC or lyso-PE.  An important group of enzymes, long-chain acyl-
CoA synthetases (ACLS) act on the long-chain fatty acid substrate generating a product (acyl-
CoA) that is used by other membrane bound enzymes known as lysophospholipid 
acyltransferases (LPLATs) [164].  LPLATs esterify the acyl-CoA product onto a lyso-PL acceptor 
and can therefore re-introduce a different fatty acid at the site of cleavage thus influencing the 
phospholipid composition of the membrane [165].   
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Figure 1.16.  Lands cycle Membrane phospholipids are remodelled through the actions of 
phospholipase A2 (PLA2) and lysophospholipid acyltransferase (LPLAT).  As an example, PLA2 
removes a fatty acid (arachidonic acid; 20:4) from the Sn2 position of phosphatidylcholine (PC) 
to produce lysophosphatidlycholine (LPC).  The fatty acid can be replaced by either the same or 
a different fatty acyl group depending on the specificity of lysoPC acyltransferase (LPCAT).  
LPCAT uses fatty acyl-CoA as a donor.  Adapted from Sugiura et al [166].   
 
Lysophosphospholipid acyl-transferase (LPLAT) enzymes are mainly involved in the acylation of 
lyso-PC, lyso-PE and lyso-PS [167].  By virtue of their name, these enzymes demonstrate a degree 
of specificity with regards to their lysophospholipid substrate and acyl-CoA donor of choice.  For 
example, LPCAT demonstrates substrate specificity for lyso-PC (Figure 1.16) in a similar manner 
to lyso-PE acyltransferase (LPEAT) for lyso-PE, however the enzymatic activity of each individual 
LPLAT is not restricted to a specific substrate [163].  The LPLATs were recently further classified 
following the identification of two protein families, the acylglycerophosphate acyltransferases 
(AGPAT) and the membrane bound O-acyl transferases (MBOAT) [168].  The majority of LPCATs 
belong to the MBOAT family, which were identified from 11 genes of the human genome [93].  
MBOAT activity occurs mainly within the endoplasmic reticulum or mitochondria, although the 
activity of the different isoforms is distributed throughout a variety of tissues.  
It is hypothesised that the availability of arachidonic acid for the COX and LOX pathways is 
regulated by the deacylation and reacylation cycle of phospholipid remodelling.  This concept 
was demonstrated in human neutrophils where inhibition of MBOAT activity led to over a 50-
fold increase in leukotriene production [169].  It is well-established that two human MBOATs 
(MBOAT 5 and MBOAT 7) preferentially utilise arachidonyl-CoA as an acyl donor [93, 170].   
Previous studies have also shown that MBOAT5 (or LPCAT 3) has the most specificity for lyso-PC 
as an acyl receptor followed by lyso-PS and then lyso-PE.  It has therefore been suggested that 
MBOAT5 has an important role in incorporating arachidonyl acid into lyso-PC, -PS and -PE [169].  
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The second identified human MBOAT using arachidonyl-CoA, MBOAT 7 (or lyso-PI 
acyltransferase 1 (LPIAT1)) has been reported to have a far more limited substrate specificity for 
lyso-PI [170].  Whilst these observations have been reported in human neutrophils, it remains 
to be determined whether they are applicable to human platelets [165].  Furthermore, the role 
of these enzymatic pathways in the generation of eoxPL in platelets and neutrophils is currently 
unknown.      
1.5 Bleeding disorders  
Inherited bleeding disorders can be broadly sub-divided according to defects in primary 
haemostasis, secondary haemostasis or fibrinolysis.  Often, the nature and presentation of 
bleeding may suggest an underlying cause which can be confirmed with specific laboratory 
investigations.  Mucocutaneous bleeding, for example is well recognised as a characteristic 
feature of primary haemostatic disorders prompting laboratory investigations for Von 
Willebrand Disease or platelet function tests [171].  
The multifunctional role of platelets provides many opportunities for an abnormality to 
manifest.  These include (i) disorders of platelet adhesion e.g. Bernard Soulier Syndrome 
characterised by a defect or deficiency of GP Ib-V-IX complex (ii) aggregation defects e.g. 
Glanzmann’s thrombasthenia due to abnormal or reduced amounts of the GP IIb/IIIa receptor 
and (iii) secretion disorders including signal processing defects and storage pool disorders.  In 
addition, platelet receptors for the soluble agonists may be defective or specific abnormalities 
may occur in arachidonic acid metabolism, for example due to cyclo-oxygenase or thromboxane 
synthase deficiency.  Several genetic defects associated with the platelet cytoskeleton such as 
the MYH-9 and Wiskott-Aldrich syndrome disorders have been characterised [172-174]. 
Clinical suspicion of a secondary haemostatic disorder is confirmed by a reduction in one or more 
coagulation factors.  Of the inherited bleeding disorders, the most prevalent are Haemophilia A 
and B caused by deficiency in Factor VIII and IX respectively.  Patients with severe haemophilia 
display a spectrum of haemorrhagic manifestations including spontaneous intra-articular 
bleeds.  Generally, the severity of bleeding symptoms correlates with a decrease in the 
coagulation factor level, although it is recognised that this is not entirely applicable to Factor XI 
deficiency [175].  Disorders of fibrinolysis are typically characterised by delayed or late-onset 
bleeding, but diagnosis is compromised by the lack of high-quality diagnostic tests.  They are 
unusual in that both haemorrhage and thrombosis may occur for example in deficiencies of the 
fibrinolytic inhibitors such as PAI-1 [176]. 
The standard tests of primary and secondary haemostasis are often normal in bleeding disorders 
associated with vascular abnormalities such as hereditary haemorrhagic telangiectasia and 
collagen disorders for example Ehlers Danlos syndrome.  Clinical manifestations of these 
disorders are usually identifiable however and can be confirmed with genetic testing [177, 178].  
Defects of platelet procoagulant activity may also have no demonstrable abnormality when 
investigated with standard platelet function tests or coagulation factor assays.  Historically, the 
prothrombin consumption index (PCI), was used as a measure of the availability of platelet 
membrane phospholipid in coagulation.  This laboratory test compares the ability of serum and 
plasma to form a clot by measuring the conversion of prothrombin to thrombin [179].  Scott 
syndrome is a well described although exceptionally rare inherited disorder of platelet 
procoagulant function, characterised by mild to severe bleeding following a haemostatic 
challenge.  In this condition there is a failure of platelets to externalise PS/PE and impaired 
shedding of microvesicles due to defective scramblase activity with causative mutations found 
in the gene encoding TMEM16F [153, 154].  Whether other subtle differences in platelet 
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phospholipid composition or externalisation may contribute to bleeding disorders of unknown 
cause has not previously been investigated.    
 
1.6. Unclassified bleeding disorders 
In a subset of patients with a significant bleeding history, no reproducible abnormality is 
identified despite extensive laboratory testing.  Such cases are defined as unclassified bleeding 
disorder (UBD).  Although the true incidence is unknown, 588 patients in the UK were formally 
registered with UBD in the 2017 and 2018 annual returns and UBD was therefore reported to 
account for 5.3% of rare bleeding disorders [180].  Other reports however suggest that the 
incidence of UBD is significantly higher with such cases representing up to 60% of mild inherited 
bleeding disorders [181].  This discrepancy is likely to result from a lack of standardised criteria 
for diagnosis and the varying number of global assays available to the testing coagulation 
laboratory.  Additionally, it is recognised that the diagnosis of UBD is not clear- cut largely due 
to lack of sensitivity of routine assays to detect abnormalities of fibrinolysis for example, and 
difficulties in the interpretation of mildly abnormal screening tests or platelet aggregation in the 
context of a subtle rather than a severe defect [182, 183].  Furthermore, other potential factors 
such as vessel wall fragility may be contributory.  Although not a new or uncommon clinical 
finding, reports regarding the diagnosis, management and the underlying pathophysiology of 
UBD are extremely scarce.  The ongoing NIHR Bioresource Rare Diseases BRIDGE BPD study was 
the first to investigate this cohort of patients with the aim of identifying the genetic basis of 
unresolved bleeding and platelet diseases by exome-sequencing.  It is reported that testing with 
a gene panel of 87 genes is informative in approximately 3.2% of UBD cases, although not all of 
patients would have been diagnosed using the same criteria [7].  Apart from BRIDGE-BPD, there 
have been only limited attempts to investigate the cause of bleeding in this cohort of patients 
to date.   
The first study to report on the investigation of UBD and the outcomes of management was from 
our Cardiff Haemophilia Centre in 2016 [184].  Currently no standardised diagnostic criteria 
exists, however the initial characterisation of UBD was based upon a positive bleeding history as 
defined by the International Society of Haemostasis and Thrombosis (ISTH) bleeding assessment 
tool and a minimum set of standard coagulation tests: - 
i) ISTH-BAT score ≥4 men, ≥6 women. 
ii) Normal platelet count (150 – 400 x 10 9/l) 
iii) Normal coagulation profile (prothrombin time (PT), activated partial thromboplastin 
time (APTT) and Clauss fibrinogen 
iv) Platelet function studies (PFA-100, platelet aggregation studies and nucleotides (total 
platelet content) 
v) Von Willebrand (VWD) screen (minimum of von Willebrand factor RiCof, VWF antigen) 
vi) Factor assays (VIII, XIII, XI) and IX. 
 
In the above report of 33 UBD patients (28 females and 5 males), the mean age of diagnosis was 
45.2 years (16-83 years).  A family history of bleeding was confirmed in 48% of cases implying a 
heritable cause.  The bleeding scores were significant in that 3 patients had an ISTH-BAT score 
between 16-20 and the remaining patients had a bleeding score between 5-10 (15 patients) and 
11-15 (15 patients).  The mean bleeding score was 9.9 (SD 3.3).  The most common haemorrhagic 
symptoms were menorrhagia (89%), bleeding post-surgery (88%) and bleeding following a 
dental extraction (85%).  Although the mechanism of action is unclear in this group of patients, 
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desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) and tranexamic acid (lysine 
analogue) were effective haemostatic agents.  In 70 out of 78 haemostatic challenges, no 
bleeding was observed using this treatment regimen [184].  
In a recent larger cohort of 124 patients with UBD from the Cambridge Haemophilia Centre, 91% 
of patients were female demonstrating a predominance consistent with the report above.  
Bleeding scores however were lower with the mean score reported as 8.8 (SD 3.8) and then 6.4 
following the deduction of menorrhagia and post-partum haemorrhage using an alternative 
bleeding assessment tool (condensed MCMDM1VWD Bleeding Questionnaire).  This suggests 
that the study population may have had a comparatively milder bleeding phenotype.  Of note, 
the investigators were unable to characterise patients with UBDs using viscoelastic haemostatic 
assays or using thrombin generation assays on platelet poor plasma.  Empirically, tranexamic 
acid and DDAVP were reported to be effective at preventing bleeding in 69 procedures and 13 
deliveries [185].   
DDAVP, a synthetic form of the human hormone L-arginine vasopressin has traditionally been 
used for its anti-diuretic effect via its action on V2 receptors in the renal collecting duct [186].  
The release of VWF from Weibel-Palade bodies is also mediated through V2 receptors on 
endothelial cells and cyclic adenosine monophosphate (AMP) dependent signalling [187].  The 
mechanism for the secondary elevation (approximately 3-fold) of FVIII is not well-defined, 
however has widened the therapeutic use of DDAVP as a haemostatic agent in mild Haemophilia 
A as well as certain sub-types of VWD.  In addition, DDAVP is used in congenital and acquired 
platelet defects, although its precise mode of action is unclear since the VWF and FVIII levels are 
normal in these patients.  It has been proposed that the increased levels of VWF following 
DDAVP administration may enhance platelet adhesion and that the subsequent release of ultra-
large VWF multimers enables this process to occur in conditions of high shear with further 
procoagulant effects from supra-normal levels of FVIII [188].  More latterly, the haemostatic 
effects of DDAVP in platelet function disorders has been attributed to the increased generation 
of COAT platelets demonstrated by enhanced surface expression of PS detected with Annexin 
V.  Furthermore, platelet-dependent thrombin generation was also observed to increase with 
enhanced intracellular sodium and calcium mobilisation proposed as a part of the underlying 
mechanism [51].  It is unknown whether impaired platelet procoagulant activity underpins the 
pathophysiology of UBD or explains the efficacy of DDAVP as a haemostatic agent in UBD.  
 
1.7 Thrombosis 
The clinical manifestations of venous thromboembolism (VTE) include pulmonary embolism (PE) 
and deep vein thrombosis (DVT).  Of these cases, two-thirds are due to DVT most often involving 
the lower extremities, and PE accounts for the remaining third.  VTE is a relatively common 
disease with an annual incidence of 1 in 1000 adults, although the risk increases with advancing 
age with estimates rising up to 7 per 1000 in those aged 70 years or above  [189, 190].  It is 
reported to be the third leading cause of cardiovascular morbidity after ischaemic heart disease 
and stroke [191] and accounts for approximately 500,000 deaths per year in Europe [192].    
Several inherited or acquired prothrombotic risk factors often contribute to a venous thrombotic 
event.  More than one risk factor is typically identified in over two thirds of patients [193].  
Acquired risk factors are by far the most common and include physical factors such as inactivity 
due to recent major surgery, trauma or hospitalisation.  Diseases such as malignancy, 
inflammatory conditions and acquired thrombophilic defects for example antiphospholipid 
syndrome are also associated with VTE as well as hormonal effects including pregnancy and oral 
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contraceptives.  Hereditary thrombophilic defects include factor V Leiden mutation, 
prothrombin G20210A mutation, antithrombin, Protein C and Protein S deficiency [194].  In 
approximately 30% of patients however, a causal risk factor cannot be identified and these 
unexplained cases are classified as idiopathic or unprovoked VTE [195].   
Virchov’s triad proposes that VTE occurs as a result of blood stasis, hypercoagulability and 
vascular endothelial damage [196].  The mechanisms for the formation of deep vein thrombi are 
recognised to differ from that of arterial thrombi.  Post-mortem studies report the characteristic 
red cell-fibrin rich thrombus that forms on an undisrupted endothelium in sinuses near venous 
valves with finely interspersed white lines of platelet-fibrin units commonly referred to as the 
‘lines of Zahn’ [197].  It is hypothesised that the hypoxic micro-environment promoted by blood 
stasis in valve sinuses may down-regulate anti-thrombotic proteins expressed on venous valves, 
namely thrombomodulin and endothelial protein C receptor [198].  Additionally, hypoxia is 
recognised to enhance the expression of P-selectin, potentially on the endothelium, which could 
trigger the recruitment of leucocytes, platelets and other inflammatory cells or microvesicles 
bearing tissue factor.  It is widely accepted that both tissue factor and P-selectin are essential 
for thrombus formation, although their exact source of origin is debatable [198, 199] [200] 
Although platelets have been implicated in the pathophysiology of arterial rather than venous 
thrombosis, there is growing interest in the potential role of platelets in VTE disease.  A recent 
review highlighted the association of VTE with genetic platelet polymorphisms [195].  Of these, 
polymorphisms in the GPIIbIIIa receptor are reported to be the most prevalent occurring in 35% 
of patients with PE (n=51) in one study compared with 14.3% of the control population 
(n=91)[200].  A well-known somatic acquired mutation in the Janus kinase 2 (JAK2) tyrosine 
kinase gene caused by a single amino acid mutation (Val617Phe) is found in up to 60% of patients 
with essential thrombocythaemia [201].  This myeloproliferative neoplasm which is 
characterised by increased clonal production of platelets is associated with a thrombotic risk 
greater than 20% [202].  Interestingly, higher levels of platelet P-selectin before and after agonist 
stimulation have been reported in ET patients compared to healthy controls including platelet-
neutrophil and platelet-monocyte complexes [203].  More recently, higher levels of PS-exposing 
blood cells (platelets, erythrocytes, leucocytes) were demonstrated in JAK2 positive ET patients, 
thus implicating an alternative mechanism for thrombosis [204].  Whilst tumour cells and 
monocytes shed membrane particles rich in tissue factor, the procoagulant function of platelet 
derived microvesicles for example is well-established to be due to exposed PS.  Elevated 
numbers of microvesicles have been associated with VTE, particularly in cancer patients 
compared with healthy controls [205].  It is currently unknown whether increased quantities of 
platelet membrane phospholipid may contribute to the occurrence of idiopathic or unexplained 
venous events.          
 
1.8. Thrombin generation (Calibrated automated tomography) 
The generation of thrombin is critical to clot formation and may therefore be of use in predicting 
an individual’s bleeding or thrombotic risk.  Standard coagulation tests such as the APTT and PT 
do not provide an accurate estimate of thrombin generation occurring in vivo since the end-
point of clot formation is determined when less than 5% of the total thrombin has been 
produced [206].  Original attempts at measuring thrombin generation began in the 1950’s and 
involved triggering coagulation in whole blood or plasma with sub-sampling over a time course 
into tubes containing fibrinogen solution.  The clotting times of the fibrinogen solution were 
used to estimate the thrombin activity derived from calibration against a thrombin standard.  
This method however was considered both time-consuming and inaccurate [207].   
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Subsequent developments involved replacement of the fibrinogen solution with a chromogenic 
substrate.  Measurements of colour change however, were influenced by the free thrombin 
available in addition to thrombin bound to α2-macroglobulin since both can cleave the 
chromogenic substrate.  In contrast, the inhibition of thrombin by antithrombin involves binding 
to the active site of thrombin which renders the complex inactive [208].  An algorithm was 
therefore required to remove the contribution from thrombin bound to α2-macroglobulin.  In 
this assay, the ‘defibrination’ of plasma was necessary to remove the limiting effect of fibrin on 
thrombin-α2-macroglobulin and to prevent turbidity [209].  This process however was 
recognised to significantly influence thrombin activity and the decay process thereby increasing 
experimental error [210].    
A further development was the use of a slowly cleaved fluorogenic substrate, which removed 
the need for the defibrination step since the fluorescent product was not influenced by turbidity.  
Furthermore, this assay could be performed using platelet rich plasma, thus increasing its clinical 
utility [211].  The thrombin concentration could not be directly correlated with the fluorescent 
signal intensity due to substrate consumption and light absorption from other product 
molecules (‘inner-filter effect’) [209].   
The calibrated automated thrombography (CAT) method devised by Hemker et al in 2003, 
circumvents the above by continuous monitoring of the separation of the fluorogenic substrate 
(Z-Gly-Gly-Arg-AMC) in parallel with a reference calibrator substance containing a known 
concentration of thrombin-like enzyme bound to α-2 macroglobulin in a parallel plasma sample 
[210].  Multiple experiments can be performed simultaneously using platelet rich plasma (PRP) 
or platelet poor plasma (PPP) with a trigger (tissue factor, phospholipids) followed by the 
addition of the fluorogenic substrate and calcium chloride.  The thrombin generated cleaves the 
fluorescent substrate releasing a fluorophore.  Measurements based on the velocity of the 
fluorescence increase (dF/dt) are taken from both test and calibrator wells and converted into 
thrombin concentrations (nM) by the Thrombinoscope software using a reference curve 
prepared by measuring the conversion rate of the fluorescent substrate with the calibrator 
substance.  The CAT method utilises an algorithm which corrects for the activity of the α-2 
macroglobulin-thrombin complex [210, 212].   
The typical parameters measured from the thrombin generation curve include:- 
(i) Lag time; the time period measured from the addition of a trigger to the initiation of 
thrombin generation  
(ii) Peak thrombin; the peak height of the curve  
(iii) Velocity index (VI); the peak height/(time to peak-lag time)  
(iv) Endogenous thrombin potential (ETP); the area under the thrombin generation curve 
[206]   
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Figure 1.17 Schematic of a thrombin generation curve using calibrated automated 
tomography (CAT).  The parameters measured include the lag time, the velocity index, the peak 
thrombin and the endogenous thrombin potential.  Adapted from Montgomery et al [213] 
 
Thrombin generation is dependent upon the available phospholipid, TF concentration and the 
source of plasma used.  Currently, no recommendations exist to standardise the phospholipid 
or TF concentrations used in the thrombin generation assay leading to a degree of heterogeneity 
associated with its clinical use.  At low concentrations of phospholipid (0-2 µM), a linear 
correlation of thrombin generation with phospholipid concentration is observed which is 
reported to plateau with concentrations of ≥ 3 µM.  Standard studies performing thrombin 
generation assays with PPP have typically used a saturating concentration of 4 µM of 
phospholipid which makes the assay insensitive to phospholipid.  Assays using PRP have 
generally omitted or used minimal concentrations of phospholipid which is supplied by the 
activated platelets [210, 214].   
Most thrombin generation studies use concentrations of TF in the range of 3-6 pM 
(corresponding to 1/2000-1/1000 final dilution of recombiplastin) which are generally 
considered to be ‘physiologically relevant’ [207, 214].  It is observed that high concentrations of 
TF favours activation of the extrinsic pathway (Factor VII, Factor X) and overwhelms the effect 
of TFPI whereas lower quantities render the reaction more sensitive to deficiencies of the 
intrinsic pathway (Factor VIII, IX, XI) because TFPI inactivates the extrinsic pathway [215, 216].  
For example, thrombin generation assays assessing the efficacy of replacement therapy in 
patients with haemophilia A and B, have used concentrations of TF ≤ 1 pM [217, 218].  Similarly, 
in Factor XI deficient patients the bleeding risk has been shown to correlate with thrombin 
generation using a trigger of only 0.5 pM TF [219] [220, 221].   
Although most studies report the final concentration of TF in the thrombin generation assay, 
this information does not necessarily give information on TF function which is also dependent 
on the phospholipid membrane in which the TF is held. Therefore, to control the characteristics 
of the assay the TF concentration and the phospholipid environment need to be known and 
adjusted.   
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The requirement for the addition of corn trypsin inhibitor (CTI) at the point of blood collection 
has previously been debated.  CTI suppresses activation of the contact pathway of coagulation 
by inhibiting Factor XIIa [222-224].  It has therefore been advocated that the addition of CTI is 
important when attempting to study the sole effect of the intrinsic tenase complex.  It is usually 
recommended that CTI should be used in thrombin generation assays using triggers with low TF 
concentrations (≤ 1 pM) [220] [223].   
 
1.9. Mass spectrometry analysis of platelet phospholipids 
Both native and oxidised phospholipids described in this thesis were identified and quantified 
using mass spectrometry methods.  For over five decades, MS has been an important tool in the 
field of lipidomics.  Recent developments in the technique have enabled in-depth structural 
analysis of specific lipid species with respect to fatty acid side chain, back-bone and head-group 
[225].  
Liquid chromatography (LC) is used to separate lipids prior to MS analysis based on their 
lipophilicity.  Under high pressure, the lipid sample is injected into a mobile phase (water/polar 
solvent) which passes through an LC column containing the stationary phase, at a specific flow 
rate.  Depending on the chemical interaction with the mobile and stationary phases, the lipids 
will elute from the column with varying retention times.  The LC/MS/MS used in this thesis was 
the hybrid quadropole tandem mass spectrometer (ABI 4000 Q trap), thus enabling targeted 
and quantitative lipid analysis. 
The fundamental principle of MS relies on the measurement of the mass-to-charge ratio (m/z) 
of a charged molecule.  The advent of electrospray ionisation (ESI) in 1988 - widely referred to 
as ‘soft ionisation’ – has enabled the formation of intact gas-phase ions from liquid-phase 
molecules with minimal disintegration.  This technique involves introducing the liquid analyte 
into the electrospray chamber through a hypodermic needle maintained at a high voltage.  The 
small, charged droplets produced undergo a desolvation process and pass through a high 
vacuum, during which the neutral solvent-molecules are removed [226].  Depending on the 
ionisation mode selected, the positively [M+H] + or negatively [M-H]- charged ions pass through 
a linear series of three quadropoles.  Each quadropole consists of four equidistant parallel rods 
through which an oscillating electric field is applied.  The first quadropole (Q1), acts as a mass 
filter which is pre-set to separate ions based on the m/z of interest.  The precursor or parent 
ions are then transmitted to a middle quadropole (Q2) where a neutral gas such as nitrogen, 
helium or argon is used to induce multiple collisions (collision-induced decompensation) 
resulting in fragmentation.  Fragmented or daughter ions pass to the second mass filter (Q3) 
which is set to scan across a range of m/z ratios.  In this way, it is possible for corresponding 
parent and daughter ions of specified m/z to be scanned through to the detector [147].  
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Figure 1.18 Triple quadrupole/tandem MS Parent ions of interest are selected in Q1.  They are 
fragmented in Q2 and the daughter ions of a fixed mass charge (m/z) are selected and scanned 
in Q3.  Adapted from O’Donnell et al. [147] 
 
An LC/MS/MS method for identification and quantification of externalised PE and PS was 
previously developed[153].  This can be used for the measurement of externalised APL on 
apoptotic or other cells, for example thrombin-activated platelets.  The approach is based on 
the use of a cell- impermeable biotinylation reagent (EZ-Link Sulfo-NHS-Biotin) used widely in 
proteomics for the labelling of primary amines (NH2).  Using this, the externally facing 
headgroups of PE and PS are biotinylated on the primary amine headgroup.  This method has 
led to the finding that human platelets externalise 5 species of PE and 3 species of PS upon 
agonist activation.  A mass shift of 226 a.m.u. enables distinction of the biotinylated lipid from 
the corresponding native derivative[153].   
LC/MS/MS analysis of HETEs, the oxidised metabolites of arachidonic acid is well established 
[225, 227].  A characteristic fragmentation pattern unique to 12-HETE can be used for the 
identification of oxidised phospholipids since the 12-HETE functional group is incorporated into 
their molecular structure.  The parent ion of 12-HETE has a m/z of 319.2 corresponding to the 
[M-H]- ion which is formed by soft ionisation.  Following fragmentation, the most abundant 
daughter ion of 12-HETE is observed at m/z 179.2 [227].  The six molecular species of 12-HETE-
PL generated by activated platelets can be identified and quantified using HETE positional 
isomers and internal standards run in parallel under the same conditions.   
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Figure 1.19 Fragmentation pattern of 12-HETE.  The parent ion is produced in the ion source 
by ‘soft ionisation’.  The removal of a proton during this process generates the [M-H] - ion 
which has a m/z of 319.2.  Following fragmentation in Q2, several daughter ions are produced, 
the most abundant of which has a m/z of 179.2.  Adapted from Murphy et al [225]   
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1.10 Hypothesis and aims 
Whilst it is known that the lipid composition of the platelet membrane is essential for effective 
coagulation, its molecular composition in health and disease has not been fully investigated.  
Previous research has identified novel oxidised lipids that are generated by activated human 
platelets and demonstrated that they promote coagulation in vitro and in vivo.  Similarly, PE/PS 
species have been characterised that are externalised by human platelets following agonist 
activation.  It is unknown whether platelet phospholipids and externalised phospholipids in 
patients with bleeding or thrombotic disorders of unknown cause differ from healthy controls, 
potentially contributing to the clinical phenotype.  Methods of measuring platelet phospholipids 
using LC/MS/MS will enable their identification and quantification.   
1.10.1 Hypothesis 
Phospholipids that are generated and externalised by activated human platelets may differ in 
UBDs and acute DVT of unknown cause compared to healthy controls.  It is hypothesised that 
increased quantities of native PL and/or higher generation of eoxPL may be found in acute 
thrombosis, whilst their deficiency may contribute to the bleeding phenotype of patients with 
UBD.   
1.10.2. Aims 
To investigate whether there are quantitative differences in externally facing non-oxidized PE 
and PS molecular species in the platelet membrane before and after activation in platelets from 
patients with UBD, DVT and healthy controls.   
To determine whether there are differences in the enzymatic generation of 12-HETE-PLs in 
patient and control platelets before and after agonist activation.  
To investigate the ability of platelets and microvesicles from healthy controls and patients to 
support coagulation ex-vivo as measured by thrombin generation. 
To investigate the effect of the haemostatic agent DDAVP on the thrombin generation and 
phospholipid composition of the platelet membrane in patients with UBD. 
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Chapter 2-Materials and Methods 
 
2.1. Study participants 
Participating individuals were recruited into one of four groups: 
1) UBD 
2) Acute DVT 
3) Healthy controls 
4) UBD receiving DDAVP as a haemostatic agent prior to a minor or major surgical 
procedure  
Informed consent was obtained from all participants and the study received approval from the 
Central London Medical Ethics Committee (16/LO/1168).  Research and Developmental (R&D) 
approval was obtained from Cardiff and Vale University Health Board.  The study was adopted 
on to the UK National Research Portfolio. 
 
2.2 Criteria for study participation 
Inclusion criteria for study participation were age 18 years or over, an established diagnosis of 
UBD or an acute episode of DVT.  In addition, patients diagnosed with UBD who were undergoing 
either a minor or major surgical procedure and required haemostatic cover with DDAVP (0.3 
µg/kg) were also included.  Exclusion criteria were pregnancy, inability to consent to the study 
and treatment with non-steroidal anti-inflammatory drugs < 72 hours prior to recruitment or 
ingestion of aspirin or other antiplatelet medication within the preceding 10-14 days.  Healthy 
controls were excluded if they had a bleeding disorder or a previous arterial or venous 
thrombotic event.   
 
Table 2.1. Criteria for UBD 
 
Significant bleeding history  
Male:     ISTH BAT > 4 
Female: ISTH BAT > 6 
Platelet count within range (150–400 × 109/L) 
Normal prothrombin time (PT)/Activated partial thromboplastin time 
(APTT)/fibrinogen 
Normal PFA‐100, platelet aggregation studies and nucleotides 
Normal von Willebrand screen (VWF: RiCoF, VWF: antigen) 
Normal factor assays (VIII, XIII, XI and IX) 
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Table 2.2 Criteria for acute DVT 
 
Criteria for acute DVT 
Positive doppler ultrasound for DVT in one of the following locations within 
24hrs of diagnosis: 
 
Below knee (distal): 
Peroneal vein 
Tibial vein 
Gastrocnemius 
Soleal 
 
Above knee (proximal): 
Popliteal vein 
Common femoral vein 
Femoral vein 
Superficial femoral vein 
Ileo-femoral vein 
 
 
2.3 Demographic data  
For all study participants age and gender was recorded.  Additional information was collected 
from hospital notes and clinical computer records for patients.  For UBD patients this included 
the International Society of Thrombosis and Haemostasis (ISTH) bleeding score, presence or 
absence of a family history of bleeding, response to previous haemostatic treatment, current 
medication and results of prior tests of haemostasis.  For UBD patients undergoing a surgical 
intervention requiring haemostatic cover with DDAVP, the nature of the procedure and the 
response to treatment was also recorded.  For patients with DVT, details regarding the site of 
thrombosis, presence of risk factors (e.g. immobility, pregnancy, surgery), family history of 
thrombosis, current medication and routine blood tests were obtained.  The proformas used to 
collect data from patients with UBD and venous thrombosis are shown in Appendix 1.   
 
2.4 Details of patient recruitment of bleeding and thrombotic disorders  
Patients with UBD were already known to the Cardiff Haemophilia Centre and were diagnosed 
based upon the criteria described above. 
Patients with acute DVT were recruited on the day of confirmation of a thrombus in a deep vein 
of the lower extremities by Doppler ultrasound.  
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2.5 Isolation of washed platelets for thrombin generation and phospholipid analysis 
The following buffer solutions were prepared prior to blood draw: 
1) Acidified citrate dextrose (ACD)  
 85 mM trisodium citrate, 65 mM citric acid, 100 mM glucose, dissolved in distilled water and 
pH adjusted to 5.0 
2) Tyrode’s buffer      
134 mM sodium chloride, 12 mM sodium bicarbonate, 2.9 mM potassium chloride, 0.34 mM 
disodium phosphate, 1 mM magnesium chloride, 10 mM HEPES, 5 mM glucose, dissolved in 
distilled water and pH adjusted to 7.4  
Method: 
To perform the planned analyses, a total of 70 ml of blood was obtained from study participants.  
Blood donations were taken via venepuncture into an antecubital vein using a wide bore 
butterfly needle (21-gauge) attached to a syringe.  To minimise the risk of platelet activation, 
vacutainers were not used for blood collection and the tourniquet was released upon blood 
draw.  A constant room temperature of 20-22 0 C was maintained for the isolation steps to 
further minimise the risk of spontaneous aggregation.    
To obtain washed platelets for thrombin generation, approximately 10.1 ml of whole blood was 
taken into two 20 ml syringes each containing 2.4 ml of ACD (ratio of blood: ACD 8.1:1.9, v/v).  
The blood was separated into two 15 ml falcon tubes, followed by centrifugation at 430 x g for 
10 minutes at room temperature (20-22 0 C) with no brake.  The platelet rich plasma (PRP) was 
aspirated and divided equally into 15 ml falcon tubes and centrifuged at 1640 x g with the brake 
mechanism off for 10 minutes at room temperature.  The platelet poor plasma (PPP) was 
transferred into a clean falcon tube and the remaining platelet pellet was resuspended in 10 ml 
of calcium - free Tyrode’s buffer containing ACD (9:1 v/v).  The resuspended platelets and the 
PPP were spun again at 1,525 x g for 8 minutes at room temperature with the brake mechanism 
off.  The supernatant was discarded, and the platelet pellet was resuspended in 1 ml of pooled 
PPP.  The PPP was collected following the centrifugation process to generate microvesicles.   
For the isolation of washed platelets for phospholipid extraction, 16.2 ml of blood was taken 
into three 20 ml syringes, each containing 3.8 ml of ACD.  The blood containing ACD from each 
syringe was separated into two 15 ml falcon tubes and underwent the same centrifugation steps 
described above to obtain PPP and the platelet pellet was resuspended in 5 ml of Tyrode’s 
buffer.  The platelets were left to rest for up to 30 minutes before the activation process.   
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2.6 Platelet concentration       
The platelet concentration was determined by performing a 1: 100 dilution in Tyrode’s buffer/ 
Tryptan blue solution (445 µl Tyrode’s buffer, 50 µl Trypan Blue solution, 5 µl platelets).  10 µl 
of the suspension was pipetted into the chamber of a Neubauer haemocytometer containing 25 
grid squares. The platelet concentration was calculated by counting the total number of platelets 
in the 4 outer squares and the central square (each large square contains 16 smaller squares and 
has a total area of 1 mm2).  The following equation was applied:  
        Platelet concentration = [(number of platelets counted/number of squares counted) x 25] 
                                                    x 100 (dilution factor) x 104 x volume of suspension (ml). 
For the purposes of thrombin generation, washed platelets were suspended in 1 ml of pooled 
PPP and diluted to 1.5 x 10 8/ml with pooled PPP.  For phospholipid analysis, a platelet 
concentration of 2 x 10 8/ml was used by diluting the 5 ml platelet suspension with further 
Tyrode’s buffer as necessary.      
 
2.7 Preparation of microvesicles 
Micovesicles were generated from PPP collected after the centrifugation steps described above.  
1 ml of PPP was collected into a 1.5 ml Eppendorf tube and centrifuged at 16,060 x g for 30 
minutes.  750 µl of supernatant was removed and the sample was re-suspended up to 1 ml with 
Tyrode’s buffer before a further centrifugation step (16,000 x g for 30 minutes).  After removal 
of the supernatant, the resultant pellet was resuspended in 250 µl of pooled PPP and used in 
the thrombin generation assay.  
 
2.8 Preparation of pooled PPP  
Pooled PPP was prepared for the resuspension and/or dilution of the washed platelets and 
microvesicles used in the thrombin generation assay.  Blood was collected from sixteen 
healthy volunteers, all of whom were free from anti-platelet and non-steroidal anti-
inflammatory medication for 14 days.  Approximately 36 ml of blood from each donor was 
drawn into a syringe containing sodium citrate and corn trypsin inhibitor (CTI) (Haematologic 
Technologic, UK) to yield a total volume of 40 ml of 0.32 % citrated blood with 0.59 U/ml of CTI 
activity.  The blood from each syringe was transferred to 2 x 50 ml falcon tubes for each donor.  
The samples were centrifuged at 460 x g at room temperature with the brake mechanism 
turned off for 10 minutes.  The resultant platelet rich plasma was collected into 2 x 15 ml 
falcon tubes for each donor and centrifuged at 1730 x g for 10 minutes with no brake.  The 
plasma was pipetted into clean 2 x 15 ml falcon tubes and spun a final time at 1730 x g for 10 
minutes with the same conditions applied.  Finally, the plasma was mixed thoroughly in a 
sterile conical flask before being distributed into 1 ml aliquots and stored at – 80 0 C.   
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2.9 Platelet activation    
For lipid extraction experiments, 1 ml of washed platelets at a concentration of 2 x 10 8/ml in 
Tyrode’s buffer was aliquoted into 1.5 ml Eppendorf tubes.  To activated samples, 1 mM calcium 
chloride was added before incubation at 37 0 C for 5 minutes with gentle mixing.  The platelets 
were then activated with 0.2 units/ml thrombin (Sigma Aldrich, UK) and incubated at 37 0 C for 
a further 30 minutes prior to lipid extraction.  
 
2.10 Biotinylation of externalised APL and total lipids 
The following reagents were prepared in advance:  
1) 5 mg/mL EZ-Link Sulfo-NHS-Biotin (11 mM) (Thermo-Fisher Scientific, UK) dissolved in 
Tyrode’s buffer. 
2) 0.04 g/mL Lysine (250 mM) (Sigma-Aldrich, UK) dissolved in Tyrode’s buffer. 
3) 6.83 mg/mL N-Hydroxysuccinimide (NHS) biotin (20 mM) (Thermo-Fisher Scientific, UK) 
dissolved in DMSO. 
Method: 
Following thrombin activation, 200 µl of activated and unactivated platelets were separately 
aliquoted into 1.5 ml eppendorf tubes.  For the biotinylation of externalised APL (PE and PS), 86 
µl of EZ-Link sulfo-NHS biotin was added to half of the samples and left at room temperature for 
10 minutes with gentle occasional inversion.  72 µl of lysine was then added as a quenching 
agent, and the samples were again left for a further 10 minutes.  At the end of the incubation 
period, 42 µl of Tyrode’s buffer was pipetted into each sample to give a total volume of 400 µl. 
 
 
Figure 2.1 Biotinylation of externally facing APL with Sulfo-NHS-Biotin reagent.  Image 
modified from Thomas et al [153] 
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To the remaining half of samples, the cell permeable analogue NHS-biotin was added for the 
biotinylation of total lipids.  20 µl of 20 mM NHS-Biotin was added to the samples and they were 
incubated at 20°C for 10 minutes.  180 µl of Tyrode’s buffer was then added to achieve a final 
volume of 400 µl.  Externalised APL could then be calculated as a fraction of the total to give a 
percentage.    
 
2.11 Lipid extraction  
Externalised APL and total lipids 
10 ng of biotinylated standards 1,2-dimyristoyl-sn-glycero3-PS (DMPS) and 1,2-dimyristoyl-sn-
glycero-3-PE (DMPE) were added to each glass extraction tube containing 1.5 ml of solvent 
mixture (chloroform: methanol 1:2).  400 µl of the platelet sample was transferred into each 
extraction tube to obtain a 1: 3.75 ratio of aqueous sample: solvent mix.  The mixture was 
vortexed thoroughly (1 minute / sample) after which 0.5 ml of chloroform was added with 
further vortexing.  Lastly, 0.5 ml of HPLC – grade water was added, and the samples were 
vortexed thoroughly.  The samples were then centrifuged for 5 minutes at 500 x g at 20 - 22 0 C.  
The lower layer was collected with a glass Pasteur pipette, taking care to avoid contamination 
with the upper layer by applying gentle positive pressure.  Following transfer to a clean glass 
extraction tube the samples were dried at 30 0C in a Rapidvap evaporation system and 
resuspended in 100 µl of methanol prior to storage at -80 0 C.   
  
To identify biotinylated PE and PS species, lipid extracts were analysed on an AB Sciex 4000 Q-
Trap mass spectrometer using an Ascentis C18 column (5 µm, 150 × 2.1 mm, Sigma-Aldrich) and 
an isocratic mobile phase consisting of methanol with 0.2% (wt/vol) ammonium acetate at a 
flow rate of 400 µl min−1.  These conditions were maintained for 25 minutes per sample.  20 µl 
of lipid extract from each sample was injected onto the HPLC column and biotinylated multiple 
reaction monitoring (MRM) transitions (parent to daughter ion) were monitored in negative ion 
mode as described in Table 2.3.  Biotinylated PE was monitored by the formation of the daughter 
ion (Sn2 carboxylate anion).  A neutral loss of 313 a.m.u. representing the biotinylated serine 
head-group was used to identify the biotinylated PS species of interest.  The collision energies 
and declustering potential for each analyte are also outlined in Table 2.3. 
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Table 2.3 Analyte and mass transition conditions for biotinylated lipids 
 
Biotinylated 
Analyte 
Biotinylated 
MRM Transition 
[M-H]- 
Declustering 
Potential (V) 
Collision 
Energy (V) 
Collision cell 
potential 
(volts) 
DMPE-B 
(14:0/14:0-PE) 
860/227 -135 -60 -13 
SpAPE-B 
(18:0p/20:4-PE) 
976/303 -160 -60 -5 
SAPE-B 
(18:0a/20:4-PE) 
992/303 -170 -58 -5 
PpAPE-B 
(16:0p/20:4-PE) 
948/303 -160 -60 -5 
SOPE-B 
(18:0a/18:1-PE) 
970/281 -170 -58 -5 
OpAPE-B 
(18:1p/20:4-PE) 
974/303 -160 -60 -5 
DMPS-B  
(14:0/14:0-PS) 
904/591 -150 -42 -17 
SOPS-B 
(18:0a/18:1-PS) 
1014/701 -140 -44 -23 
DOPS-B 
 (18:1a/18:1-PS) 
1012/699 -150 -46 -23 
SAPS-B  
(18:0a/20:4-PS 
1036/723 -145 -42 -23 
 
 
2.12 Synthesis of biotinylated standards 
To quantify externalised APL (PE/PS), the following lipid standards were purchased from Avanti 
Polar Lipids: 
1,2-Dimyristoyl-sn-glycero-3-PS (DMPS; 14:0/14:0-PS) 
1,2-Dioleoyl-sn-glycero-3-PS (DOPS; 18:1a/18:1-PS) 
1-Stearoyl-2-oleoyl-sn-glycero-3-PS (SOPS; 18:0a/18:1-PS) 
1-Stearoyl-2-arachidonoyl-sn-glycero-PS (SAPS; 18:0a/20:4-PS) 
1,2-Dimyristoyl-sn-glycero-3-PE (DMPE; 14:0/14:0-PE) 
1-(1Z-stearoyl)-2-arachidonoyl-sn-glycero-3-PE (SpAPE; 18:0p/20:4-PE) 
1-stearoyl-2-arachidonoyl-sn-glycero-3-PE (SAPE; 18:0a/20:4-PE) 
1-stearoyl-2-oleoyl-sn-glycero-3-PE (SOPE; 18:0a/18:1-PE) 
To synthesise the biotinylated standards, 1 mg of each lipid was added to a 1.5 ml glass vial and 
evaporated to dryness under a nitrogen stream.  220 µl of chloroform and 110 µl of methanol 
were then added and the solvent mixture vortexed.  6 mg of NHS-Biotin was weighed and 
transferred to the vial with further vortexing.  3.3 µl of triethylamine was added to the solvent 
mixture which was then incubated at room temperature for 30 minutes.  The sediment of the 
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excess NHS-Biotin was removed following centrifugation at 500 x g for 5 minutes at 20 0C.  The 
resultant solvent was carefully transferred to a clean glass vial and a further 220 µl of chloroform 
and 110 µl of methanol were added to the original vial containing the NHS biotin sediment.  The 
solvent mixture was vortexed thoroughly and the centrifugation step repeated.  The solvent 
fractions were finally combined and pipetted into a clean pre-weighed glass vial.  The sample 
was then evaporated to dryness under a nitrogen stream and the vial was re-weighed.  The 
difference was calculated and used to quantify the amount of lipid in the vial prior to 
resuspension in methanol.  The standards were stored at -80 0 C. 
The biotinylated standards were purified using reverse-phase HPLC on a Discovery C18 column 
(25 cm x 4.6 mm, 5 µm).  The mobile phase consisted of 5 mM ammonium acetate in water 
(mobile phase A) and 5 mM ammonium acetate in methanol (mobile phase B).  The flow rate 
used was 1 ml/minute.  Initially, 50 % of mobile phase B was increased to 100 % over 15 minutes 
and then maintained at 100% for 20 minutes before re-equilibration to 50 %.  The UV absorbance 
was measured at 205 nm.  The biotinylated lipid standards were dried by evaporation under a 
nitrogen stream, weighed and reconstituted in methanol.   
 
2.13 Quantification of biotinylated phospholipids 
To quantify each biotinylated lipid, standard curves were produced by varying the concentration 
of the analyte standard with the addition of a fixed amount of the internal standard.  
Biotinylated internal standards (DMPE-B and DMPS-B) were each diluted to a concentration of 
0.02 ng/µl.  The synthesised analyte standards (SpAPE-B, SAPE-B, SOPE-B, DOPS-B, SAPS-B, 
SOPS-B) were mixed with methanol so each had a concentration of 2 ng/µl.  The analyte mix was 
then serially diluted as shown in Table 2.4.  Finally, 100 µl of each dilution of analyte mix was 
added to 100 µl of internal standard.  The standard curve was then analysed using LC/MS/MS.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
  
Table 2.4 Dilution method of standard curve analytes used for biotinylated lipids 
 
Dilution 
sample 
Dilution method Concentration 
of each 
analyte 
standard 
Final 
concentration 
after adding 
internal 
standard 
Amount on 
column 
(final) 
1. 
 
Undiluted analyte mixture 2 ng/µl 1 ng/µl 10 ng 
2. 150 µl of (1) with 150 µl 
of Methanol 
1 ng/µl 0.5 ng/µl 5 ng 
3. 60 µl of (2) with 240 µl of 
Methanol 
0.2 ng/µl 0.1 ng/µl 1 ng 
4. 150 µl of (3) with 150 µl 
of Methanol 
0.1 ng/µl 50 pg/µl 500 pg 
5. 60 µl of (4) with 240 µl of 
Methanol 
20 pg/µl 10 pg/µl 100 pg 
6. 150 µl of (5) with 150 µl 
of Methanol 
10 pg/µl 5 pg/µl 50 pg 
7. 60 µl of (6) with 240 µl of 
Methanol 
2 pg/µl 1 pg/µl 10 pg 
8. 150 µl of (7) with 150 µl 
of Methanol 
0.5 pg/µl 0.5 pg/µl 5 pg 
9. 60 µl of (8) with 240 µl of 
Methanol 
0.2 pg/µl 0.1 pg/µl 1 pg 
 
 
Standard curves were constructed by integrating the peak area measured in counts per second 
(c.p.s.) for each biotinylated lipid.  The peak area of each analyte was divided by the peak area 
of the biotinylated internal standard of the corresponding lipid species to obtain a ratio e.g. 
SpAPE-B /DMPE-B, DOPS-B/DMPS-B.  Similarly, the ratio of analyte (A) to internal standard (IS) 
was calculated for nanogram (ng) amounts of lipid in each standard vial.  Finally, the ratios of 
A:IS (cps) and A:IS (ng) were plotted against each other and a gradient was calculated for each 
analyte.  The amount of internal standard (I ng) added in all cases was 10ng.  The following 
equation was applied to determine the nanograms of lipid in each sample: 
Ang      = (Acps/IScps) x (Ing/gradient of the standard curve) 
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Where analyte standards were not commercially available (PpAPE and OpAPE), the standard 
curve of the most structurally related biotinylated lipid was used for quantification (i.e. SpAPE-
B).  
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Example of a standard curve generated for quantification of the biotinylated 
analyte SpAPE-B.  The ratio of the analyte (A): internal standard (IS) peak area in counts per 
second (cps) is plotted on the y axis.  The concentration ratio of analyte (A): internal standard 
(IS) is shown on the x axis, which in this example is measured in picograms (pg).  The gradient of 
the standard curve was 0.5892. 
 
2.14 Lipid extraction 
Esterified 12-HETE-PLs 
Prior to extraction, 10 ng each of 1,2-Dimyristoyl-sn-glycero-3-PE (DMPE) and 1,2-distearoyl-sn-
glycero-3-phosphocholine (DMPC) were added to 2.5mls of extraction solvent (hexane: 
isopropanalol: 1M Acetic acid (30:20:2)).  1 ml of platelets at a concentration of 2 x 108 /ml was 
added to each extraction tube and vortexed (1 minute/tube) followed by the addition of 2.5 ml 
of hexane.  After further mixing, the tubes were centrifuged at 1500 rpm for 5 minutes at 40 C.  
The upper layer was recovered before a further 2.5 ml of hexane was added to the original 
extraction tube and the extraction cycle was repeated.  The resultant upper layers were 
combined and dried in a Rapidvap evaporation system.  The samples were then resuspended in 
200 µl of methanol and stored at – 80 0 C prior to analysis with LC/MS/MS.     
Lipid extracts were separated on an Accucore C30 2.6 µm, 100 x 3 mm column 
(ThermoScientific) with a gradient of 50-100 % B over 10 minutes, followed by an increase to 
100 % B for 30 minutes before re-equilibration to 50:50 A: B for a further 10 minutes [A, 20 % 
acetonitrile: 80 % water: 5 mM ammonium acetate: 0.1 % glacial acetic acid; B, 30 % 
acetonitrile: 70 % isopropanol: 5 mM ammonium acetate: 0.1 % glacial acetic acid].  The flow 
rate used was 0.2 ml/min.   
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20 µl from each sample was injected onto the column and analysed by MS/MS in negative mode 
using MRM transitions of the parent – daughter ion (m/z 179.2) specific for the 12-HETE 
positional isomer (this is for an internal daughter ion from the 319 product ion) as specified in 
Table 2.5.  
 
Table 2.5 Instrument settings and precursor to product mass transitions for oxidised PL 
 
Analyte MRM transition Declustering 
Potential 
(volts) 
Collision Energy 
(volts) 
Collision cell 
potential 
(volts) 
PE(18:0a_12-HETE) 782.6 → 179.2 -140 -50 -10 
PC(16:0a_12-HETE) 782.6 → 179.2 -140 -50 -10 
PC(18:0a_12-HETE) 810.9 → 179.2 -140 -50 -10 
PE(18:0p_12-HETE) 766.6 → 179.2 -140 -50 -10 
PE(18:1p_12-HETE) 764.6 →179.2 -140 -50 -10 
PE(16:0p_12-HETE) 738.6 →179.2 -140 -50 -10 
DMPE 634.5 → 227.2 -140 -50 -10 
DMPC 662.5 → 227.2 -140 -50 -10 
 
2.15 Quantification of eoxPL 
The six molecular species of 12-HETE PL listed in Table 2.5 were quantitated using standard 
curves.  This was generated by using a fixed quantity of an internal standard solution consisting 
of DMPE and DMPC, and serial dilutions of the analyte standards PE(18:0a_12-HETE) and 
PC(18:0_12-HETE).  The oxidised lipid standards were synthesised in-house and provided by Dr 
Victoria Tyrell.   
To prepare the internal standard mixture, DMPE and DMPC stocks were each diluted in 
methanol to a concentration of 0.02 ng/µl.  The analyte standards PE(18:0a_12-HETE) and 
PC(18:0a_12-HETE) were also diluted in methanol so that each had a concentration of 2 ng/µl.  
The analyte mix was serially diluted as shown below.  Lastly, 100 µl of analyte mix was added to 
100 µl of the internal standard solution to produce the final concentration. 
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Table 2.6 Dilution method of standard curve analytes used for oxidised PL 
 
 
      
The standard curve was then analysed using LC/MS/MS and monitored using precursor to 
product transitions listed in Table 2.5.  The oxidised phospholipids were quantified in the same 
manner as described in Section 2.13.  Following integration of the peak area of each lipid, the 
ratio of analyte to internal standard was calculated in counts per second and then for ng 
amounts of lipid.  A standard curve was generated from plotting the two ratios against each 
other such that the amount of lipid in each sample can be calculated from the gradient.  A peak 
was only integrated if it was at least 3 times the height of the baseline noise (signal: noise ratio) 
otherwise it was considered below the limit of detection. 
 
 
 
 
 
 
 
  
Dilution 
sample 
Dilution method Concentration 
of each 
analyte 
standard 
Final 
concentration 
after adding 
internal 
standard 
Amount on 
column 
(final) 
1. 
 
Undiluted analyte 
mixture 
2 ng/µl 1 ng/µl 10 ng 
2. 150 µl of (1) with 150 µl 
of Methanol 
1 ng/µl 0.5 ng/µl 5 ng 
3. 60 µl of (2) with 240 µl 
of Methanol 
0.2 ng/µl 0.1 ng/µl 1 ng 
4. 150 µl of (3) with 150 µl 
of Methanol 
0.1 ng/µl 50 pg/µl 500 pg 
5. 60 µl of (4) with 240 µl 
of Methanol 
20 pg/µl 10 pg/µl 100 pg 
6. 150 µl of (5) with 150 µl 
of Methanol 
10 pg/µl 5 pg/µl 50 pg 
7. 60 µl of (6) with 240 µl 
of Methanol 
2 pg/µl 1 pg/µl 10 pg 
8. 150 µl of (7) with 150 µl 
of Methanol 
0.5 pg/µl 0.5 pg/µl 5 pg 
9. 60 µl of (8) with 240 µl 
of Methanol 
0.2 pg/µl 0.1 pg/µl 1 pg 
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2.16 Thrombin generation using calibrated automated tomography (CAT) 
All phospholipids used in the assay were purchased from Avanti Polar Lipids (Alabaster, 
Alabama, USA).  The following buffers were prepared: 
Liposome buffer.  
20 mM HEPES, 100 mM NaCl, dissolved in distilled water and pH adjusted to 7.35. 
Fluo-buffer.  
20 mM HEPES, 0.6% BSA, 0.02 % sodium azide, dissolved in distilled water. 
 
2.17 Generation of TF-containing liposomes 
Thrombin generation was triggered by TF- bearing liposomes.  The liposomes were synthesised 
using 65% 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 30% 1-stearoyl-2-arachidonoyl-
sn-glycero-3-PE (SAPE) and 5% 1-Stearoyl-2-arachidonoyl-sn-glycero-PS (SAPS) (lipid stocks 1 
mg/ml).  Specifically, 27.1 µl of DSPC, 11.5 µl of SAPE and 2.09 µl of SAPS were dried in a glass 
vial by evaporation under nitrogen and resuspended in 460 µl of liposome buffer.  40 µl of a 25 
nM stock of recombinant tissue factor (rTF) (Cambridge Biosciences, UK) was added to the 
mixture prior to 10 freeze thaw cycles with liquid nitrogen, with each cycle lasting up to 1 
minute.  Liposomes were generated by passing the mixture through a Lipsofast TM mini - 
extruder with 100 nm pore membranes (Avestin) nineteen times.  Innovin was not used because 
the TF concentration and phospholipid composition is unknown.  The amount of TF incorporated 
into the trigger liposomes was not determined.         
2.18 Measurement of thrombin generation by Calibrated Automated Tomography (CAT)   
Washed platelets at a concentration of 1.5 x 108/ml were used obtained by the methods 
described above (Section 2.1).  To determine the ability of the platelets to support thrombin 
generation, 80 µl of washed platelets were added in triplicate to wells of a 96-well plate.  
Similarly, the washed microvesicle suspension (80 µl) was added to the plate in triplicate and as 
a control, 80 µl of the pooled PPP was pipetted separately into the wells of the plate.  The pooled 
PPP used as a control for each experiment was from the same pool used to resuspend and dilute 
the washed platelets and microparticles.   
Prior to addition of the trigger solution, a further dilution of the liposomes was made by adding 
487.7 µl of liposome buffer to 12.5 µl of liposomes (2.5 µM lipid/50 pM recombinant TF).  20 µl 
of the diluted trigger solution was then added to each well to yield a final concentration of 0.5 
µM phospholipid and a nominal final concentration of 10 pM recombinant TF.  The nominal final 
concentration of TF quoted assumes that all TF had been incorporated into the liposomes. The 
actual final concentration of TF added to the assay was unknown and almost certainly less than 
10 pM. The amount of liposomes used to trigger the assay was adjusted empirically to ensure 
that the assay was sensitive to the platelet phospholipid surface (for details see Chapter 4).  For 
every plate that was run, a separate calibrator well containing thrombin calibrator (α-2 
macroglobulin) without liposomes was used.   
The plate was placed into a Fluoroskan Ascent Reader and incubated at 37 0C for 10 minutes.  
Thrombin generation was initiated by an automated washing step with calcium chloride and 
subsequently the addition of fluorogenic substrate (Z-Gly-Gly-Arg from Bachem, UK) in fluo-
buffer to yield a final concentration of 5 mM fluorogenic substrate and 20 mM calcium chloride.  
The reaction was then allowed to proceed for 60 minutes.  
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2.19 Statistical analysis 
For each sample, experiments were carried out in triplicate with the data point for each sample 
representing the mean.  Mass spectrometry data was processed using MultiQuant Software for 
the purposes of integration of peak area.  Data was analysed using Graph Pad Prism 5.  The 
statistical significance of difference between two sets of data from separate study groups was 
calculated using the Mann Whitney U test.  Analysis of the relationship between variables within 
a study group was performed using Pearson’s correlation.  A p value of < 0.05 was considered 
statistically significant.      
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                                        Chapter 3- Patient demographics 
                                                                          
3.1. Demographics and clinical data of UBD and DVT patients   
A total of 82 participants were recruited into the study.  There were 29 healthy controls 
recruited from the local population in accordance with the inclusion and exclusion criteria 
detailed in Chapter 2.  The median age of healthy controls was 45 years (IQR 40-58).  Details of 
age and gender of the healthy volunteers compared with UBD and thrombosis patients are 
shown in Table 3.1.   
In the UBD cohort, a total of 21 patients were recruited, all of whom were known to the Cardiff 
Haemophilia Centre and had been diagnosed using the criteria outlined in Chapter 2 (Table 
2.1).  The median age of patients with UBD at recruitment was 66 years and there was a 
marked female predominance (19 females, 2 males).  The median ISTH bleeding score was 10 
(IQR 7-12).  Bleeding following surgery, post-dental extraction and menorrhagia were the most 
frequent symptoms, each occurring in 76% of cases.  All but 2 had previously undergone a 
haemostatic challenge covered with either tranexamic acid alone or in combination with 
DDAVP.  Of the 21 UBD patients, 19 had previously participated in the BRIDGE BPD study.  This 
had led to the identification of a genetic mutation in two patients.  In one case (PL016),  a 
single nucleotide variant was identified in the gene encoding the actin cytoskeletal regulator 
tropomyosin (TPM4) in megakaryocytes and platelets [228].  In the second case (PL021), a 
variant in the MYH9 gene was reported, although there were no associated clinical features of 
renal impairment, hearing loss or cataract formation.  In both cases, the platelet count was 
within normal range. 
Additionally, 2 patients with known platelet PL or prothrombin consumption defects were 
included in the analysis to provide direct comparison of known conditions of phospholipid 
dysfunction with the undetermined platelet procoagulant activity of the UBD cohort.  These 
included a patient with Scott syndrome confirmed by absent Annexin V binding on flow 
cytometry and definitively by the presence of compound heterozygous TMEM16F mutations 
[229] and 1 patient with an abnormal prothrombin consumption index (43%) in whom Scott 
syndrome was excluded by normal annexin V binding.  Lastly, one patient with a known 
platelet function defect (PFD) was included in the analysis on the effect of DDAVP on platelet 
phospholipids (Chapter 7).  This patient was confirmed to have a reproducible absent response 
to epinephrine on platelet aggregometry testing after inclusion in the study.  Full details 
including bleeding score and information regarding previous haemostatic challenges are 
shown in Appendix 1.       
27 patients with DVT were recruited from the acute DVT service of Cardiff and Vale University 
Health Board using the criteria outlined in Chapter 2 (Table 3.3).  The median age of the DVT 
patient was 65 years.  All patients were screened for risk factors for thrombosis using a clinical 
proforma (Appendix 1).  9/27 patients (33%) had a previous thrombotic event and in 4/27 
(15%) of cases, no precipitating factor was identified.  Baseline blood investigations including 
full blood count (FBC), renal function (U&E), liver function tests, bone profile and a coagulation 
profile were performed at diagnosis.  None of the patients had a diagnosis of antiphospholipid 
syndrome or a known hereditary thrombophilia.  Details of the site of thrombosis and existing 
risk factors are detailed in Table 3.2.  
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Table 3.1 Demographics of healthy controls, UBD and DVT patients 
 Healthy 
control n=29 
UBD patients 
n=21 
DVT patients 
n=27 
Male (n) 16 2 18 
Female (n) 13 19 9 
Minimum age 
(years) 
21 31 30 
Maximum age 
(years) 
69 82 79 
Median age (years) 45 66 65 
IQR (years) 40-58 58-75 49-70 
Mean age (years) 46.9 63.7 59.4 
SD 11.7 12.8 14 
SE 2.3 2.8 2.7 
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Table 3.2 Details of the site and risk factors of thrombosis in DVT patients 
 
Patient Age/gender Site of 
thrombosis 
Risk factors Family history of 
thrombosis 
PL025 66 F Left femoral DVT • Previous DVT Yes – sister (after 
lower limb surgery) 
PL026 70 M Right femoral 
DVT 
• Previous DVT/PE 
• Oesophageal 
cancer 
No 
PL041 61 M 
 
 
Left 
gastrocnemius 
DVT 
• Trauma (fall from 
ladder 10 days 
prior) 
Yes – mother (after 
surgery; knee 
replacement) 
PL042 54M 
  
Right femoral-
popliteal DVT 
• Previous DVT Yes – father 2 
DVT’s (unknown 
circumstances) 
PL045 73M 
 
Left popliteal 
DVT 
• Nil No 
PL046 79M 
 
Left ilio-femoral 
DVT 
•  BMI>30 No 
PL048 72F Right popliteal 
vein DVT 
• Previous DVT No 
PL049 68F 
 
Left tibial vein 
DVT 
• Hormone 
replacement 
therapy 
Yes – sister DVT 
(post- partum) 
PL051 45M 
 
Left tibial vein 
DVT 
• Previous DVT x 2  
1st – unprovoked 
2nd – following 
knee surgery 
Yes – mother 
(related to 
combined oral 
contraceptive pill) 
PL052 66F Right peroneal 
DVT 
• BMI> 30 
• Previous DVT   
No 
PL053 41F Left peroneal 
DVT 
• Nil No 
PL054 54M Left femoral-
popliteal DVT 
• Travel > 4 hours No 
PL055 70M Left popliteal 
DVT 
• Previous DVT 
(following leg 
fracture) 
No  
PL056 66M Right popliteal 
DVT 
•  Previous DVT 
(unprovoked) 
Yes 
PL059 78F 
 
Left ilio-femoral 
DVT 
• BMI>30 
• Travel >4 hours 
No  
PL062 34M Right popliteal 
DVT 
• Nil Yes- mother DVT 
(unknown 
circumstances) 
PL064 49F  Right peroneal 
DVT 
• Recent surgery in 
12 weeks 
(anterior cruciate 
ligament repair) 
No 
PL065 30M Right tibial vein 
DVT 
• Recent trauma 
(fracture of fibula) 
No 
PL068 36M  Left femoral DVT • Nil No 
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PL069 55M  Right popliteal 
DVT 
• Previous DVT 
(unprovoked) 
Yes – mother 
DVT/PE (unknown 
circumstances) 
PL070 46F  Right peroneal 
DVT 
• Travel > 4 hours 
• Varicose veins 
No 
PL071 76M  Left femoral DVT • Family history of 
DVT 
Yes – mother DVT 
(unknown 
circumstances) 
PL073 65M  Left popliteal 
DVT 
• Travel > 4 hours Unknown 
PL077 72M  Left tibial DVT • BMI>30 
• Recent surgery in 
12 weeks 
(manipulation of 
total hip 
replacement) 
• Recent inpatient 
stay in 12 weeks  
No 
PL079 49M Left tibial DVT • Trauma lower 
limb 
No 
PL080 68F Left peroneal 
DVT 
• Malignancy 
• Previous PE 
• Family history of 
DVT 
Yes – sister DVT 
(post-surgery), 
mother DVT (post-
partum) 
PL081 61M Right popliteal 
DVT 
• Recent trauma 
(fracture distal 
fibula 1 week 
prior) 
No 
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3.2 Sample collection  
There were 72 samples used for thrombin generation measurements and 66 lipid extracts 
available for analysis in the experiments conducted in Chapters 4, 5 and 6 of the thesis.  There 
were 4 healthy controls who did not re-attend for all experiments to be performed and 
therefore there was insufficient sample available for complete analysis.  In 3 DVT patients, 
spontaneous platelet aggregation occurred in all samples during the initial stages of the 
isolation process and therefore these samples could not be used in any of the experiments.  In 
3 other DVT patients, visible partial platelet clumping was evident in the resting stage 
following their isolation, in at least in half of the samples (n=3).  In 2 DVT patients, fine ‘grains’ 
of platelets were visible in samples following thrombin activation and the incubation step, but 
aggregation had not occurred.  No platelet aggregation was seen in the UBD patients and 
partial aggregation was seen in one healthy control.  As described in Chapter 2, methods for 
platelet isolation were optimised in order to minimise the risk of platelet aggregation.  This 
involved the use of a wide bore needle (21 gauge), removal of the tourniquet before the blood 
draw and maintaining room temperature at 20-220 C.  Despite the above, an increased 
incidence of spontaneous platelet aggregation was observed in the DVT cohort compared to 
healthy controls and UBD patients.  In the event of complete spontaneous platelet 
aggregation, samples were discarded and not analysed further.   
 
Table 3.3 Details of samples available for analysis 
Cohort 
 
Number of 
samples available 
for analysis 
Spontaneous Platelet 
aggregation 
 
 
Non-returners 
(within 48 hours) 
       TG               PL    Partial                 Complete  
Healthy controls 
n=29 
27                24 1                            0 4 
UBD patients 
n =20 
20                20 0                            0 0 
Scott syndrome 
n=1 
1                    1 0                            0 0 
Abnormal PCI 
n=1 
1                    1 0                             0 0 
DVT patients 
n=27 
23                20 3                            3 1 
 
(TG; thrombin generation PL; phospholipid, partial platelet aggregation; affecting either TG or 
PL samples, complete platelet aggregation; affecting both TG and PL samples; UBD = 
Unclassified bleeding disorder; DVT= Deep vein thrombosis; PCI = prothrombin consumption 
index) 
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Chapter 4 - The ability of platelet and microvesicle phospholipid surfaces 
to support thrombin generation in patients with UBD, DVT and healthy 
controls 
4.1 Introduction 
The experiments detailed in this chapter sought to investigate the ability of healthy control 
and patient platelets and microvesicles to provide a phospholipid surface to support 
coagulation using the thrombin generation assay.  The same pooled plasma was used for all 
tests so that variation in pro- and anticoagulant factors did not affect the results. The assays 
were tailored so that thrombin generation was dependent on the phospholipid surface 
supplied by the platelets or microvesicles.  This assay was used to compare individuals with an 
acute thrombosis and unexplained bleeding disorders with healthy controls. 
Commercial trigger solutions that are available to initiate coagulation in the thrombin 
generation assay such as “Stago PPP low” and “Stago PPP high” have TF concentrations of 1 
pM and 5pM respectively, however the exact composition and concentration of phospholipid 
is unspecified.  Similarly, the phospholipid and TF composition of Innovin is unknown.  This 
means that, although the amount of TF protein is known, the specific activity of TF will vary 
because this is crucially dependent on the phospholipid membrane in which the tissue factor is 
reconstituted.  Furthermore, in most thrombin generation assays an excess of PE/PS is added 
making the assay insensitive to platelet-derived phospholipid.  In order to investigate the 
ability of phospholipids in the membranes of platelets or microvesicles to support 
procoagulant enzyme complexes, the trigger solution used in the experiments described here 
was standardised using liposomes composed of a relatively low concentration of lipids (65% 
DSPC, 30% SAPE, 5% SAPS) and a fixed concentration of recombinant tissue factor (rTF). The 
nominal final concentration of rTF in the liposomes was 10 pM, however, this assumes that all 
the rTF has been incorporated.  Although 10 pM TF would usually be considered to be high in a 
standard thrombin generation assay, the activity of the TF cannot be compared to Stago 
reagents or Innovin because the phospholipid environment is different.  The trigger liposomes 
were adjusted so that a background amount of FXa and thrombin would be produced in the 
pooled plasma activating FVIIIa and FVa before the Xa was inactivated by TFPI, as shown in 
Figure 4.1.  The FVIIIa and FVa then allowed additional thrombin to be generated through the 
tenase and prothrombinase compexes supported by phospholipids on the surface of washed 
platelets and microvesicles.  The contribution of the phospholipid surfaces could be calculated 
by subtracting the thrombin generated by the control liposomes alone.  
As shown in Figure 4.1, sequential lowering of the lipid concentration in the rTF- bearing 
liposome with the same nominal TF concentration resulted in increased thrombin generation.  
This pattern was observed when the liposome was used to trigger coagulation in PPP.  Whilst 
this observation seems paradoxical, this was demonstrated on three separate occasions.  
Possible explanations could be that the reduced surface area conferred by lowering the 
phospholipid content of liposomes may increase the likelihood of coagulation factors binding 
in a more concentrated manner.  In addition, reducing the phospholipid whilst maintaining the 
same TF concentration, would increase the number of TF molecules relative to phospholipid 
leading to a higher density of TF molecules in the membrane.  It is possible that this combined 
effect was not as apparent when the control liposome was used to trigger coagulation in PRP 
due to the additional lipid provided by the platelets.   
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Figure 4.1. Lowering the phospholipid concentration in the rTF - bearing liposome results in 
increased thrombin generation in PPP  (A-B) 4 µM lipid 10 pM rTF  in PRP and PPP (C-D) 2 µM 
lipid 10 pM rTF in PRP and PPP (E-F) 1 µM lipid 10 pM rTF in PRP and PPP (G-H) 0.5 µM lipid 10 
pM rTF in PRP and PPP. 
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Using the control liposome to activate coagulation, a series of dilutions of washed platelets 
from a healthy volunteer were resuspended in PPP as shown in Figure 4.2.  Previous studies 
report a saturating effect with platelet concentrations above 2 x 10 8/ml, which could render 
the assay insensitive to platelet-derived phospholipid [210].  A platelet count of 1.5 x 10 8/ml 
was therefore used for the thrombin generation experiments performed in this thesis.  To 
provide the same conditions of coagulation factors and inhibitors, the same pooled PPP taken 
into citrate and CTI was used to resuspend washed platelets and the microvesicle pellet in all 
experiments.   
 
 
 
Figure 4.2 Dilutions of washed platelets from a healthy control in pooled PPP using a control 
liposome.  The trigger used in all dilutions was the same control liposome (0.5 µM lipid, 10 pM 
rTF).  The washed platelets were sequentially diluted as follows: (A) 2 x 108/ml (B) 1.5 x 108/ml 
(C) 1.0 x 108/ml (D) 0.5 x 108/ml. 
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For each experiment performed, washed platelets were diluted to 1.5 x 108/ml and the 
standard trigger liposome was utilised (Figure 4.3).  This was used for the calculation of each 
parameter for both washed platelets and microvesicles.  An example from a healthy control is 
shown below. 
Figure 4.3 Example of measuring peak thrombin using washed platelets and microvesicles 
from a healthy control.  (A) Thrombin generation supported by washed platelets activated by 
a control liposome in standardised PPP (B) Thrombin generation measured in a control 
liposome in standardised PPP (C) Thrombin generation supported by microvesicles activated 
by a control liposome in standardised PPP.  The control liposome (B) generates a measurable 
amount of thrombin shown by the horizontal black line.  The vertical black arrows represent 
the additional amount of thrombin generated by washed platelets (A) and microvesicles (C) 
respectively which was subtracted from the background amount of thrombin measured from 
the control liposome (B).  This principle was applied to each parameter which results in the lag 
time being reported as negative seconds. 
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4.2 Results  
4.2.1 Thrombin generation supported by washed platelets in UBD patients 
Lower peak thrombin generation was observed in the UBD cohort compared to healthy 
controls (P=0.03) although there was substantial overlap between the groups.  There was no 
statistically significant difference observed in the ETP, velocity index and lag time between 
UBD patients and healthy controls (Figure 4.4).  The results of each measured parameter are 
detailed in Table 4.1.  As expected, washed platelets from the single patient with Scott 
syndrome generated only a minimal amount of thrombin with similar negligible changes 
observed in velocity index.  A significant reduction in ETP was demonstrated in comparison 
with healthy controls and UBD patients.  Addition of Scott platelets to the control liposome did 
not result in a shortening of the lag time.  The finding that Scott syndrome platelets were 
unable to support thrombin generation confirms that the assay is sensitive to reduction of 
externalised procoagulant phospholipids.  
 
  
 
 
 
Figure 4.4 Measurements of peak thrombin are lower in UBD patients.  The peak thrombin 
(A), velocity index (B), ETP (C) and lag time (D) measured from washed platelets in healthy 
controls and UBD patients is shown above.  Thrombin generation parameters are shown for 
healthy controls (black dots) and UBD patients (coloured dots with individuals labelled 
consistently through the panels).  Data from a patient with Scott syndrome (red star) and 
abnormal prothrombin consumption index (black star) is shown.  Data shown are mean values 
(long horizontal black bar) and the standard error of the mean (short horizontal black bars).  P 
values were calculated using the Mann Whitney U test excluding the Scott syndrome and 
prothrombin consumption index patients. 
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Table 4.1 Descriptive data for each parameter of the thrombin generation assay are shown 
for healthy controls and patients with UBD. 
 
Peak thrombin generation 
(nM) 
Healthy controls (n=27) UBD patients (n=20) 
Median  86.16 65.91 
25% percentile 68.04 56.93 
75% percentile 121.3 87.68 
Mean 96.00 76.82 
Standard deviation 36.65 31.45 
Standard error 7.054 7.032 
 
Velocity index (nM/min) Healthy controls (n=27) UBD patients (n=20) 
Median 11.63 8.02 
25% percentile 6.820 4.73 
75% percentile 20.61 10.09 
Mean 14.60 9.73 
Standard deviation 11.47 8.08 
Standard error 2.208 1.81 
 
ETP (nM/min) Healthy controls (n=27) UBD patients (n=20) 
Median 923.0 889.5 
25% percentile 831.9 806.0 
75% percentile 1134 984.0 
Mean 980.8 919.7 
Standard deviation 244.4 198.7 
Standard error 47.04 44.42 
 
Lag time (mins) Healthy controls (n=27) UBD patients (n=20) 
Median -1.560 -1.22 
25% percentile -2.330 -2.97 
75% percentile -1.000 -0.55 
Mean -1.621 -2.25 
Standard deviation 0.9632 2.96 
Standard error 0.1854 0.66 
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4.2.2 Thrombin generation supported by washed platelets in DVT patients 
An increase in peak thrombin, velocity index and ETP was observed in DVT patients compared 
to healthy controls, although there was no significant difference in lag time.  The peak 
thrombin and velocity index were notably higher in 4 patients within the thrombotic cohort 
suggesting that, in at least some patients, platelets may contribute to a prothrombotic 
phenotype at the time of a DVT.  There was no visible evidence of spontaneous platelet 
aggregation in these 4 patients at the time of testing.    
 
 
Figure 4.5 Measurements of peak thrombin, velocity index and ETP are increased in DVT 
patients.  The peak thrombin (A), velocity index (B), ETP (C) and lag time (D) measured from 
washed platelets in healthy controls and DVT patients is shown above.  Healthy controls and 
DVT patients are represented by black dots and green squares respectively.  Data shown are 
mean values (long horizontal black bar) and the standard error of the mean (short horizontal 
black bars).  P values were calculated using the Mann Whitney U test. 
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Table 4.2 Descriptive data for each parameter of the thrombin generation assay are shown 
for healthy controls and patients with DVT. 
 
Thrombin generation (nM) Healthy controls (n=27) DVT patients (n=23) 
Median  86.16 122.2 
25% percentile 68.04 97.02 
75% percentile 121.3 151.1 
Mean 96.00 143.5 
Standard deviation 36.65 76.54 
Standard error 7.054 15.96 
 
Velocity index (nM/min) Healthy controls (n=27) DVT patients (n=23) 
Median  11.63 20.05 
25% percentile 6.820 13.39 
75% percentile 20.61 35.70 
Mean 14.60 38.22 
Standard deviation 11.47 42.64 
Standard error 2.208 8.891 
 
Lag time (mins) Healthy controls (n=27) DVT patients (n=23) 
Median  -3.670 -3.890 
25% percentile -2.330 -2.220 
75% percentile -1.000 -0.4800 
Mean -1.621 -1.429 
Standard deviation 0.9632 1.079 
Standard error 0.1854 0.2476 
 
ETP (nM/min) Healthy controls (n=27) DVT patients (n=23) 
Median  923.0 1086 
25% percentile 831.9 920.0 
75% percentile 1134 1355 
Mean 980.8 1157 
Standard deviation 244.4 307.9 
Standard error 47.04 64.21 
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4.3.1 Thrombin generation supported by microvesicles in UBD patients 
As observed with washed platelets, peak thrombin generation supported by washed 
microvesicles was significantly lower in UBD patients compared with healthy controls (P = 
0.01).  As seen with washed platelets there was substantial overlap between the UBD patients 
and healthy controls (Figure 4.6).  Similarly, an overall reduction in velocity index was 
demonstrated in the bleeding cohort although no difference in lag time or ETP was observed.  
The microvesicle pellet suspension obtained from the single patient with Scott syndrome 
generated only small amounts of thrombin as expected, although this was comparable with 
the peak thrombin concentrations measured in other UBD patients and some controls.     
 
 
Figure 4.6 Measurements of peak thrombin and velocity index are lower in microvesicles 
isolated from UBD patients.   Peak thrombin (A), velocity index (B), ETP (C) and lag time (D) 
measured from microvesicles in healthy controls and UBD patients.  Thrombin generation 
parameters are shown for both healthy controls (black dots) and UBD patients (white squares).  
Data from a patient with Scott syndrome is shown (red star).  Data shown are mean values 
(long horizontal black bar) and the standard error of the mean (short horizontal black bars).  P 
values were calculated using the Mann Whitney U test excluding the Scott patient. 
 
 
 
 
 
 
 64 
 
 
4.3.2 Thrombin generation supported by microvesicles in DVT patients 
In contrast, the peak thrombin generated by washed microvesicles of DVT patients showed no 
difference when compared with measurements from healthy controls.  The velocity index, lag 
time and ETP parameters were similar in the thrombotic group and the healthy controls.   
 
 
Figure 4.7 The ability of microvesicles from DVT patients and healthy controls to support 
thrombin generation is similar.  The peak thrombin (A), velocity index (B), ETP (C) and lag time 
(D) measured from microvesicles in healthy controls and DVT patients.  Thrombin generation 
parameters are shown for both healthy controls (black dots) and DVT patients (green squares).  
Data shown are mean values (long horizontal black bar) and the standard error of the mean 
(short horizontal black bars).  P values were calculated using the Mann Whitney U test. 
 
To investigate whether the peak thrombin generation supported by washed platelets was 
associated with the peak thrombin generation supported by microvesicles in healthy controls, 
UBD patients and the DVT cohort, scatter plots were constructed (Figure 4.8).  No relationship 
between these parameters was observed in the healthy controls or the in the disease groups, 
however the same clustering pattern was seen in the 4 outlying DVT patients.  These results 
suggest that the ability of an individuals’ washed platelets to support thrombin generation 
does not parallel that of their microvesicles, either in the resting state or at the time of acute 
thrombosis.  It is important to note that the microvesicles used in the thrombin generation 
assay were not purely derived from platelets, but also from other cells including neutrophils 
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and monocytes some of which may have been expressing TF.  This may add a degree of 
complexity to the association and in part, account for the lack of correlation observed between 
the two parameters.        
 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.8 Correlation of peak thrombin measurements in washed platelets and 
microvesicles.  The correlation of peak thrombin generation supported by washed platelets 
with the corresponding value of peak thrombin generation thrombin generation supported by 
the individuals’ microvesicles is shown for healthy controls (A), DVT patient (B) and UBD 
patients (C).  For each scatter plot, the correlation co-efficient (r squared) with the 
corresponding p-values (P) is shown.  The Scott syndrome patient has been excluded from the 
analysis.   
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4.4 Discussion  
The aim of this chapter was to investigate the ability of patient and control platelets to support 
coagulation measured by a thrombin generation assay adjusted to be sensitive to the 
contribution of phospholipid membranes.  Using the methods outlined in Chapter 2, the peak 
thrombin and velocity index were associated with changes in both the UBD and the thrombosis 
cohorts compared to the controls.  Both these parameters were associated with statistically 
significant differences in the thrombotic group, with higher levels of peak thrombin 
concentration (p = 0.008) and velocity index (p=0.003).  Peak thrombin generation was 
significantly reduced in the bleeding cohort (P=0.03), whilst a trend towards lower velocity 
index (P=0.09) was observed in UBD patients compared with the control group. In addition, the 
microvesicle fraction of patients with UBDs supported lower peak thrombin and velocity index 
compared to healthy controls.   
These results suggest that the ability of the platelet surface to support coagulation may play a 
role in UBDs and venous thrombosis.  In the patients with excess bleeding, the ability of both 
their platelets and microvesicles to support global coagulation was reduced suggesting a 
potential novel mechanism for their bleeding.  More patients will need to be investigated to 
establish whether the trend towards a decreased velocity index is a genuine finding.  The 
platelets were investigated in the non-bleeding state and so reflect the normal baseline state 
in these patients.  The ability of platelets to support coagulation is critical to normal 
haemostasis in vivo but is not assessed in any standard haemostatic assay and so would not 
have been seen in this cohort during routine clinical investigation.  Whether these changes are 
a contributory cause of the excess bleeding in these patients will require further work and the 
study needs to be repeated in an independent cohort to assess whether the findings are 
reproducible.  
The increased ability of the platelets of patients with venous thrombosis to support 
coagulation may play a role in the development of a thrombus.  This enhanced ability to 
support global coagulation may interact with increased levels of coagulation factors known to 
predispose to thrombosis, such as FVIII and FII, or with clotting factors resistant to inactivation 
such as FV Leiden to induce a thrombus.  FII, FVa and FVIIIa function and Protein C activation 
all require phospholipid surfaces and it is possible that the environment available to these 
coagulation factors influences their role in disease states.  The samples from UBDs were taken 
in a non-bleeding state and so represent the baseline state of these patients.  However, it is 
important to recognise that the samples from the DVT cohort were taken at the time of a 
thrombotic event and changes may have been a consequence of that event rather than 
causative.   
There were 4 DVT patients whose platelets supported substantially higher amounts of 
thrombin generation compared to other patients in the cohort and controls.  Although these 4 
patients did not have a higher thrombotic disease burden (site and extent) at the time of 
testing, all of them had been previously diagnosed with one or more episodes of unprovoked 
VTE and therefore had a pre-existing prothrombotic tendency.  A total of 9 patients had 
previous VTE as a risk factor, and therefore the association with this risk factor does not fully 
explain the higher thrombin generation observed in these 4 outliers.  Overall, there was a 
higher incidence of spontaneous platelet aggregation in DVT patients, which has also been 
reported in other studies [146].  It is possible that there was a higher degree of platelet hyper-
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reactivity in these four samples, although there was no macroscopic evidence of platelet 
aggregation.  Alternatively, other pro-coagulant factors and pathways other than the 
thrombin-generating capacity of the platelet surface membrane may have been influential in 
promoting the pro-thrombotic process in these patients.   
In other studies, ETP is considered to be one of the most useful thrombin generation 
parameters in demonstrating associations with a thrombotic or bleeding phenotype due to 
changes in the balance of pro- and anti-coagulant factor [221, 230].  It was anticipated that the 
ETP would not differ significantly amongst participants in this study because patient and 
control washed platelets were resuspended in the same plasma pool.  Therefore, the same 
amount of prothrombin was in each assay potentially normalising the ETP.  The same pooled 
plasma was used to remove the wide variability of different donor coagulation factors and 
plasma anticoagulants, thus increasing the sensitivity of the assay to interactions of 
coagulation factors with the platelet surface membrane.  The TF/phospholipid vesicles were 
designed to initiate coagulation by generating a small amount of thrombin but provide 
minimal support for the propagation phase and limited support for the prothrombinase 
complex.  TFPI was expected to inactivate further TF/FVIIa-dependent thrombin generation 
caused by the liposomes alone.  The washed platelets or microvesicles in the assay were 
intended to provide support for the intrinsic tenase and prothrombinase complexes.  This was 
successfully achieved as shown in Figure 4.1.  It is therefore not surprising that the assay was 
unable to detect any changes in the lag time.    
In the Cambridge study, 124 UBD patients were assessed with a thrombin generation assay to 
determine whether any diagnostic pattern was apparent.  A prolonged lag time was observed 
in 26% of patients and a decreased ETP was reported in 19% and therefore not consistently 
demonstrated in the UBD cohort [185].  The thrombin generation assay used in the Cambridge 
study however, was performed in PPP and designed to be sensitive to coagulation factors in 
the plasma rather than to the platelet phospholipid surface.  A phospholipid concentration of 4 
µM was used rather than the minimal concentration of phospholipid used in the experiments 
described in this thesis.     
The ability of microvesicles from healthy controls, UBD and thrombotic patients to support 
coagulation in standardised pooled plasma using the thrombin generation assay was also 
investigated.  The ability of microvesicle phospholipid to support thrombin generation as 
shown by the parameters, peak thrombin generation and velocity index, was significantly 
lower in the UBD cohort compared to healthy controls suggesting a possible mechanism for 
the increased risk of bleeding in these patients.  This is in addition to the decreased ability of 
platelet phospholipids from these people to support peak thrombin generation.  The number 
of microvesicles in the supernatant of each subject was not assessed.  It is not known whether 
the reduced thrombin generation in the UBD group was related to fewer microvesicles being 
present or differences in the ability of microvesicles to support coagulation.  There was no 
difference in the ability of microvesicles in DVT patients to support thrombin generation 
despite the observed increase in thrombin generation associated with their platelets. This 
suggests that microvesicles are unlikely to play a major role in supporting enhanced activation 
of coagulation in this patient group.  
It is important to note that the microvesicle pellet used in the thrombin generation assay was 
generated from resident microvesicles in the PPP supernatant of each patient.  These 
microvesicles were formed in vivo and so reflect the innate ability of that individuals 
microvesicles to support coagulation.  Experiments were not performed using microvesicles 
derived from agonist-activated washed platelets in vitro.  It is possible that different results 
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would have been found using platelet-derived microvesicles formed from activation with a 
platelet agonist such as thrombin or collagen in-vitro but these would have had less 
physiological relevance.  Although high-speed centrifugation is a recognised method for 
isolating microvesicles [231] there has been increasing recognition that the pellet obtained by 
this means may contain non-vesicular components.  In recent years this has led to increasing 
use of size exclusion chromatography as a means of selectively isolating vesicles from platelet-
free supernatant of platelet concentrates [232].  However, the unmanipulated extract used 
here is what is in the patient and hence may be considered of potential physiological 
relevance.      
In summary, the ability of washed platelets to support thrombin generation in patients with 
UBD may contribute to the increased risk of bleeding observed in these patients.  The role of 
platelets in venous thrombosis is less clear and the increased ability of washed platelets to 
support global haemostasis may be clinically significant or a consequence of the thrombotic 
event.  Microvesicles of UBD patients supported lower amounts of thrombin but this was not 
seen in patients with DVT.  If reproducible in an independent cohort of UBD patients, these 
findings may have implications for the cause of bleeding in UBD and potentially for identifying 
patients at risk of these disorders.  
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Chapter 5 - Native platelet aminophospholipids in UBD and DVT patients 
5.1. Introduction  
The composition of the platelet phospholipid membrane is important in regulating coagulation 
reactions and so the changes in thrombin generation described in Chapter 4 could be a 
consequence of differences in externalised APL and this question is addressed in the following 
chapter.  
In the resting state PC, an inert phospholipid is distributed predominantly in the external 
leaflet and the polar APLs, PE and PS are retained in the internal leaflet [102].  Following 
scramblase activation, externalisation of PE and PS occurs which allows interaction between PE 
and PS with the Gla domains of plasma coagulation factors as discussed in Chapter 1 [233].  
This event is essential for the assembly of key enzymatic complexes which ultimately result in 
thrombin generation occurring in vivo.   
There are very limited data on the role of specific PE/PS species of the platelet membrane in 
relation to bleeding and thrombotic disease.  It is evident that a failure of platelets to 
externalise PE and PS is pathological, as exemplified by the bleeding observed in Scott 
syndrome [154].  It remains to be proven however, whether less marked quantitative 
reductions in PE/PS exposure occur in uncharacterised bleeding disorders, or in contrast 
whether significant increases in externalised APL are contributory to the pathogenesis of 
venous thrombosis.  Increased PS exposure has recently been reported in circulating 
leucocytes and platelets from patients with essential thrombocythaemia (ET) who were 
positive for the JAK 2 mutation and therefore considered be prothrombotic, although this has 
not been demonstrated in venous thrombosis without ET or any other acquired prothrombotic 
disorder [204].  Increased PE and PS- expressing microvesicles are known to be present in both 
arterial and venous thrombotic disorders [205, 234] which may mirror the composition of the 
platelet phospholipid surface however this has not been fully investigated to date.    
The development of a lipidomics assay utilising a cell impermeable reagent has enabled the 
identification and measurement of externalised PE and PS by LC/MS/MS.  Furthermore, this 
assay has enabled the identification of 5 species of PE and 3 species of PS exposed on the 
platelet surface following activation [153].  The aim of this chapter is to determine whether 
there are quantitative differences in externalised PE/PS in the platelets of patients with UBD 
and venous thrombosis.  In addition, the correlation between the amount of thrombin 
generated with externalised PE and PS species on the surface of platelets was explored.   
 
5.2 Methodology of the biotinylation assay 
Biotin is a vitamin B7 compound, otherwise referred to as Vitamin H [235].  Since the late 
1980’s, it has been used mainly in the field of proteomics for the labelling of primary amine-
containing molecules including cell surface proteins and antibodies [236].  In a similar way, the 
reagent EZ-link sulfo-NHS-biotin (SNB) can be utilised to derivatize externally facing APL due to 
the reaction between the NHS part of the compound and the amine (NH2) headgroup of the 
phospholipid.  SNB is readily soluble in water but is unable to penetrate the cell membrane 
and can therefore be used for the labelling of external APL species.  N-
hydroxysuccinimidobiotin (NHS-Biotin) however, is poorly soluble in aqueous solutions but is 
cell permeable on dissolving in an organic solvent such as DMSO.  The biotinylation of total 
cellular lipids using NHS-biotin enables the percentage of externalised APL to be calculated.   
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The biotinylation method for measuring the amount of the individual species of PS and PE on 
the external leaflet of an activated or apoptotic cell was originally described by Thomas et al 
[153].  In contrast to native PC, PE and PS contain a primary amine headgroup which allows 
these phospholipids to be derivatized.  Biotinylated species of externalised PE and PS are 
differentiated from their native forms by virtue of a mass change of + 226 a.m.u.  The synthesis 
of biotinylated internal and primary standards of PE and PS as described in Chapter 2 is 
required for the detection and quantification of individual molecular species (Figure 5.1) [153].     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Generation of a biotinylated standard.  An example of a biotinylated form of PS is 
shown.  The biotinylated reagent (NHS-Biotin) reacts with the primary amine head-group of a 
phospholipid.  The NHS is a by-product of the reaction.  The biotinylated species of PS can be 
distinguished from its native form by a mass change of 226 a.m.u.  Image modified from 
https://assets.thermofisher.com/TFSAssets/LSG/manuals/MAN0011206_EZ_NHS_Biotin_Reag
_UG.pdf 
The measurement of externalised APL was conducted using the LC/MS/MS method described 
in Chapter 2 on separate occasions for UBD and DVT patients.  The LC/MS/MS analysis of 
biotinylated lipid extracts from 16 healthy controls and 20 UBD patients was completed in July 
2018.  The remaining analyses of 10 healthy controls and the 22 thrombosis patients was 
conducted approximately 12 months later.  It was anticipated that biotinylated standards 
would remain stable over the course of the study period allowing the data to be combined 
over the two runs.  The original method stipulates that the standard curve can be reused for 
up to 3 months if stored at -80 0C and that standards can be stored for up to 1 year [153].  
Beyond this however, experience of the stability of the biotinylation assay over a longer time 
period is unknown.  In this study, the synthesised biotinylated standards were stored over a 
period of 2.5 years during recruitment, and separate standard curves were synthesised from 
main stocks for every LC/MS/MS analysis as recommended.    
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Two examples of a biotinylated PE and PS species from each run are shown in Figure 5.2.  It 
was observed that the biotinylated standards from the initial stock used to generate the 
standard curves, resulted in significantly lower gradients for each analyte in the second run (C-
D) performed in July 2019 compared with those performed in July 2018 (A-B).  The gradients 
and R2 values for each biotinylated lipid are shown in Table 5.1. 
 
 
 
 
Figure 5.2 Standard curves for biotinylated species of PS and PE from two separate analyses 
12 months apart. Run 1 (A-B) demonstrates the standard curve that was generated from 
biotinylated lipid stocks to quantify samples analysed in July 2018.  The corresponding 
standard curves for the same species from Run 2 (C-D) were generated from the same lipid 
stocks approximately 12 months later and have noticeably lower gradients.  The gradient (y) 
and R2 value for each standard curve is shown.   
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Table 5.1 Gradients of standard curves with time.  Run 1 and Run 2 represent LC/MS/MS 
analysis of the standard curves that were run with samples over the study period.  These 
independent runs were conducted approximately 12 months apart.  
 
Biotinylated 
species 
Gradient of standard curves in 
Run 1 (July 2018) 
Gradient of standard curves  
          in Run 2 (July 2019) 
DOPS-B y=0.3689x      R2=0.9903 y=0.2264        R2= 0.9775 
SOPS-B y=0.5233x      R2=0.9921 y=0.1940        R2=0.9662 
SAPS-B y=0.4906x      R2=0.9907 y=0.1594        R2=0.9746 
SOPE-B y=0.6383x      R2=0.9986  y=0.1347        R2=0.9998 
SpAPE-B y=0.5892x      R2=0.9993 y=0.2149        R2=0.9996 
SAPE-B y=0.5319x      R2=0.9971 y=0.1179        R2=0.9998 
 
Analysis of PS and PE biotinylated standard by using direct infusion and Q1 scans were 
performed which confirmed the characteristic fragmentation pattern of the biotinylated lipid 
with no native species detected, excluding the possibility of degradation or loss of biotin 
(Figure 5.3).   
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Figure 5.3 Q1 scans for biotinylated PE and PS species (A) Biotinylated DMPE (m/z 860 [M-H]-) 
is seen on direct infusion with no evidence of the native PE species (m/z 634 [M-H]-).  (B) 
Biotinylated DMPS (m/z 904 [M-H]-) is seen on direct infusion with no evidence of the native 
PS species (m/z 678 [M-H]-).  
 
The two primary and six internal standards from initial stocks were subsequently re-weighed 
following their synthesis.  Biotinylated standards had been synthesised to a concentration of 1 
mg/ml and were re-weighed approximately 2.5 years later, at the end of the study recruitment 
period to investigate the change in gradients of the standard curves.  For each biotinylated 
lipid, a known amount was transferred to a pre-weighed glass vial and then dried with liquid 
nitrogen.  The glass vial was then re-weighed and the difference in weights recorded.  All 
biotinylated standards had lower weights than those recorded initially following their 
synthesis.  It is possible that due to their inherent stickiness as lipids, they may have stuck to 
the glass vial thus accounting for their change in concentration over time. 
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Table 5.2 Re-weighed primary and internal biotinylated standards over a timescale of 2.5 
years 
 
Original stock 
1 mg/ml 
Pre-weighed 
vial 
Amount of lipid 
transferred to vial 
Weight of vial 
with dried 
lipid 
Amount of 
lipid after re-
weighing 
% of 
original 
weight 
DMPE-B 2613.605 mg 600 µg 2614.043 mg 438 µg 73 % 
SOPE-B 2598.303 mg 600 µg 2598.762 mg 459 µg 76.5 % 
SpAPE-B 2606.808 mg 500 µg 2607.206 mg 398 µg 79.6 % 
SAPE-B 2618.849 mg 500 µg 2619.225 mg 376 µg 75.2 % 
DMPS-B 2591.656 mg 600 µg 2592.121 mg 465 µg 77.5 % 
DOPS-B 2613.458 mg 700 µg 2613.847 mg 389 µg 55.6 % 
SOPS-B 2617.350 mg 500 µg 2617.726 mg 376 µg 75.2 % 
SAPS-B 2636.851mg 400 µg 2637.154 mg 303 µg 74.5 % 
 
 
 
5.3 Results 
5.3.1. Measurement of native APL in healthy controls obtained from independent LC/MS/MS 
analyses 
As discussed in Chapter 2, methods for quantification of lipids require the standard curve to be 
run simultaneously and analysed with the samples of interest, however for Run 2 this would 
have yielded discrepant results due to the change in concentrations of the standards with 
time.  The standard curve generated in July 2018 was therefore used for the quantification of 
externalised lipids in samples of Run 2.  For each biotinylated lipid species apart from SpAPE, 
there was no difference in the amount of lipid externalised in the platelets of healthy controls 
from Run 1 (n=16) and Run 2 (n=10) using the original standard curves for quantification.  
Despite, the apparent normalisation of results shown using the original standard curve, the 
results from the separate runs have been analysed independently for the remainder of the 
chapter. 
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Figure 5.4 The quantity of externalised PE/PS species in the platelet membrane of healthy 
controls from Cohort 1 and Cohort 2 is the same using the original standard curve for 
quantification.  For each biotinylated lipid species, the quantity of PE and PS externalised is 
shown using the standard curve generated in July 2018.  The original standard curve was used 
in the LC/MS/MS analyses of Cohort 1 and was run with biotinylated lipid samples 
simultaneously.  The standard curve used in Run 1 was used to retrospectively quantify the 10 
healthy controls from Run 2 (Cohort 2) 12 months later due to the change in concentration of 
the biotinylated standards with time.   P values were calculated using the Mann Whitney U 
test. 
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5.3.2 Characterisation of native APL and total platelet lipids in UBD patients.   
Following thrombin activation of platelets, there was no significant difference in the amount of 
externalised PE/PS in healthy controls compared with UBD patients (Figure 5.5).  This was also 
the case for basal concentrations of APL, which were measured in lower quantities compared 
with activated samples (Appendix 1).  The total amount of PE and PS in the platelet membrane 
was the same irrespective of whether the platelet was in the resting state or following the 
addition of thrombin (Figure 5.6).  It is notable that whilst the percentage of lipid externalised 
by the platelets of the Scott patient was lower than the average of both the UBD and healthy 
controls, it was comparable with some of the subjects in both cohorts suggesting that a 
minimal degree of APL exposure occurs on the surface of Scott syndrome platelets.   
  
 
 
 
Figure 5.5. Externalised PE and PS species following thrombin activation in platelets of 
healthy controls and UBD patients is similar.  Washed platelets were isolated and activated 
with thrombin.  External facing APL were biotinylated using the cell impermeable reagent SNB 
and then extracted using a Bligh and Dyer method as described in Section 2.11.  Lipid extracts 
were then analysed using LC/MS/MS and quantitated as detailed in Chapter 2.  Individual 
species of externalised PS are shown for healthy controls (blue) and patients with UBD (red) 
(A).  The quantities of the most abundant species of PE (B) and the three least abundant 
species of PE (C) are shown.  Data shown are median values (horizontal black bar), 
interquartile range (box) and maximum and minimum values (whiskers).  P values were 
calculated using the Mann Whitney U test.  
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Figure 5.6 The total amount of PS and PE measured in the platelet membrane basally or 
following thrombin activation is the same in UBD patients and healthy controls.  The cell 
permeable reagent, NHS-Biotin was added to an individuals’ washed platelets in the 
unactivated state and following activation with thrombin.  Biotinylated total cellular lipids 
were then extracted and analysed using LC/MS/MS as detailed in Section 2.13, Chapter 2.  
Individual molecular species of PE and PS were quantitated and then combined to determine 
the total quantity of PE and PS.  The total amount of PS and PE measured in the resting and 
activated platelet membrane for both healthy controls (blue) and UBD patients (red) is shown 
(A-B).  Data shown are median values (horizontal black bar), interquartile range (box) and 
maximum and minimum values (whiskers).  P values were calculated using the Mann Whitney 
U test.  
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Figure 5.7 The percentage (%) of externalised PE and PS following thrombin activation in 
platelets of healthy controls and UBD patients is the same.  The biotinylation of external APL 
using SNB and total lipids using cell permeable NHS-biotin enables the percentage of each 
individual species of PE and PS to be determined.  Data from the Scott patient is depicted by 
the red triangle.  Data shown are median values (horizontal black bar), interquartile range 
(box) and maximum and minimum values (whiskers).  There were no statistically significant 
differences between healthy controls and UBD patients.  
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5.3.3 Correlation of peak thrombin generation with externalised PE and PS in UBD patients. 
Subsequently, a correlation between peak thrombin generation from washed platelets 
(Chapter 4) with externalised PE and PS was investigated.  A weakly positive correlation was 
observed in healthy controls and a moderate correlation was seen in the UBD cohort.  The 
strongest correlations were evident in the UBD cohort and were more marked for the 
abundant lipid species (SAPS, SpAPE and SAPE) (F, N and P).   
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Figure 5.8 Positive correlations of externalised PE/PS species and peak thrombin generation 
supported by washed platelets are shown in healthy controls and UBD patients.  The linear 
correlation for each species of PE and PS with peak thrombin generation is shown from the 
most abundant lipid to the least for both healthy controls (black dots) and the UBD cohort 
(coloured dots).  The peak thrombin measurements were derived using the individuals’ 
washed platelets (1.5 x 108/ml) and a standardised liposome (0.5 µM phospholipid/10 pM TF) 
using the thrombin generation assay described in Section 4.2.1, Chapter 4.  For each 
correlation plot, the correlation co-efficient (r squared) with the corresponding p-value (P) is 
shown.  The Scott syndrome patient has not been included in the analysis.    
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5.3.4 Characterisation of native and total platelet lipids in DVT patients 
The quantity of externalised PE and PS in thrombin-activated platelets was similar between 
healthy controls and patients with DVT (Figure 5.9).  This was observed for each individual 
species of PS and PE when DVT patients were compared with healthy controls from the same 
run (i.e. Run 2) and in combination with healthy controls from Run 1.  The original standard 
curve was used for the quantification of externalised lipid due to the decrease in standards 
with time, however the corresponding data generated from standard curves run with the 
samples (i.e. Run 2) is also shown for comparison.  The fold change between results using the 
gradients of the two sets of standard curves (Table 5.2) is shown for each biotinylated lipid.  
Similarly, basal amounts of externalised APL in the platelet membrane of DVT patients were 
not increased compared with healthy controls suggesting that higher quantities of PE/PS were 
not contributory to the thrombotic phenotype of these patients (Appendix 1). 
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Figure 5.9 Externalised PE and PS species following thrombin activation in platelets of 
healthy controls and DVT patients is similar.  Individual species of externalised PS and PE are 
shown for healthy controls (blue) and patients with DVT (green) (A-H).  The quantities of 
individual species of PE and PS have been quantitated using the original standard curve (OSC) 
from Run 1 and also the new standard curve (NSC) from Run 2.  The factor by which the results 
differ using the two sets of standard curve is shown for each biotinylated lipid.  Data shown are 
median values (horizontal black bar), interquartile range (box) and maximum and minimum 
values (whiskers).  P values were calculated using the Mann Whitney U test.  
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The total amount of PS and PE in the platelet membrane was the same in the resting state and 
following thrombin activation (Figure 5.10).  No difference was observed in the percentage of 
externalised lipid between healthy controls and DVT patients for all biotinylated species except 
for SAPE (Figure 5.11).  Although DVT patients externalised similar amounts of SAPE as shown 
in Figure 5.9, the percentage of externalised SAPE appears to be significantly lower due to a 
relatively high abundance of this lipid in the platelet membrane in thrombotic patients.  In one 
outlying DVT patient, there was a higher percentage of biotinylated lipid externalised, however 
this is because the total quantity of PS and PE extracted from the platelets of this patient was 
abnormally low and is likely to represent an incomplete lipid extraction. 
 
 
 
 
Figure 5.10. The total amount of PS and PE measured in the platelet membrane (at rest or 
following thrombin activation) is the same in DVT patients and healthy controls.  The total 
quantity of PS and PE measured in the resting and activated platelet membrane for both 
healthy controls (blue) and UBD patients (green) is shown (A-B).  Data shown are median 
values (horizontal black bar), interquartile range (box) and maximum and minimum values 
(whiskers).  P values were calculated using the Mann Whitney U test.  
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Figure 5.11 The percentage (%) of externalised PE and PS following thrombin activation in 
platelets of healthy controls and DVT patients is the same.  The percentage of each individual 
species of PE and PS is shown.  Data from the an outlying DVT patient is depicted by the green 
triangle.  Data shown are median values (horizontal black bar), interquartile range (box) and 
maximum and minimum values (whiskers).  There were no statistically significant differences 
between healthy controls and DVT patients.   
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5.3.5 Correlation of peak thrombin generation with externalised PE and PS in DVT patients. 
Whilst the peak thrombin generated from washed platelets in the control group showed a 
weak positive correlation with externalised PE and PS, no correlation was observed in the 
thrombotic cohort (Figure 5.12).  Furthermore, the values in each scatter plot were not 
uniformly distributed with 4 thrombotic outliers identified in the thrombin generation assay, 
forming a separate and distinct cluster from others within the DVT cohort.  Despite generating 
significantly higher amounts of peak thrombin in the thrombin generation assay, these 4 
patients were shown to externalise only modest quantities of PE and PS.  This shows that 
platelet associated factors other than externalised lipids are important in promoting the 
enhanced support for global coagulation seen in these patients and potentially contributing to 
the thrombotic episodes in these patients.      
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Figure 5.12 Externalisation of PE/PS in thrombin-activated platelets does not correlate with 
peak thrombin generation supported by washed platelets of DVT patients.  The linear 
correlation for each species of PE and PS with peak thrombin generation is shown from the 
most abundant lipid to the least for both healthy controls (black dots) and DVT patients (green 
dots).  The peak thrombin measurements were derived using the individuals’ washed platelets 
(1.5 x 10 8/ml) and a standardised liposome using the thrombin generation assay described in 
Section 4.2.2, Chapter 4.  For each scatter plot, the correlation co-efficient (r squared) is shown 
with the corresponding p-value (P).   
 
 
5.4 Discussion 
This aim of this chapter was to examine whether differences in PE/PS externalisation in 
thrombin-activated platelets of patients with UBDs and venous thrombosis differ from healthy 
controls and are potentially contributory to the pathogenesis of these disorders.  The 
importance of APL exposure in supporting coagulation in human disease has previously been 
demonstrated in Scott syndrome, whereby failure of platelets to externalise PE/PS due to 
defective scramblase activity results in bleeding symptoms [95].  It was therefore hypothesised 
that the platelets of UBD patients may have reduced ability to externalise PE and PS akin to a 
mild form of Scott syndrome.  However, the quantities of PE or PS externalised following 
thrombin activation were similar between the UBD patients and healthy controls providing no 
support for this hypothesis.  Similarly, no changes in PE or PS externalisation were observed in 
thrombotic patients compared with healthy controls.   
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It is well established that the exposure of PS on the activated platelet surface membrane is 
essential for the interaction with calcium and the Gla domains of Vitamin K dependent clotting 
factors thus promoting coagulation in vitro.  The function of PS is enhanced by PE  [106, 107].  
This is supported by the data from the Scott syndrome patient reported here where very low 
levels of thrombin generation are associated with limited externalisation of PS and PE.  The 
data presented in this chapter show that externalisation of PS and PE does not contribute to 
the excessive bleeding in UBDs or to increased coagulation in patients with venous thrombosis. 
This means that the reduced ability of washed platelets to support peak thrombin generation 
reported in Chapter 4 in UBD patients cannot be explained by decreased externalisation of PS 
or PE and other mechanisms need to be sought.     
Apart from Scott syndrome the APL composition of the platelet membrane has not been 
extensively investigated in other bleeding or thrombotic disorders to date.  Recent work has 
demonstrated increased numbers of PS- positive platelets in hypercoagulable conditions 
including cancer and essential thrombocythaemia although to date this has been limited to 
techniques such as annexin V or lactadherin binding.  These techniques confirm the presence 
of externalised PS or PE rather than measuring the actual quantity of individual species as 
conducted in this study for the first time [204, 237].  There is increasing evidence to suggest 
that other blood cells and their interaction with platelets are important in thrombus 
formation.  For example, eosinophils were recently shown to expose APL on ADP activation, 
thus enhancing thrombin generation [238].  Furthermore, it was reported that the contact of 
platelets with red blood corpuscles is important in mediating PS exposure on red blood cells 
and promoting platelet activation and adhesion in pathological thrombi through FAS-L/FAS-R 
interactions [239].  As demonstrated here, increased APL exposure was not observed in 
platelets of DVT patients when they were activated and investigated following their isolation 
from whole blood.   
The second aim of this chapter was to investigate the contribution of externalised species of 
PE and PS to the measured peak thrombin generation.  Moderately positive correlations were 
demonstrated in the UBD cohort showing that the thrombin generation assay performed on 
washed platelets was, at least in part, sensitive to the amount of externalised PS and PE.  
However, when the amount of externalised PS and PE was directly compared it was found to 
be similar in the UBD patients and the healthy controls (Figure 5.5 and 5.7). This suggests that 
the decreased ability of washed platelets from patients with UBDs to support peak thrombin 
generation was not due to decreased externalisation of PS and PE.    
Positive correlations between peak thrombin and native phospholipids were also seen in 
healthy controls, although the associations tended to be weaker than for the bleeding disorder 
cohort.  Possible explanations for weaker correlations in the controls could include the age and 
gender difference between the disease and control group.  It is notable that there was a clear 
female predominance in the bleeding cohort (18 females, 2 males), most of whom were within 
a similar age group (45-81 years).  This contrasts with the control group, which consisted of a 
more equal gender mix (16 females, 13 males) spanning over a wider age range (21- 69 years).  
The effect of age and gender on the externalisation of platelet lipids is unknown although 
reports of an association with gender exist in the generation of oxidised phospholipids in 
human platelets[240]. 
No association was found between the amount of externalised APL and peak thrombin 
generation in the thrombotic group. This suggested that the thrombin generation assay was 
not sensitive to externalised PS/PE in this situation and that the increased ability of the 
platelets of thrombosis patients to support global coagulation was not primarily due to 
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increased externalisation of phospholipids. This was confirmed when the amounts of 
externalised PS/PE were directly measured (Figure 5.8 and 5.10) as similar amounts were 
found in the thrombosis patients and healthy controls. The increased ability of the platelets 
from the thrombosis patients to support thrombin generation was likely, therefore, to be 
caused by mechanisms other than externalised PS/PE and further studies will be required to 
investigate this.  
The four thrombosis patients whose platelets supported substantially higher amounts of 
thrombin generation compared to other patients in the cohort and controls had widely 
variable amounts of externalised phospholipids.  It is important to note that samples for 
thrombin generation and lipid analysis were collected separately on consecutive days and as 
discussed previously, a higher incidence of spontaneous platelet aggregation occurred in DVT 
patients suggesting a degree of platelet hyper-reactivity.  This implies that platelets in patients 
at the time of thrombosis may behave in a less predictable or uniform manner compared to 
non-thrombotic states.  Differences in the in-vivo environment may account for this for 
example exposure to local pro-inflammatory stimuli which are considered to be influential in 
the formation of venous thromboembolism [241].   
In contrast to platelets, there is extensive evidence supporting the role of platelet and other 
cell-derived microvesicles in promoting both arterial and venous thrombosis.  Experiments 
determining the quantities of individual PE and PS species from platelet-derived microvesicles 
of patients within the thrombotic or bleeding cohorts were not carried out here, and further 
work is needed to investigate this fully.  The experiments conducted in this chapter did not 
identify changes in APL externalisation in thrombin-activated platelets that could account for 
the bleeding or thrombotic symptoms of the two independent cohorts.  It is therefore possible 
that changes in other lipids in the platelet membrane may be influential in UBD and 
thrombotic patients.  Further research is required to evaluate these findings in other bleeding 
and arterial thrombotic disorders, as well as examine the inter-relationship between APL and 
oxidised lipids in haemostatic disorders.  
In conclusion the changes in thrombin generation described in patients with UBDs and venous 
thrombosis cannot be attributed to externalisation of unoxidised PS and PE and other 
mechanisms needed to be considered. Therefore, the potential role of eoxPLs was investigated 
and this is described in the next chapter.   
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Chapter 6 - The generation of eoxPL by activated human platelets in UBD 
and DVT patients 
6.1 Introduction 
It has been almost a decade since a family of oxidized phospholipids were shown to be 
generated enzymatically via 12-LOX in human platelets.  Specifically, thrombin-activated 
platelets were demonstrated to generate six molecular species of 12-HETE-PLs, consisting of 
four 12-HETE-PEs ((PE (16:0p_12-HETE), PE(18:1p_12-HETE), PE(18:0p_12-HETE) and 
PE(18:0a_12-HETE-PE)) and two 12-HETE-PCs (PC(16:0a_12-HETE, PC(18:0a_12-HETE-PC)) as 
described in Chapter 1 [134].  Since this discovery, there have been further advances in the 
understanding of the role of eoxPL in haemostasis and thrombosis. 
Following observations that both 12-HETE-PEs and 12-HETE-PCs could promote coagulation by 
enhancing the function of externalised PS in vitro, subsequent studies in vivo have supported 
these findings [146, 149].  Firstly, it was shown that mice lacking the Alox15 or Alox12 gene 
were more susceptible to haemorrhage after a haemostatic challenge and that injection of 12-
HETE-PE and 12-HETE-PC resulted in a reduction in bleeding [146].  In human platelets from 
patients with antiphospholipid syndrome and venous thrombosis, increased amounts of 12-
HETE-PE were measured in lipid extracts compared with those from healthy controls [146].  In 
patients post cardiopulmonary bypass (CPB) who have an increased risk of bleeding, 12-HETE-
PE generation was shown to be reduced in platelets compared to pre-operatively [149].  Thus, 
there is increasing evidence to suggest that HETE-PLs have a role in maintaining haemostasis 
and that they may be implicated in the pathogenesis of bleeding and thrombotic disorders.            
Methods of analysing HETE-PLs in previous studies have used a targeted lipidomics approach 
using LC/MS/MS on a Q-Trap instrument (Applied Biosystems 4000 Q-Trap) operating in the 
negative mode [134].  The same method of analysis was used for the work described in this 
chapter.  Products were analysed using multiple reaction monitoring (MRM) enabling the 
detection of several compounds at the same time by monitoring specific transitions from the 
parent ion to the daughter ion (m/z 179.2).  
The experiments in this chapter sought to identify whether there were differences in the 
amounts of HETE-PLs generated by platelets from UBD and DVT patients without an associated 
prothrombotic condition such as antiphospholipid syndrome.  
  
 
 
  
 93 
 
6.2 Results 
6.2.1 Identification of 12-HETE-PLs generated by thrombin-activated platelets 
To characterise 12-HETE-PL generation, isolated platelets were left unstimulated or activated 
with thrombin and incubated for 30 minutes prior to lipid extraction in UBDs, DVT patients and 
in healthy controls.  The four molecular species of 12-HETE-PE and the two molecular species 
of 12-HETE-PC were identified with precursor LC/MS/MS scanning in negative mode, using the 
179.2 m/z fragment (the daughter ion of 12-HETE 319.2 m/z) for their detection.   
In 6 out of 73 lipid extracts analysed in this section of the study, it was apparent that platelet 
activation had not occurred as there was no evidence of 12-HETE-PL generation.  This occurred 
in 1 UBD patient, 3 DVT patients and 2 healthy controls.  The UBD patient was re-called as this 
may have had implications with regards to the bleeding diagnosis and repeat testing confirmed 
the presence of six species of 12-HETE-PL on thrombin activation and repeat scanning by 
LC/MS/MS.  The remaining samples (n=5) were excluded as HETE-PL had not been generated 
which was assumed to be due to experimental error with the activation process at the time.  
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6.2.2 Basal concentrations of 12-HETE-PL in UBDs, DVT patients and healthy controls 
Basal concentrations of HETE-PL were detected in very small quantities and therefore, the 
most abundant positional isomer of 12-HETE-PE and -PC was used to examine whether there 
were any differences exhibited by platelets in the disease cohorts compared with healthy 
controls.  Basal amounts of both PE(18:0a_12-HETE) and PC (18:0a_12-HETE) were similar in 
UBD patients compared to healthy controls, and were not increased in DVT patients.  This 
differs from previous reports of elevated basal amounts of HETE-PE (platelets and neutrophils) 
in a thrombotic cohort of patients with antiphospholipid syndrome.  It is notable however, that 
in 7 of the 12 antiphospholipid patients included, the unactivated platelets spontaneously 
aggregated during isolation.  Here, despite the higher incidence of platelet aggregation in DVT 
patients compared with healthy controls as described in Chapter 3, samples were not analysed 
further in the event of visible clumping.  It is possible that higher quantities of 12-HETE-PE may 
have been detected in the platelet isolates of these DVT patients if they had been analysed. 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Basal concentrations of 12-HETE-PL are similar in healthy controls, UBDs and DVT 
patients Washed platelets were isolated from healthy controls, UBD and DVT patients and left 
unstimulated for up to 30 minutes.  Basal concentrations of the most abundant 12-HETE 
positional isomer for PE and PC is shown.  Platelet isolates which spontaneously aggregated 
during the isolation process were discarded.  Healthy controls are depicted in blue, UBD 
patients in red and DVT patients in green.  Data is shown in bar charts and expressed as mean 
basal concentration +/- S.E.   
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6.2.3 Generation of 12-HETE-PL by thrombin- activated platelets of UBD patients 
 
In healthy controls and disease cohorts, all six molecular species of 12-HETE-PL were 
generated following thrombin activation displaying a similar pattern of distribution.  There was 
a trend towards lower quantities of 12-HETE-PE in thrombin-activated platelets of UBD 
patients compared to healthy controls, although this did not reach statistical significance.  
Platelets from the Scott syndrome patient generated all four molecular species of 12-HETE-PE 
in comparable amounts to healthy controls and the UBD cohort as previously shown[134].  
However, unlike the native externalised species of PE and PS, the amount of externalised 12-
HETE-PE in the platelets of the Scott patient was not measured in this study.  Therefore, 
conclusions about the contribution of 12-HETE-PE in supporting coagulation in the Scott 
patient cannot be inferred from this data.  
 
  
 
Figure 6.2a. A trend towards lower quantities of the four molecular species of 12-HETE-PE is 
shown in thrombin-activated platelets of UBD patients.  Lipid extracts from washed human 
platelets were activated with 0.2 units/ml thrombin for 30 minutes at 37 0C and separated 
using LC/MS/MS with negative precursor scanning for 179.2 m/z (the daughter ion of 12-HETE 
319.2 m/z) as described in Section 2.14, Chapter 2.  The four molecular species of 12-HETE-PE 
(PE (16:0p_12-HETE), PE(18:1p_12-HETE), PE(18:0p_12-HETE) and PE(18:0a_12-HETE-PE)) 
generated in response to thrombin activation in platelets from healthy controls (blue) and UBD 
patients (red) is shown.  Data from a patient with Scott syndrome is depicted by the red star.  
Data shown are median values (horizontal black bar), interquartile range (box) and maximum 
and minimum values (whiskers).  P values were calculated using the Mann Whitney U test 
excluding the Scott patient. 
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Table 6.1. Descriptive data for 12-HETE-PE species 
PE(18:0a_12-HETE) 
(ng/2 x 107 platelets) 
UBD patients 
N=20  
Healthy controls 
N=25 
DVT patients 
N=20 
Median 9.72 14.66 20.58 
25th centile 5.19 7.71 10.90 
75th centile 14.85 20.79 27.70 
Mean 10.35 14.68 22.20 
Std Deviation 5.81 9.46 12.73 
Std Error 1.30 1.89 2.85 
 
PE(16:0p_ 12 HETE) 
(ng/2 x 107 platelets) 
UBD patients 
N=20 
Healthy controls 
N=25 
DVT patients 
N=20 
Median 1.05 1.32 2.29 
25th centile 0.49 0.71 1.69 
75th centile 1.58 2.38 3.45 
Mean 1.21 1.59 2.56 
Std Deviation 1.01 1.59 1.54 
Std Error 0.23 0.21 0.34 
 
PE(18:1p_ 12 HETE) 
ng/2 x 107 platelets 
UBD patients 
N=20 
Healthy controls 
N=25 
DVT patients 
N=20 
Median 1.61 3.24 4.68 
25th centile 0.91 1.42 3.32 
75th centile 3.02 5.11 6.65 
Mean 2.03 3.35 4.90 
Std Deviation 1.59 1.59 2.52 
Std Error 0.36 0.36 0.56 
 
PE(18:0p 12 HETE) 
ng/2 x 107 platelets 
UBD patients 
N=20 
Healthy controls 
N=25 
DVT patients 
N=20 
Median 1.61 3.24 4.68 
25th centile 0.91 1.42 3.32 
75th centile 3.02 5.11 6.65 
Mean 2.03 3.35 4.90 
Std Deviation 1.59 1.59 2.52 
Std Error 0.36 0.36 0.56 
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There was significantly less PC(18:0a_12-HETE) generated in the thrombin activated platelets 
in the UBD group (median IQR 9.5 ng/2 x 107 platelets (3.5-18.9)) compared to healthy controls 
(30.7 ng/2 x 107 platelets (13.8-41.8).  This finding is of potential clinical interest since 12-HETE-
PCs would be expected to be on the outer leaflet of the activated platelet where they can 
promote coagulation, and therefore reduced amounts could be associated with the bleeding 
that is observed in these patients.  There were also somewhat lower quantities of 
PC(16:0a_12-HETE) but this was not statistically significant.  Platelets from the Scott syndrome 
patient were shown to generate normal quantities of 12-HETE-PC and may explain why Scott 
platelets are able to support a low level of thrombin generation despite the reduced ability to 
externalise native PE and PS as previously reported [134]. 
 
Figure 6.2b. A trend towards lower quantities of the two molecular species of 12-HETE-PC 
generation is shown in thrombin-activated platelets of UBD patients.  Washed platelets from 
UBD patients, healthy controls and a patient were Scott syndrome were thrombin- activated 
and then the lipids were extracted and analysed to detect 12-HETE-PC species.  The quantities 
of the two molecular species of 12-HETE-PC generated by activated platelets of healthy 
controls (blue) and UBD patients (red) is shown.  Data from a patient with Scott syndrome is 
depicted by the red star.  Data shown are median values (horizontal black bar), interquartile 
range (box) and maximum and minimum values (whiskers).  P values were calculated using the 
Mann Whitney U test excluding the Scott patient. 
 
 
 
 
 
 
 
 
 
 98 
 
Table 6.2. Descriptive data for 12-HETE-PC species 
 
18:0a 12 HETE PC 
ng/2 x 107 platelets 
UBD patients 
N=20 
Healthy controls 
N=25 
DVT patients 
N=20 
Median 9.52 30.74 28.58 
25th centile 3.50 13.84 18.54 
75th centile 18.94 41.76 49.53 
Mean 14.46 30.01 34.94 
Std Deviation 15.80 19.13 20.16 
Std Error 3.82 3.825 4.51 
 
16:0a 12 HETE PC 
ng/2 x 107 platelets 
UBD patients Healthy controls DVT patients 
Median 21.81 42.15 39.10 
25th centile 10.47 18.25 24.12 
75th centile 35.63 51.84 79.23 
Mean 30.17 39.60 57.12 
Std Deviation 28.14 24.50 45.03 
Std Error 6.293 4.900 10.07 
 
 
 
6.2.4 Generation of 12-HETE-PL by thrombin-activated platelets of DVT patients 
After the activation of platelets with thrombin, all four 12-HETE-PE species were increased in 
the thrombotic cohort compared with the healthy controls.  This was statistically significant in 
for 3 of the species and borderline for one (Figure 5.3b).  This may have potential implications 
as 12-HETE-PE supports increased thrombin generation and so may contribute to the 
prothrombotic phenotype of this cohort.  It is not known whether the increased amounts of 
HETE-PE were causally associated with the thromboses or a consequence of the event as 
samples were taken at the time of the acute thrombotic episode.    
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Figure 6.3a. Higher quantities of 12-HETE-PE species are generated by thrombin-activated 
platelets in DVT patients.  Platelets were prepared and activated as described in The four 
molecular species of 12-HETE-PE (PE (16:0p_12-HETE), PE(18:1p_12-HETE), PE(18:0p_12-HETE) 
and PE(18:0a_12-HETE)) generated in response to activation with thrombin in platelets from 
healthy controls (blue) and DVT patients (blue) is shown. Data shown are median values 
(horizontal black bar), interquartile range (box) and values with maximum and minimum 
values (whiskers).  P values were calculated using the Mann Whitney U test. 
 
No differences were observed between the generation of 12-HETE-PC in the healthy controls 
and the DVT patients.  This suggests that the platelets in the thrombotic cohort were not 
systemically activated and the increased amounts of HETE-PE observed could not be attributed 
to this potential mechanism.     
 
Figure 6.3b. Generation of 12-HETE-PC species in thrombin-activated platelets of healthy 
controls and DVT patients is similar.  The two molecular species of 12-HETE-PC (PC (18:0a_12-
HETE) and PC(16:0a_12-HETE) generated in response to activation with thrombin in platelets 
from healthy controls (blue) and DVT patients (green) is shown.  Data shown are median 
values (horizontal black bar), interquartile range (box) and maximum and minimum values 
(whiskers).  P values were calculated using the Mann Whitney U test. 
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6.3.1 Correlation of 12-HETE-PL with peak thrombin generation in UBD patients 
The correlation between measurements of peak thrombin (derived from Chapter 4) and the 
most abundant species of 12-HETE-PL was examined.  In healthy controls, no relationship was 
demonstrated between the amount of thrombin generation supported by washed platelets 
and the most abundant species of 12-HETE-PE and 12-HETE-PC generated after platelet 
activation.  Similarly, no correlation was seen in the UBD cohort for 12-HETE-PE and 12-HETE-
PC.  The washed platelets in the thrombin generation assay were intrinsically activated instead 
of directly with an exogenous agonist, and therefore it is possible that this may have provided 
an insufficient stimulus for the complete generation of eoxPL which may account for the lack 
of correlation. 
 
 
Figure 6.4 Correlation of 12-HETE-PL with peak thrombin generation supported by washed 
platelets in healthy controls and UBD patients.  Thrombin generation supported by washed 
platelets was initiated by addition of a standardised liposome (0.5µM phospholipid/10pM TF) 
as described in Chapter 4.  The correlation of peak thrombin measurements with the 
quantities of PE(18:0a_12-HETE) and PC(18:0_12-HETE) (ng/2 x 10 7 platelets) generated from 
thrombin-activated platelets is shown for both healthy controls (black) and UBD patients 
(coloured dots).  For each correlation plot, the correlation co-efficient (r squared) is shown 
with corresponding p-values (P).   
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6.3.2 Correlation of 12-HETE-PL with peak thrombin generation in DVT patients 
Finally, the correlation between peak thrombin and the 18:0/12-HETE positional isomer was 
also examined in the DVT cohort.  As with healthy controls and UBD patients, no relationship 
was demonstrated between the amount of thrombin generated by washed platelets and the 
most abundant species of 12-HETE-PE and 12-HETE-PC.  The same non-uniform pattern of 
clustering was observed between the 4 thrombotic outliers that were identified in the previous 
chapters and the rest of the DVT cohort.     
 
Fig 6.5 Correlation of 12-HETE-PL with peak thrombin generation supported by washed 
platelets in healthy controls and DVT patients.  Washed platelets (1.5 x 108/ml) from healthy 
controls and DVT patients were added to liposomes and thrombin generation was measured 
as described in Chapter 4.  The correlation with PE(18:0a_12-HETE) and PC(18:0a_12-HETE) is 
shown for both healthy controls (black) and DVT patients (green dots).  For each scatter plot, 
the correlation co-efficient (r squared) is shown with the corresponding p-value (P).   
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6.4 Discussion 
The aim of this chapter was to investigate whether there were differences in the amounts of 
HETE-PLs generated from platelets in patients with UBD and DVT.  Overall patients with UBDs 
had a trend towards lower quantities of 12-HETE-PC and 12-HETE-PE whilst those with a 
thrombotic event had higher 12-HETE-PE but no change in 12-HETE-PC.   
The reduction in 12-HETE-PC species in UBDs was statistically significant for PC(18:0a_12-HETE) 
and the median level was significantly lower than in the healthy control group.  Incorporation 
of 12-HETE-PC into a membrane enhances thrombin generation and so the reduced amount 
found in the platelets of patients with UBDs would be anticipated to limit their ability to form 
clots in vivo.  In addition, there was a trend towards low levels of PC(16:0a_12-HETE) and all 
species of 12-HETE-PE.  It is possible that the combined effect of the reduced levels of these 
species might contribute to the ability of these platelets to support coagulation in vivo.  
Overall, the reduced levels of 12-HETE-PL species may explain at least in part, why the platelets 
of patients with UBDs supported lower peak levels of thrombin in the functional experiments 
despite externalising normal amounts of PS and PE.  This may also explain the increased 
bleeding seen at the time of invasive procedures. It is interesting to note that patients with 
UBDs do not bleed spontaneously but only at the time of invasive procedures or haemostatic 
challenge such as menstruation.  Similarly, mice lacking the ability to produce HETE-PE and 
HETE-PC only bleed after a haemostatic challenge such as tail transection which could be 
analogous to the operative procedures that were undergone by UBD patients recruited into 
this study [238].   
Although there was a reproducible trend towards lower quantities of all 12-HETE-PE species in 
the UBD cohort this did not reach statistical significance.  This may reflect the limited numbers 
of patients available to the study and the inherent wide variability of HETE-PE levels.  The 
alternative explanation is that HETE-PE levels are not reduced in patients with UBD and this 
will need to be resolved by investigating further patients.   
There was wide variation in the quantities of the six species of 12-HETE-PL generated by 
healthy donors and the disease cohorts.  Previous studies have reported similar findings 
amongst platelets from donors with regards to the formation of HETE-PLs.  For example, 
following activation with thrombin, levels of approximately 6 ng +/-1.42 ng/4 x 10 7 platelets 
(12-HETE-PE) and 18 +/- 4.61 ng/4 x 107 platelets (12-HETE-PC) were measured in 5 healthy 
donor platelets [134].  In another study, quantities of 12-HETE-PE in human platelets were 
reported to be in the range of 23 ng/4 x 107 platelets [146].  Here, the average quantity of 
PE(18:0a_12-HETE) in healthy controls was 14 ng/2 x 10 7platelets (SE 1.8) and the average 
quantity of PC(18:0a_12-HETE) was 30 ng/2 x 10 7 platelets (SE 3.8).  
Whilst 12-LOX mediates the oxidation of free fatty acids into 12-HETE, the formation of HETE-
PL is a rapid process which is governed by a series of enzymatic reactions involved in the Lands 
cycle [141].  As described in Chapter 1, the hydrolysis of a Sn2 fatty acid by phospholipase A2 
yields the fatty acid substrate which is available for oxidation by lipoxygenase.  The resultant 
lysophospholipid is then re-esterified by acyl coA-ligases and lysophospholipid acyltransferases 
(LPLATs) or membrane bound O-acyl transferases (MBOATs) to re-form the specific 
phospholipid species [166, 167].  The substrate preference of these enzymes for different 
species of oxidised fatty acids however is not yet established in human platelets.  As PC is the 
most abundant phospholipid in the platelet membrane, it would be anticipated that lyso-PC 
would be plentiful in supply as a substrate.  It is therefore possible that reduced activity in an 
LPLAT or MBOAT enzyme that has greater specificity for the acylation of oxidised fatty acids 
into lyso-PC rather than lyso-PE could account for differences in the generation of 12-HETE-PC 
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and 12-HETE-PE that was shown here.  However, at the current time this is unknown and 
future work will be required to inform this.    
It is important to note, that whilst levels of 12-HETE-PC were lower overall in the UBD cohort, 
some of the patients generated levels comparable with healthy controls.  This suggests that 
whilst some UBDs might be associated with reduced 12-HETE-PC, the group as a whole is 
heterogenous and the causes of bleeding may be attributable to more than one factor which 
may differ from one individual to another.  A reduction in procoagulant 12-HETE-PC was 
observed in the whole group of UBD patients, demonstrating that reduced levels are present in 
proportion of this cohort of patients, other patients are likely to have different underlying 
causes for bleeding.  This finding should be considered as hypothesis generating and would 
need to be reproduced in an independent group of UBD patients before any conclusion can be 
made regarding the potential contribution of 12-HETE-PC to the bleeding phenotype of these 
patients.  This could potentially be a focus for future work and would require collaboration 
with other haemophilia centres.   
In the patients with acute DVT, higher quantities of 12-HETE-PE species were observed 
compared to healthy controls and this was statistically significant for 3 species and borderline 
for the fourth.  The amount of 12-HETE-PC was unchanged suggesting that the raised 12-HETE-
PE levels were a specific finding and not simply due to systemic activation of platelets at the 
time of the thrombotic event.  It has previously been shown that 12-HETE-PE enhances 
thrombin generation through the intrinsic tenase and prothrombinase reactions. The increased 
platelet HETE-PE found in this study may explain the ability of washed platelets from patients 
with venous thrombosis to support enhanced thrombin generation.  In addition, they could 
support enhanced thrombin generation in vivo and hence could potentially contribute to the 
prothrombotic state.  In animal studies, mice that are unable to make HETE-PEs are protected 
against an induced thrombosis [238].  It is possible, however that the thrombosis caused the 
increased HETE-PEs.  In a recent study, increased HETE-PE were measured in circulating 
leucocytes and platelets of patients with a past history of thrombosis associated with the 
antiphospholipid syndrome [146] suggesting that the changes may persist.  To investigate 
further the patients in this study could be retested to establish whether their HETE-PE levels 
are still raised.  
Lastly, as changes in eoxPL were demonstrated in the experiments conducted in this chapter, 
their correlation with the peak thrombin measurements from Chapter 4 was investigated.  It 
was hypothesised that lower quantities of 12-HETE-PC may contribute to the lower thrombin 
generation observed in the UBD patients and the higher quantities of 12-HETE-PEs may play a 
role in the higher thrombin generation seen in the DVT cohort.  As described in Chapter 4, the 
platelets used in the thrombin generation assay were intrinsically activated whereas 12-HETE-
PLs were generated following activation of platelets with thrombin.  It is possible, that there 
was incomplete generation of 12-HETE-PL in the platelets used in the thrombin generation 
assay in the absence of an exogenous agonist.       
In summary, the experiments in this chapter identified trends in lower quantities of 12-HETE-
PE and 12-HETE-PC in UBD patients compared with healthy controls.  Further studies in an 
independent cohort of UBD patients is required to confirm these findings.  Higher quantities of 
12-HETE-PE were demonstrated in the thrombotic cohort, supporting a potential role for these 
HETE-PL in promoting coagulation.  These findings require further confirmation in larger 
studies. 
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Chapter 7- The effect of DDAVP on the thrombin generating capacity and 
phospholipid composition of the platelet membrane in patients with 
UBD 
7.1 Introduction 
Red cell transfusion due to intra-operative blood loss is common in everyday clinical practice.  
Anaemia following surgery is a recognised predictor of increased morbidity and mortality [242].  
The transfusion of blood and its derivatives is associated with potential risks however, such as 
volume overload, blood group incompatibility, transfusion - related acute lung injury and 
transfusion transmitted infections [243]. 
Over the past decade, it has been shown that early administration of the antifibrinolytic drug 
tranexamic acid (TXA) improves survival of patients with major traumatic haemorrhage and is 
also of value in the setting of post-partum and surgical haemorrhage [244] [245].  In patients 
with acquired platelet dysfunction, for example those undergoing cardiopulmonary bypass, 
there is evidence to suggest that the haemostatic agent DDAVP is of value in reducing bleeding 
and transfusion requirements in the perioperative period [246].  Similarly, its use is advocated 
in the setting of excessive bleeding and platelet dysfunction due to uraemia [188, 247].  
DDAVP is an established treatment in patients with congenital defects of platelet function and 
is recommended in guidelines for the bleeding associated with acquired platelet dysfunction 
[188] [247].  By increasing von Willebrand factor release and FVIII, the mechanism of action of 
DDAVP in the treatment of sub-types of von Willebrand disease and mild haemophilia A is well 
established.  Its mechanism of action in managing bleeding in patients with platelet dysfunction 
is not well established but it has recently been attributed to its potential role in increasing 
procoagulant platelets [51]. 
It is reported that up to 88% of patients with UBD experience bleeding at the time of surgery.  In 
a study of 33 UBD patients, 18 patients in the cohort (54.5%) had received red cell transfusion 
and other blood products including fresh frozen plasma (FFP) and cryoprecipitate following 
haemostatic challenges.  It has recently been shown that TXA either alone or in combination 
with DDAVP is an effective management strategy for UBD patients undergoing surgery.  This 
regimen was reported to have efficacy in 90% of patients undergoing both minor and major 
invasive procedures, although the exact mechanism of action of DDAVP in this cohort of patients 
is unknown [184]. 
The aim of this chapter was to investigate the effect of DDAVP on externalised species of PE and 
PS in UBD patients undergoing a haemostatic procedure.  In addition, the effect of DDAVP on 
the generation of eoxPL and thrombin generation supported by washed platelets was also 
examined.   
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7.2 Demographics and clinical details of UBD patients receiving DDAVP 
Three patients diagnosed with UBD and 1 patient with a platelet function defect (PFD) were 
admitted for a planned elective invasive procedure and were therefore recruited to this section 
of the study.  The diagnosis of UBD was made in 3 patients in accordance with criteria outlined 
in Chapter 2.  The remaining patient had been diagnosed with a PFD following presentation with 
easy bruising and had a reproducible absent response to adrenaline on platelet aggregometry 
testing.  The patient demographics, bleeding score and details of previous haemostatic 
challenges are shown in Table 7.1.   
   
Table 7.1 Details of bleeding score and previous haemostatic challenges in UBD patients 
undergoing a haemostatic challenge. 
 
Age/gender Diagnosis ISTH BAT 
Bleeding 
score 
Previous haemostatic challenge 
(agent) 
Clinical 
outcome of 
previous 
treatment 
58 F UBD 11 Endometrial ablation & insertion 
of a mirena coil (DDAVP & TXA) 
No bleeding 
56 F UBD 11 Discectomy (DDAVP & TXA) 
Bunion removal (DDAVP &TXA) 
No bleeding 
67F UBD 6 Shoulder arthroscopy x 3 (DDAVP 
& TXA) 
Bunion removal (DDAVP &TXA) 
No bleeding 
54F PFD 3 3 x dental extraction (TXA) No bleeding 
(UBD = Unclassified bleeding disorder; PFD = Platelet function disorder; DDAVP = 
Desmopressin; TXA = Tranexamic acid; F = Female, ISTH BAT = International Society of 
Thrombosis and Haemostasis Bleeding Assessment Tool) 
 
A blood draw (in the absence of DDAVP) was taken from each patient and the washed platelets 
were isolated as outlined in Chapter 2.  Baseline thrombin generation supported by washed 
platelets was measured and phospholipids were extracted from thrombin-activated platelets 
using the experimental methods detailed previously.  DDAVP was administered to all patients 
either intravenously (IV) or subcutaneously (SC) at a dose of 0.3 µg/kg prior to the haemostatic 
procedure.  A further blood draw was taken 1.5- 2 hours following drug administration and 
both thrombin generation and phospholipid extraction were re-performed.  Details and clinical 
outcome of the procedure are shown in Table 7.2. 
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Table 7.2 Details and clinical outcome of haemostatic procedure in UBD patients receiving 
DDAVP 
Patient Diagnosis Drug/route Procedure Clinical 
outcome 
1 UBD DDAVP SC Dental extraction No bleeding 
2 UBD DDAVP IV Fundoplication & banding of 
haemorrhoids  
No bleeding 
3 UBD DDAVP SC Excision of skin lesion No bleeding 
4 PFD DDAVP IV Bowel resection No bleeding 
(UBD = Unclassified bleeding disorder; PFD = Platelet function disorder; DDAVP = 
Desmopressin SC = Subcutaneous; IV = intravenous) 
7.3 Results 
7.3.1 The effect of DDAVP on thrombin generation in UBD patients 
Thrombin generation supported by washed platelets was measured before and after DDAVP.  In 
all 3 UBD patients an increase in peak thrombin generation and velocity index was demonstrated 
after drug administration.  This was not statistically significant for the group probably due to 
insufficient numbers (Figure 7.1).  There was insufficient time to recruit more patients because 
they could only be tested at the time of an invasive procedure when DDAVP was due to be 
administered.  The peak thrombin generation for the 3 UBD patients at baseline (before DDAVP) 
was in a range of 50-73.5 nM which is low compared to healthy controls but comparable to other 
UBD patients as shown previously (Figure 4.4 and Table 4.1).   No change in these parameters 
occurred in the patient with PFD apart from a shortening in the lag time.  DDAVP had no effect 
on the ETP or the lag time in the UBD patients. 
Patients 1 and 3 were treated with subcutaneous DDAVP and their peak thrombin generation 
increased 1.3 and 1.5 fold, respectively. Patient 2 was treated with intravenous DDAVP and their 
peak thrombin generation increased 2.2 fold suggesting that this mode of administration was 
associated with a larger effect of thrombin generation. However, more patients will need to be 
studied to establish whether there is a reproducible association between mode of 
administration of DDAVP and effect on thrombin generation. 
Two of the 3 UBD patients (Patient 1 and Patient 2) had been recruited previously.  Their peak 
thrombin generation on initial testing and subsequently during investigation of the effect of 
DDAVP are shown in Table 7.3.  The baseline thrombin generation of the two patients was 
reproducibly low compared to healthy controls demonstrating that the finding was consistent 
over time.     
Table 7.3 Peak measurements of thrombin at baseline and following DDAVP 
Peak TG 
(UBD range:- 
56.93-87.68nM) 
Baseline peak TG 
(nM) 
 
Baseline peak TG 
(nM) (pre-DDAVP) 
 
Peak TG (nM) 
(post-DDAVP) 
 
Date of sample 
collection 
Autumn 2017 Spring 2019 Spring 2019 
Patient 1 80.71 50.00 65.72 
Patient 2 56.85 73.50 157.86 
Patient 3 ---- 64.04 93.00 
 (UBD= unclassified bleeding disorder; DDAVP = desmopressin; TG = thrombin generation) 
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Fig 7.1 Trends towards increased measurements of peak thrombin and velocity index are 
shown in UBD patients after DDAVP infusion.  Baseline measurements of peak thrombin 
generation, velocity index, lag time and ETP are shown for UBD patients (n=3) and a patient 
with PFD (n=1).   Patient 1, 2 and 3 are represented by red, blue and green coloured shapes 
(dots and squares) respectively.  Patient 4 is the single patient with PFD and is represented by 
black dots and squares.  The P values were calculated using the Wilcoxon matched pairs test (2 
tailed). 
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7.3.2 The effect of DDAVP on externalised PE and PS in UBD patients 
Using methods described in Chapter 2, washed platelets were activated with thrombin and the 
externalised lipids were extracted and quantitated using LC/MS/MS.  In all 3 UBD patients, 
there was a statistically significant increase in externalisation of all species of PS (P< 0.05) after 
DDAVP.  A trend towards an increase in individual PE species was observed in the patient with 
PFD and the 3 UBD patients, although this did not reach statistical significance.  These trends 
were consistent for each species of lipid as shown in Figure 7.2. 
The amounts of species of PS and PE at initial testing when first enrolled and subsequently 
tested during investigation of the effect of DDAVP are shown in Table 7.3 for Patient 1 and 
Patient 2 who were recruited previously.  The results show that the levels were broadly 
reproducible.    
Table 7.4 Measurements of externalised PE/PS species at baseline and following DDAVP 
  
 
 
 
Patient 1 Baseline (1st time) 
Ext aPL 
ng/4x107platelets 
 
Baseline (pre-DDAVP) 
Ext aPL 
ng/4x107platelets 
 
Post DDAVP 
Ext aPL 
ng/4x107platelets 
 
Date of 
sample 
collection 
Autumn 2017 Spring 2019 Spring 2019 
DOPS 1.71 1.42 2.79 
SOPS 5.61 3.50 6.91 
SAPS 7.25 5.37 11.07 
PpAPE 11.00 9.66 14.32 
SOPE 1.91 1.18 2.04 
SpAPE 20.8 49.5 47.67 
SAPE 18.7 11.60 16.87 
Patient 2 Baseline (1st time) 
Ext aPL 
ng/4x107platelets 
 
Baseline (pre-DDAVP) 
Ext aPL 
ng/4x107platelets 
 
Post DDAVP 
Ext aPL 
ng/4x107platelets 
 
Date of 
sample 
collection 
Autumn 2017 Spring 2019 Spring 2019 
DOPS 0.73 0.53 2.06 
SOPS 3.11 1.74 6.91 
SAPS 3.92 2.65 10.71 
PpAPE 4.44 4.58 26.25 
SOPE 1.7 0.52 2.04 
SpAPE 13.9 24.29 112.59 
SAPE 5.9 6.11 26.46 
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Figure 7.2 Externalisation of PS species is increased in UBD patients after DDAVP infusion.  
Measurements of each species of PE and PS is shown for the UBD patients (n=3) and the 
patient with PFD (n=1) at baseline and following administration of DDAVP.  P values for the 
UBD cohort were calculated using the Wilcoxon matched pairs test (two-sided) with the 
exclusion of the patient with PFD.   
 
7.3.3 The effect of DDAVP on 12-HETE-PL in UBD patients 
Lastly, to evaluate whether DDAVP would have an influence on the generation of eox PL, lipid 
extracts from thrombin-activated washed platelets were fragmented by LC-MS/MS and the six 
12-HETE-PE and -PC species were identified using the 12-HETE daughter ion m/z 179.2.  A high 
degree of variability was observed amongst the 4 patients.  There was no clear pattern evident 
in terms of the response to treatment with DDAVP (Figure 7.3) although there was a trend for 
HETE-PE to increase.  Further patients need to be investigated to address this question. 
The results of HETE-PL generated from thrombin-activated platelets at baseline and 
subsequently following DDAVP are shown in Table 7.4 for Patient 1 and Patient 2 who were 
recruited previously.   
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Table 7.5 Generation of 12-HETE-PL at baseline and following DDAVP 
 
 
Patient 1 Baseline (1st time) 
12-HETE-PL 
ng/2x107platelets 
 
Baseline (pre-DDAVP) 
12-HETE-PL 
ng/2x107platelets 
 
Post DDAVP 
12-HETE-PL 
ng/2x107platelets 
 
Date of sample 
collection 
Autumn 2017 Spring 2019 Spring 2019 
PE(18:0a_12-HETE) 19.55 20.47 20.35 
PE(16:0p_12-HETE) 1.32 1.83 2.13 
PE(18:1p_12-HETE) 0.91 0.79 1.14 
PE(18.0p_12-HETE) 3.22 3.88 4.92 
PC(18:0a_12-HETE) 9.44 40.58 30.59 
PC(16:0a_12-HETE) 20.00 60.44 36.30 
Patient 2 Baseline (1st time) 
12-HETE-PL 
ng/2x107platelets 
 
Baseline (pre-DDAVP) 
12-HETE-PL 
ng/2x107platelets 
 
Post DDAVP 
12-HETE-PL 
ng/2x107platelets 
 
Date of sample 
collection 
Autumn 2017 Spring 2019 Spring 2019 
PE(18:0a_12-HETE) 6.41 8.77 20.35 
PE(16:0p_12-HETE) 0.79 0.81 3.96 
PE(18:1p_12-HETE) 0.35 0.29 1.90 
PE(18.0p_12-HETE) 1.36 1.75 9.33 
PC(18:0a_12-HETE) 15.07 19.50 29.95 
PC(16:0a_12-HETE) 31.07 27.12 29.31 
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Figure 7.3. DDAVP has a variable effect on the generation of 12-HETE-PL species in UBD 
patients.  Measurements of each species of 12-HETE- PE and 12-HETE-PC is shown for the UBD 
patients (n=3) and the patient with PFD (n=1) at baseline and following administration of 
DDAVP.  P values for the UBD cohort were calculated using the Wilcoxon matched pairs test 
(two-sided) with the exclusion of the patient with PFD.   
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7.4 Discussion 
In this chapter, the effect of DDAVP on the thrombin generating-capacity of washed platelets 
in UBD patients was investigated.  In addition, its effect on the externalisation of PE/PS species 
and generation of eoxPL in this patient cohort was also explored. 
Following DDAVP infusion, an increase in peak thrombin was demonstrated in all 3 patients 
with UBD although this did not reach statistical significance.  Recruitment was limited by the 
small number of UBD patients undergoing a haemostatic procedure during the study period.  
Using these data to inform a power calculation (using an alpha of 0.05 and a power of 0.9), a 
sample size of 8 UBD patients would be required to identify whether DDAVP has a significant 
effect on thrombin generation.   
The re-testing of the two UBD patients on two separate occasions was associated with 
reproducibly low results but variability over time was seen.  This is reflected in the high co-
efficient of variance (CV 40%) of the thrombin generation assay, and the significant overlap 
between peak thrombin measurements in the UBD cohort and healthy controls as observed in 
Chapter 6.  As a result, there will be a wide ‘acceptable’ range defining ‘normal’ peak thrombin 
generation (68-121 nM) which in this assay overlaps with that of the UBD cohort (56-87nM).  
This suggests that the thrombin generation assay as currently set up is imprecise for diagnostic 
purposes but does appear to demonstrate that people with UBDs as a group have a 
reproducibly reduced ability to support thrombin generation.  
An increase in thrombin generation was observed in all 3 patients after DDAVP, however only 
in Patient 2 was the concentration above the normal range.  Patient 2 was the only patient to 
receive intravenous DDAVP and further work needs to assess whether this is a chance finding 
or of potential clinical importance. Of note, the peak thrombin generation in this patient after 
DDAVP was comparable with the DVT cohort (97-151 nM)  
 The quantities of externalised PE and PS in patients 1 and 2 were largely consistent over time 
(Table 7.4).  In contrast, wide variability was observed in the generation of eoxPL, which 
suggests that their formation although enzymatically controlled, is a far more dynamic and 
temporal process than that which governs the externalisation of native PE/PS (Table 7.5).  It 
may however be too simplistic to expect a high degree of homogeneity between the assays of 
these patients at two very different time points.  Specifically, biological factors such as dietary 
intake, blood levels of lipid and stress hormones in the peri-operative or peri-procedural 
period may be influential as well as the diurnal and seasonal effects on fatty acid metabolism 
[248-250].    
Although no direct comparisons can be made for UBD patients, notable observations can be 
drawn from a study investigating the effect of DDAVP in patients with platelet dysfunction.  In 
38 PFD patients, an increase in thrombin- generating rate was measured following DDAVP 
infusion using platelet rich plasma and gel filtered platelets reconstituted in FV deficient 
plasma.  Furthermore, these patients had generated an increase in PS-exposing procoagulant 
platelets as measured by annexin V binding following DDAVP infusion.  The platelets of these 
PFD patients were activated with convulxin and thrombin prior to measurements of both 
thrombin generation and flow cytometry to promote the generation of procoagulant or 
‘collagen and thrombin-activated (COAT) platelets.’  It is therefore likely that more significant 
differences in peak thrombin generation following DDAVP would have been demonstrated in 
the UBD patients described here, if the platelets had been dually activated with these agonists 
rather than relying on their intrinsic activation induced by the initial thrombin produced in the 
assay by the TF-bearing liposomes.              
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Consistent with the findings of the study above, the 3 UBD patients externalised increased 
quantities of PS following DDAVP infusion and this was also seen in the patient with PFD.  A 
trend towards increased PE species was also observed in all patients but further subjects will 
need to be studies to establish whether this is a statistically significant finding.  It is reported 
that at least 5% of patients with PFD do not respond to the effect of DDAVP in terms of 
enhancing COAT generation as detected by annexin V binding.  In addition, the generation of 
procoagulant platelets in responding patients is reported to continue to increase 2 hours post-
DDAVP peaking at 4 hours after administration.  In the studies reported here samples were 
taken 1.5 hours after DDAVP and despite mass spectrometry being a more sensitive method in 
detecting PE and PS, it is possible that further increases may have been observed if 
measurements had been taken at these later time points.  Although DDAVP appeared to have 
a procoagulant effect in terms of promoting PE/PS externalisation in the 3 UBD patients, it is 
possible a proportion of non-responders may exist as reported in PFD patients.   
In UBD patients, it is known that DDAVP reduces the risk of bleeding at the time of surgery and 
is effective treatment in this group of patients.  Within the limitations of the assay, the finding 
that peak thrombin generation was higher in all 3 UBD patients following DDAVP compared 
with the baseline value at the same time-point, coupled with increased externalised PE/PS 
provides insights into a potential mechanism for its clinical efficacy in UBD patients.  This raises 
the possibility that one of the mechanisms of action of DDAVP to prevent abnormal bleeding at 
the time of surgery may be related to increased thrombin generation due to PS/PE 
externalisation on the surface of platelets.  More data are required to test this hypothesis.      
The mechanism of action of DDAVP in enhancing the ability to form procoagulant platelets has 
been associated with increased platelet intracellular fluxes of Na+ and Ca2+.  It is proposed that 
Na+ entry may occur from activation of non-selective cation channels which interact with 
Na+/Ca2+ exchangers, thereby increasing the intracellular Ca2+ that is necessary for PS/PE 
exposure, particularly when dually activated by collagen and thrombin [251].  It is notable that 
the platelets used in the phospholipid assays of this study were solely activated with thrombin.  
It is possible further differences between pre and post DDAVP samples may have been 
demonstrated following activation of platelets with both agonists. 
It is anticipated that following the generation of eoxPL by activated platelets, the subsequent 
exposure of 12-HETE-PE may parallel that of PS although it is not established whether this 
process occurs by independent mechanisms.  As 12-HETE-PCs are already located on the 
external leaflet of the platelet membrane, it may also be hypothesised that DDAVP may 
enhance their generation.  Within the limitations of this data set, observations of such trends 
or alternatively a counter-effect with native lipids were not apparent. 
In summary, an increase in peak thrombin generation was observed in all 3 UBD patients 
following the administration of DDAVP.  An increase in PE/PS externalisation in the 3 UBD 
patients was demonstrated although no consistent effect was evident with regards to the 
generation of 12-HETE-PL.  The increased externalisation of platelet PS/PE by DDAVP may 
explain why DDAVP is a useful treatment in this situation.  Larger studies on the effect of 
DDAVP in UBD patients are required to confirm these findings and investigate their clinical 
significance.    
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Chapter 8 - General discussion 
The main aim of this thesis was to investigate whether the phospholipid surface of the platelet 
membrane is implicated in bleeding disorders of unknown cause and in venous thrombosis.  
This was investigated using a combination of functional assays tailored to be sensitive to the 
platelet surface and a lipidomics approach specifically focusing on native PE/PS externalised by 
platelets and eoxPL generated following agonist activation.  It is now widely acknowledged 
that APL and eoxPL are procoagulant classes of lipids based on in vitro research demonstrating 
that these specific species of lipids enhance coagulation by increasing thrombin generation 
through the tissue factor FVIIa, tenase and prothrombinase complexes [146, 149].  
Furthermore, platelet phospholipid dysregulation and resultant haemostatic failure in humans 
is best exemplified by the exceptionally rare bleeding disorder Scott syndrome.  In this 
disorder, platelets are able to externalise only very limited amounts of PE and PS and severe 
bleeding occurs at the time of invasive procedures [134, 155] 
The first aim of the thesis was to assess the ability of the platelet phospholipid surface to 
support thrombin generation in patients with UBD and in individuals with acute DVT.  The 
results show that the platelets of patients with UBD have reduced ability to support thrombin 
generation, which may in part explain their bleeding phenotype.  The thrombin generation 
assay was designed to be sensitive to the platelet phospholipid surface, hence a minimal 
amount of phospholipid (0.5 µM) was used in the TF- bearing liposomes in order to increase 
the sensitivity of the assay to the lipid composition of the platelet membrane.  
 In a recent study by Thomas et al, a standard phospholipid composition of 4 µM was used to 
trigger coagulation and there was no difference in the amount of thrombin generated from the 
platelet poor plasma of UBD patients and healthy controls [185].  This study did not investigate 
the patients’ platelets and used excess phospholipid to make the assay sensitive to coagulation 
factors in the plasma.  This demonstrates the importance of the phospholipid composition in 
haemostatic assays and further implicates the phospholipid composition of the platelet 
membrane as having an influence on the underlying pathophysiology of this disorder.  Despite 
the lower peak thrombin measurements and velocity index in the cohort of UBDs 
demonstrated in Chapter 4 of this thesis, there was significant overlap in these parameters 
with the ranges obtained from healthy controls.  The washed platelet thrombin generation 
assay as described in this thesis therefore cannot be used for the diagnosis of UBD in the 
clinical setting but provides some insight into the global pathology underlying UBDs.  However, 
a more sensitive assay might be developed by adjusting the TF and phospholipid composition 
of the triggering liposomes or using FXa/FVa cleavage of FII as the read- out rather than pooled 
plasma.         
Higher peak thrombin generation and velocity index were demonstrated in thrombosis 
patients, however whilst this may suggest an increased ability of the platelet surface to 
support thrombin generation a degree of caution with regards to over-interpretation is 
required due to the increased platelet hyper-reactivity observed from samples collected from 
these individuals.  Although moderate correlations of peak thrombin generation with APL 
externalisation were observed in the healthy controls and UBD patients, changes in 
externalised PS/PE could not explain the increased peak thrombin generation because this was 
shown to be the same in the two groups. The changes in thrombin generation might more 
accurately reflect changes in eoxPL that were observed in the two cohorts of patients in 
Chapter 6.  The lack of correlation between measurements of peak thrombin generation and 
eoxPL for individual study participants could be due to the intrinsic activation of platelets in 
the assay rather than exogenously with thrombin for example.   
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Additionally, it was shown that the microvesicles of UBD patients had reduced ability to 
support thrombin generation which may be an additional risk factor for the bleeding observed 
in UBD patients.  As discussed previously, these microvesicles were derived from the 
supernatant of the individuals’ platelet poor plasma and were therefore not only platelet-
derived but are likely to also have been generated from white cells or endothelial cells.  The 
microvesicles isolated and tested in this thesis were representative of resident microvesicles in 
the patients’ plasma in the ‘resting state’.  The thrombin generation supported by the 
microvesicles of DVT patients was not increased compared to healthy controls, which differs 
from reports of their elevation in cancer associated thrombosis and their proposed role in 
promoting arterial and venous thrombosis [205, 234].  It is possible that isolating platelet-
derived microvesicles following activation with an agonist may have demonstrated differences 
in this regard.  Further in-depth investigation of platelet-derived microvesicles in UBDs and 
thrombosis patients is required in a specialist laboratory using ISEV recommendations for their 
isolation and detection.  The profiling of APL externalisation and eoxPL in platelet microvesicles 
was not carried out in this thesis and will require further investigation.    
The results presented in Chapter 5 did not identify a reduction in APL externalisation in UBDs 
or alternatively an increase in their synthesis in cases of DVT with no known inherited or 
acquired thrombophilia.  These observations demonstrate that whilst thrombin generation on 
washed platelets is decreased in UBDs and increased in patients with venous thrombosis, this 
cannot be attributed to changes in externalised APL. The techniques to investigate 
phospholipids in platelets are specialised and outside the remit of a specialist haemostasis 
laboratory.  Possible screening tests include annexin V binding and prothrombin consumption 
index but these are not routine practice and disorders associated with abnormalities of these 
would therefore remain undiagnosed.  As outlined in Chapter 5, analysing samples using the 
biotin assay over a prolonged study period had experimental limitations which require further 
consideration for other studies.  One possible approach would be to extract and analyse 
samples at the same time, although dependent on the number of samples involved this may 
prove highly labour intensive.   
Although a small number of studies have reported on increased APL externalisation in 
prothrombotic conditions it is important to note that these were investigated using flow 
cytometry rather than mass spectrometry methods and were in association with other 
pathologies such as malignancy and myeloproliferative neoplasms in contrast to the 
thrombotic cohort investigated here.  It is therefore possible that other associated 
procoagulant factors such as TF and TF-bearing cells may have been influential. 
The experiments in Chapter 6 suggest eoxPL rapidly generated by activated platelets may 
contribute to the bleeding phenotype observed in UBDs.  A significant reduction in 
procoagulant 12-HETE-PC was demonstrated in the UBD cohort compared with healthy 
controls.  The trends towards lower quantities of 12-HETE-PE generated by the platelets of 
UBD patients were not as clear cut as those of 12-HETE-PC and this may be due to the small 
study population.  The finding may also implicate a defect in the synthesis or remodelling 
pathway of the different species of 12-HETE-PL.  To date, the genetic defect in UBDs is 
unknown and there may be multiple minor defects rather than a single major abnormality.  As 
discussed in Chapter 3, 19 UBD patients described in this thesis were enrolled into BRIDGE-
BPD, and only two had a causative mutation identified.  These were a variant in the gene 
encoding the actin cytoskeletal regulator  tropomyosin 4 (TPM4) of megakaryocytes and 
platelets and a variant in the MYH9 gene [228].  Another study recently reported on an 
absence of genetic pathogenic variants in 45 UBD patients who underwent investigation with 
thrombogenomics [185].  The results of BRIDGE-BPD showed that of 619 patients enrolled with 
 118 
 
UBDs, a mutation was only identified in 3.2%.  BRIDGE-BPD selected a panel of 87 coagulation 
genes and platelet genes associated with bleeding and the very low yield suggests that 
mutations in the genes tested are very unlikely to be implicated[7].  Investigating whether 
mutations in genes implicated in the synthesis and remodelling of 12-HETE-PL in this patient 
cohort would be interesting.  The observations of reduced 12-HETE-PC that were shown in this 
thesis warrant investigation in a large independent cohort of UBD patients to validate these 
findings and establish whether they are reproducible.   
Consistent with a study of thrombotic patients with antiphospholipid syndrome, increased 
quantities of 12-HETE-PE were demonstrated in the DVT cohort in this thesis as shown in the 
experiments concluding Chapter 5 [146].  Interestingly, quantities of 12-HETE-PC generated by 
activated platelets were similar with those measured in healthy controls, suggesting that 
systemic activation of the platelet did not occur at the time of the thrombotic event and that 
the increased 12-HETE-PE cannot be explained by this mechanism.  It remains unknown 
whether the increased synthesis of 12-HETE-PE was contributory to the thrombotic event or a 
resultant feature and repeat testing of these individuals outside of the acute setting would be 
required for clarification.  
Lastly the effect of DDAVP, the haemostatic agent used empirically in UBDs was investigated in 
Chapter 7.  Interestingly, trends towards higher peak thrombin generation and velocity index 
were observed following DDAVP administration in 3 patients with UBD undergoing a 
haemostatic challenge.  Furthermore, this was associated with an increase in externalisation of 
all species of PS (P<0.05).  This is consistent with the work of Colucci et al, who proposed a 
novel mechanism of action of DDAVP in selectively enhancing the role of procoagulant 
platelets [51].  Whilst this was demonstrated in patients with platelet function defects using 
annexin V binding, the experiments in this chapter confirmed these finding in UBD patients 
using LC/MS/MS to profile the APL species.  This provides interesting insights into the 
underlying mechanisms of DDAVP in platelet disorders and UBDs.  Increases in 12-HETE-PL in 
contrast were not uniform or significant, however experiments were limited by the small 
number of UBD patients undergoing a haemostatic challenge at the time of recruitment.  
Further studies are required in a larger independent cohort of UBD patients to confirm and 
expand these findings. 
This thesis has raised some areas requiring further work.  Firstly, a larger study confirming the 
findings of eoxPL is required in an independent cohort of UBD patients.  If validated, this needs 
to be combined with genomic studies looking for potential variants in genes coding for 
enzymes involved in the phospholipid remodelling pathway.  The question also arises whether 
an increase in procoagulant eoxPL occurs in other thrombotic disorders for example in arterial 
disorders such as acute coronary syndrome and whether their increased generation is an 
independent risk factor for a thrombotic event or is associated with a recurrent episode.  The 
elevation of eoxPL in venous thrombotic disease requires investigation following the acute 
thrombotic event to fully elucidate their contribution in enhancing thrombin generation.  In 
addition, the role of APL in other thrombotic disorders requires clarification.  For example, 
does an increased externalisation of APL occur in atherosclerosis or other acquired thrombotic 
disorders such as cancer-associated venous thrombosis.  The role of DDAVP in increasing APL 
externalisation in UBD and other platelet disorders needs validating in a large study, using 
specialised LC/MS/MS techniques for in-depth analysis.  Furthermore, the role of other lipids in 
the platelet membrane, specifically sphingolipids and cholesterol require future research in 
disorders of haemostasis and thrombosis.   
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Finally, whilst the thrombin generation assay was able to demonstrate global changes in the 
phospholipid platelet membrane for example in each of the disease cohorts versus healthy 
controls and following the administration of DDAVP, it could not be used for diagnostic 
purposes.  Whilst high donor intra-variation is inevitable despite the standardisation of plasma 
and liposome composition, this assay requires further refinement to further assess the ability 
of the thrombin generation assay in differentiating patients with UBD in order to increase its 
clinical utility.  In attempting to mirror the coagulation reactions at the level of the platelet 
phospholipid surface, it is evident that multiple variables were introduced which compromised 
the precision of the assay.      
In summary, the results of the experiments conducted in this thesis support the original 
hypothesis that the platelet phospholipid membrane may be implicated in patients with UBD 
and potentially in venous thrombosis of unknown aetiology.  Whilst externalisation of PE and 
PS was not altered in either disease state, a reduction in the procoagulant 12-HETE-PC was 
observed in UBD patients suggesting that there may be a defect in the pathway of how these 
phospholipids are synthesised and remodelled.  Increased generation of 12-HETE-PE was 
observed in the thrombotic cohort supporting evidence of their role in promoting thrombin 
generation in human disease.  In patients with UBD, a reduced ability of platelets and 
microvesicles to support thrombin generation was observed, however the thrombin 
generation assay as currently configured could not be used for diagnostic purposes.  The 
increased ability of platelets to support thrombin generation in the thrombotic cohort may 
represent procoagulant factors other than the PL membrane composition not specifically 
tested here.  For the management of bleeding in UBD patients, DDAVP is effective and may 
exert its procoagulant action by increasing PS externalisation in platelet disorders and bleeding 
disorders of undetermined aetiology.  Finally, this thesis initiates investigation of procoagulant 
phospholipids in disorders of haemostasis and raises further areas for future research.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
 
References 
 
1. Hoffbrand A.V., C.D., Tuddenham E.G.D and Green A.R., Postgraduate Haematology. 
Sixth Edition ed. 2011, Chichester, West Sussez: Wiley Blackwell. 
2. Cattaneo, M. and C. Gachet, ADP receptors and clinical bleeding disorders. 
Arteriosclerosis, thrombosis, and vascular biology, 1999. 19(10): p. 2281-2285. 
3. Corkrey, H.A., et al., Thrombosis and platelets: an update. European Heart Journal, 
2016. 38(11): p. 785-791. 
4. Ni, H. and J. Freedman, Platelets in hemostasis and thrombosis: role of integrins and 
their ligands. Transfusion and Apheresis Science, 2003. 28(3): p. 257-264. 
5. Harrington, W.J., et al., Demonstration of a thrombocytopenic factor in the blood of 
patients with thrombocytopenic purpura. The Journal of laboratory and clinical 
medicine, 1951. 38(1): p. 1-10. 
6. Ruggeri, Z.M., Mechanisms initiating platelet thrombus formation. Thrombosis and 
haemostasis, 1997. 78(01): p. 611-616. 
7. Downes, K., et al., Diagnostic high-throughput sequencing of 2,396 patients with 
bleeding, thrombotic and platelet disorders. Blood, 2019: p. blood. 2018891192. 
8. Turro, E., et al., A dominant gain-of-function mutation in universal tyrosine kinase 
<em>SRC</em> causes thrombocytopenia, myelofibrosis, bleeding, and bone 
pathologies. Science Translational Medicine, 2016. 8(328): p. 328ra30-328ra30. 
9. Stritt, S., et al., A gain-of-function variant in DIAPH1 causes dominant 
macrothrombocytopenia and hearing loss. Blood, 2016. 127(23): p. 2903-2914. 
10. Lentaigne, C., et al., Inherited platelet disorders: toward DNA-based diagnosis. Blood, 
2016. 127(23): p. 2814-2823. 
11. Ogawa, M., Differentiation and proliferation of hematopoietic stem cells. Blood, 1993. 
81(11): p. 2844-2853. 
12. Harrison, P. and A.H. Goodall, “Message in the platelet”–more than just vestigial 
mRNA! Platelets, 2008. 19(6): p. 395-404. 
13. Patel, S.R., J.H. Hartwig, and J.E. Italiano, Jr., The biogenesis of platelets from 
megakaryocyte proplatelets. The Journal of clinical investigation, 2005. 115(12): p. 
3348-3354. 
14. Kaushansky, K., Thrombopoietin: a tool for understanding thrombopoiesis. Journal of 
Thrombosis and Haemostasis, 2003. 1(7): p. 1587-1592. 
15. Kaushansky, K., Historical review: megakaryopoiesis and thrombopoiesis. Blood, 2008. 
111(3): p. 981-986. 
16. Kaushansky, K., The molecular mechanisms that control thrombopoiesis. The Journal of 
clinical investigation, 2005. 115(12): p. 3339-3347. 
17. Thon, J.N. and J.E. Italiano, Platelets: production, morphology and ultrastructure, in 
Antiplatelet Agents. 2012, Springer. p. 3-22. 
18. Falet, H., Anatomy of the platelet cytoskeleton, in Platelets in thrombotic and non-
thrombotic disorders. 2017, Springer. p. 139-156. 
19. Italiano Jr, J. and E. Battinelli, Selective sorting of alpha‐granule proteins. Journal of 
Thrombosis and Haemostasis, 2009. 7: p. 173-176. 
20. Sharda, A. and R. Flaumenhaft, The life cycle of platelet granules. F1000Research, 
2018. 7: p. 236-236. 
21. Ruiz, F.A., et al., Human platelet dense granules contain polyphosphate and are similar 
to acidocalcisomes of bacteria and unicellular eukaryotes. Journal of Biological 
Chemistry, 2004. 279(43): p. 44250-44257. 
22. Shattil, S.J. and P.J. Newman, Integrins: dynamic scaffolds for adhesion and signaling in 
platelets. Blood, 2004. 104(6): p. 1606-1615. 
23. Bennett, J., B. Berger, and P. Billings, The structure and function of platelet integrins. 
Journal of Thrombosis and Haemostasis, 2009. 7: p. 200-205. 
 121 
 
24. Bennett, J.S., Structure and function of the platelet integrin α IIb β 3. The Journal of 
clinical investigation, 2005. 115(12): p. 3363-3369. 
25. Offermanns, S., Activation of platelet function through G protein-coupled receptors. 
Vol. 99. 2007. 1293-304. 
26. White, J. and G. Escolar, The blood platelet open canalicular system: a two-way street. 
European journal of cell biology, 1991. 56(2): p. 233-242. 
27. Ebbeling, L., et al., Rapid ultrastructural changes in the dense tubular system following 
platelet activation. Blood, 1992. 80(3): p. 718-723. 
28. White, J.G. and J.M. Gerrard, Ultrastructural features of abnormal blood platelets. A 
review. The American journal of pathology, 1976. 83(3): p. 589-632. 
29. Wang, G.R., et al., Mechanism of platelet inhibition by nitric oxide: in vivo 
phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. 
Proceedings of the National Academy of Sciences of the United States of America, 
1998. 95(9): p. 4888-4893. 
30. Varga-Szabo, D., I. Pleines, and B. Nieswandt, Cell adhesion mechanisms in platelets. 
Arteriosclerosis, thrombosis, and vascular biology, 2008. 28(3): p. 403-412. 
31. Clemetson, K.J., Platelets and primary haemostasis. Thrombosis research, 2012. 
129(3): p. 220-224. 
32. Sandoo, A., et al., The endothelium and its role in regulating vascular tone. The open 
cardiovascular medicine journal, 2010. 4: p. 302-312. 
33. Wagner, D.D., Cell biology of von Willebrand factor. Annual review of cell biology, 
1990. 6(1): p. 217-242. 
34. Johnsen, J. and J.A. López, VWF secretion: what's in a name? Blood, 2008. 112(4): p. 
926-927. 
35. Dhanesha, N., et al., Endothelial Cell–Derived von Willebrand Factor Is the Major 
Determinant That Mediates von Willebrand Factor–Dependent Acute Ischemic Stroke 
by Promoting Postischemic Thrombo-InflammationHighlights. Arteriosclerosis, 
thrombosis, and vascular biology, 2016. 36(9): p. 1829-1837. 
36. Ruggeri, Z.M. and G.L. Mendolicchio, Adhesion mechanisms in platelet function. 
Circulation research, 2007. 100(12): p. 1673-1685. 
37. Watson, S., et al., GPVI and integrin αIIbβ3 signaling in platelets. Journal of Thrombosis 
and Haemostasis, 2005. 3(8): p. 1752-1762. 
38. Blake, R.A., G.L. Schieven, and S.P. Watson, Collagen stimulates tyrosine 
phosphorylation of phospholipase C‐γ2 but not phospholipase C‐γ1 in human platelets. 
FEBS letters, 1994. 353(2): p. 212-216. 
39. Putney, J.W. and T. Tomita, Phospholipase C signaling and calcium influx. Advances in 
biological regulation, 2012. 52(1): p. 152-164. 
40. Lian, L., et al., The relative role of PLCβ and PI3Kγ in platelet activation. Blood, 2005. 
106(1): p. 110-117. 
41. Surin, W.R., M.K. Barthwal, and M. Dikshit, Platelet collagen receptors, signaling and 
antagonism: emerging approaches for the prevention of intravascular thrombosis. 
Thrombosis research, 2008. 122(6): p. 786-803. 
42. Nieswandt, B. and S.P. Watson, Platelet-collagen interaction: is GPVI the central 
receptor? Blood, 2003. 102(2): p. 449-461. 
43. Payrastre, B., et al., The integrin αIIb/β3 in human platelet signal transduction. 
Biochemical pharmacology, 2000. 60(8): p. 1069-1074. 
44. Stefanini, L. and W. Bergmeier, CalDAG-GEFI and platelet activation. Platelets, 2010. 
21(4): p. 239-243. 
45. Stefanini, L., R.C. Roden, and W. Bergmeier, CalDAG-GEFI is at the nexus of calcium-
dependent platelet activation. Blood, 2009. 114(12): p. 2506-2514. 
46. Grover, S.P., W. Bergmeier, and N. Mackman, Platelet Signaling Pathways and New 
Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018. 38(4): p. e28-e35. 
 122 
 
47. Mosawy, S., Effect of the Flavonol Quercetin on Human Platelet Function: A Review. 
Food and Public Health, 2015. 5: p. 1-9. 
48. Parise, L.V., Integrin αIIbβ3 signaling in platelet adhesion and aggregation. Current 
opinion in cell biology, 1999. 11(5): p. 597-601. 
49. Stegner, D. and B. Nieswandt, Platelet receptor signaling in thrombus formation. 
Journal of molecular medicine, 2011. 89(2): p. 109-121. 
50. Nakahata, N., Thromboxane A2: physiology/pathophysiology, cellular signal 
transduction and pharmacology. Pharmacology & therapeutics, 2008. 118(1): p. 18-35. 
51. Colucci, G., et al., The effect of desmopressin on platelet function: a selective 
enhancement of procoagulant COAT platelets in patients with primary platelet function 
defects. Blood, 2014. 123(12): p. 1905-1916. 
52. Podoplelova, N.A., et al., Coagulation factors bound to procoagulant platelets 
concentrate in cap structures to promote clotting. Blood, 2016. 128(13): p. 1745-1755. 
53. Travers, R.J., S.A. Smith, and J.H. Morrissey, Polyphosphate, platelets, and coagulation. 
International journal of laboratory hematology, 2015. 37 Suppl 1(0 1): p. 31-35. 
54. Weitz, J.I. and J.C. Fredenburgh, Platelet polyphosphate: the long and the short of it. 
Blood, 2017. 129(12): p. 1574-1575. 
55. Dahlbäck, B., Blood coagulation. The Lancet, 2000. 355(9215): p. 1627-1632. 
56. Mandal, S.K., U.R. Pendurthi, and L.V.M. Rao, Cellular localization and trafficking of 
tissue factor. Blood, 2006. 107(12): p. 4746-4753. 
57. Drake, T.A., J. Morrissey, and T. Edgington, Selective cellular expression of tissue factor 
in human tissues. Implications for disorders of hemostasis and thrombosis. The 
American journal of pathology, 1989. 134(5): p. 1087. 
58. Landers, S.C., M. Gupta, and J. Lewis, Ultrastructural localization of tissue factor on 
monocyte-derived macrophages and macrophage foam cells associated with 
atherosclerotic lesions. Virchows Archiv, 1994. 425(1): p. 49-54. 
59. Butenas, S., et al., The nature of LPS-stimulated monocyte tissue factor activity. 2008, 
Am Soc Hematology. 
60. Rao, L.V.M., H. Kothari, and U.R. Pendurthi, Tissue factor encryption and decryption: 
facts and controversies. Thrombosis research, 2012. 129 Suppl 2(Suppl 2): p. S13-S17. 
61. Morrissey, J.H., B.G. Macik, and P.F. Neuenschwander, Quantitation of activated factor 
VII levels in plasma using a tissue factor mutant selectively deficient in promoting 
factor VII activation. Blood, 1993. 81(3): p. 734-744. 
62. Butenas, S., K.G. Mann, and Butenas, Blood Coagulation. Biochemistry (Moscow), 
2002. 67(1): p. 3-12. 
63. Smith, S.A., R.J. Travers, and J.H. Morrissey, How it all starts: initiation of the clotting 
cascade. Critical reviews in biochemistry and molecular biology, 2015. 50(4): p. 326-
336. 
64. Renné, T., et al., In vivo roles of factor XII. Blood, 2012. 120(22): p. 4296-4303. 
65. Renné, T., et al., Defective thrombus formation in mice lacking coagulation factor XII. 
Journal of experimental medicine, 2005. 202(2): p. 271-281. 
66. Kleinschnitz, C., et al., Targeting coagulation factor XII provides protection from 
pathological thrombosis in cerebral ischemia without interfering with hemostasis. 
Journal of Experimental Medicine, 2006. 203(3): p. 513-518. 
67. Morrissey, J.H. and S.A. Smith, Polyphosphate as modulator of hemostasis, thrombosis, 
and inflammation. Journal of thrombosis and haemostasis : JTH, 2015. 13 Suppl 1(0 1): 
p. S92-S97. 
68. Yang, A., et al., High Molecular Weight Kininogen Binds Phosphatidylserine and 
Opsonizes Urokinase Plasminogen Activator Receptor–Mediated Efferocytosis. The 
Journal of Immunology, 2014: p. 1302590. 
69. van der Meijden, P.E., et al., Dual role of collagen in factor XII–dependent thrombus 
formation. Blood, 2009. 114(4): p. 881-890. 
 123 
 
70. Wu, Y., Contact pathway of coagulation and inflammation. Thrombosis Journal, 2015. 
13(1): p. 17. 
71. Broze, G.J., Jr. and T.J. Girard, Tissue factor pathway inhibitor: structure-function. 
Frontiers in bioscience (Landmark edition), 2012. 17: p. 262-280. 
72. Girard, T.J., et al., Protein Z, protein Z-dependent protease inhibitor (serpinA10), and 
the acute-phase response. Journal of thrombosis and haemostasis : JTH, 2013. 11(2): p. 
375-378. 
73. Cramer, T.J., J.H. Griffin, and A.J. Gale, Factor V is an anticoagulant cofactor for 
activated protein C during inactivation of factor Va. Pathophysiology of haemostasis 
and thrombosis, 2010. 37(1): p. 17-23. 
74. Shen, L. and B. Dahlbäck, Factor V and protein S as synergistic cofactors to activated 
protein C in degradation of factor VIIIa. Journal of Biological Chemistry, 1994. 269(29): 
p. 18735-18738. 
75. Roemisch, J., et al., Antithrombin: a new look at the actions of a serine protease 
inhibitor. Blood coagulation & fibrinolysis, 2002. 13(8): p. 657-670. 
76. Björk, I. and U. Lindahl, Mechanism of the anticoagulant action of heparin. Molecular 
and Cellular Biochemistry, 1982. 48(3): p. 161-182. 
77. Carrell, R.W., Reactive-Centre Variants of ClrAntitrypsin. A New Range of Anti-
inflammatory Agents. Biotechnology and Genetic Engineering Reviews, 1986. 4(1): p. 
291-310. 
78. Tollefsen, D.M., Insight into the mechanism of action of heparin cofactor II. Thrombosis 
and haemostasis, 1995. 74(05): p. 1209-1214. 
79. Schmidt, B., et al., Alpha-2-macroglobulin is an important progressive inhibitor of 
thrombin in neonatal and infant plasma. Thrombosis and haemostasis, 1989. 62(04): p. 
1074-1077. 
80. Longstaff, C. and K. Kolev, Basic mechanisms and regulation of fibrinolysis. Journal of 
Thrombosis and Haemostasis, 2015. 13: p. S98-S105. 
81. Cesarman-Maus, G. and K.A. Hajjar, Molecular mechanisms of fibrinolysis. British 
Journal of Haematology, 2005. 129(3): p. 307-321. 
82. Lorand, L., Factor XIII and the clotting of fibrinogen: from basic research to medicine. 
Journal of Thrombosis and Haemostasis, 2005. 3(7): p. 1337-1348. 
83. Bagoly, Z., et al., Factor XIII, clot structure, thrombosis. Thrombosis research, 2012. 
129(3): p. 382-387. 
84. Chapin, J.C. and K.A. Hajjar, Fibrinolysis and the control of blood coagulation. Blood 
reviews, 2015. 29(1): p. 17-24. 
85. Singer, S.J. and G.L. Nicolson, The Fluid Mosaic Model of the Structure of Cell 
Membranes. Science, 1972. 175(4023): p. 720-731. 
86. Fritsma, G.A., Platelet Structure and Function. American Society for Clinical Laboratory 
Science, 2015. 28(2): p. 125-131. 
87. Dean, J.M. and I.J. Lodhi, Structural and functional roles of ether lipids. Protein & cell, 
2018. 9(2): p. 196-206. 
88. Nagan, N. and R.A. Zoeller, Plasmalogens: biosynthesis and functions. Progress in lipid 
research, 2001. 40(3): p. 199-229. 
89. Lee, A.G., How lipids affect the activities of integral membrane proteins. Biochimica et 
Biophysica Acta (BBA)-Biomembranes, 2004. 1666(1-2): p. 62-87. 
90. Maulucci, G., et al., Fatty acid-related modulations of membrane fluidity in cells: 
detection and implications. Free radical research, 2016. 50(sup1): p. S40-S50. 
91. Hanna, V.S. and E.A.A. Hafez, Synopsis of arachidonic acid metabolism: A review. 
Journal of advanced research, 2018. 
92. Boesze-Battaglia, K. and R.J. Schimmel, Cell membrane lipid composition and 
distribution: Implications for cell function and lessons learned from photoreceptors and 
platelets. Vol. 200. 1998. 2927-36. 
 124 
 
93. Chang, C.C.Y., J. Sun, and T.-Y. Chang, Membrane-bound O-acyltransferases (MBOATs). 
Frontiers in Biology, 2011. 6(3): p. 177. 
94. Marcus, A.J., et al., Platelet phosphatides. Their fatty acid and aldehyde composition 
and activity in different clotting systems. The Journal of clinical investigation, 1962. 
41(12): p. 2198-2212. 
95. Clark, S.R., et al., Characterization of platelet aminophospholipid externalization 
reveals fatty acids as molecular determinants that regulate coagulation. Proceedings 
of the National Academy of Sciences, 2013: p. 201222419. 
96. Braverman, N.E. and A.B. Moser, Functions of plasmalogen lipids in health and disease. 
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2012. 1822(9): p. 
1442-1452. 
97. Takamura, H., et al., Ether Phospholipid Molecular Species in Human Platelets. The 
Journal of Biochemistry, 1989. 105(2): p. 168-172. 
98. Leray, C., J.-P. Cazenave, and C. Gachet, Platelet phospholipids are differentially 
protected against oxidative degradation by plasmalogens. Lipids, 2002. 37(3): p. 285-
290. 
99. ZOELLER, R.A., et al., Plasmalogens as endogenous antioxidants: somatic cell mutants 
reveal the importance of the vinyl ether. Biochemical Journal, 1999. 338(3): p. 769-776. 
100. Iuliano, L., et al., Oxygen free radicals and platelet activation. Free Radical Biology and 
Medicine, 1997. 22(6): p. 999-1006. 
101. Qiao, J., et al., Regulation of platelet activation and thrombus formation by reactive 
oxygen species. Redox biology, 2018. 14: p. 126-130. 
102. Zwaal, R.F. and A.J. Schroit, Pathophysiologic implications of membrane phospholipid 
asymmetry in blood cells. Blood, 1997. 89(4): p. 1121-1132. 
103. Daleke, D.L., Regulation of transbilayer plasma membrane phospholipid asymmetry. 
Journal of lipid research, 2003. 44(2): p. 233-242. 
104. van Helvoort, A., et al., MDR1 P-glycoprotein is a lipid translocase of broad specificity, 
while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell, 1996. 
87(3): p. 507-517. 
105. van Meer, G., et al., ABC lipid transporters: extruders, flippases, or flopless activators? 
FEBS letters, 2006. 580(4): p. 1171-1177. 
106. Falls, L.A., et al., The ω-loop region of the human prothrombin γ-carboxyglutamic acid 
domain penetrates anionic phospholipid membranes. Journal of Biological Chemistry, 
2001. 276(26): p. 23895-23902. 
107. Tavoosi, N., et al., Molecular determinants of phospholipid synergy in blood clotting. 
Journal of Biological Chemistry, 2011: p. jbc. M111. 251769. 
108. Gilbert, G.E., et al., Conservative mutations in the C2 domains of factor VIII and factor V 
alter phospholipid binding and cofactor activity. Blood, 2012. 120(9): p. 1923-1932. 
109. Wakabayashi, H., A.E. Griffiths, and P.J. Fay, Factor VIII lacking the C2 domain retains 
cofactor activity in vitro. The Journal of biological chemistry, 2010. 285(33): p. 25176-
25184. 
110. Lü, J., et al., A membrane-interactive surface on the factor VIII C1 domain cooperates 
with the C2 domain for cofactor function. Blood, 2011. 117(11): p. 3181-3189. 
111. Morrissey, J., E. Tajkhorshid, and C. Rienstra, Nanoscale studies of protein‐membrane 
interactions in blood clotting. Journal of Thrombosis and Haemostasis, 2011. 9: p. 162-
167. 
112. Wiedmer, T., et al., Role of calcium and calpain in complement-induced vesiculation of 
the platelet plasma membrane and in the exposure of the platelet factor Va receptor. 
Biochemistry, 1990. 29(3): p. 623-632. 
113. Nieuwland, R., et al., Platelet-Derived Microparticles. 2002. 403-413. 
114. Yuana, Y., A. Sturk, and R. Nieuwland, Extracellular vesicles in physiological and 
pathological conditions. Blood reviews, 2013. 27(1): p. 31-39. 
 125 
 
115. Falati, S., et al., Accumulation of tissue factor into developing thrombi in vivo is 
dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. 
Journal of Experimental Medicine, 2003. 197(11): p. 1585-1598. 
116. Henriksson, C.E., et al., Discrepancy between tissue factor activity and tissue factor 
expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. 
Thrombosis and haemostasis, 2005. 94(12): p. 1236-1244. 
117. Zillmann, A., et al., Platelet-associated tissue factor contributes to the collagen-
triggered activation of blood coagulation. Biochemical and biophysical research 
communications, 2001. 281(2): p. 603-609. 
118. Panes, O., et al., Human platelets synthesize and express functional tissue factor. 
Blood, 2007. 109(12): p. 5242-5250. 
119. Bouchard, B.A., K.G. Mann, and S. Butenas, No evidence for tissue factor on platelets. 
Blood, 2010. 116(5): p. 854-855. 
120. Bouchard, B.A., J. Krudysz-Amblo, and S. Butenas, Platelet tissue factor is not expressed 
transiently after platelet activation. Blood, 2012. 119(18): p. 4338-4339. 
121. Rauch, U., et al., Transfer of tissue factor from leukocytes to platelets is mediated by 
CD15 and tissue factor. Blood, 2000. 96(1): p. 170-175. 
122. Brambilla, M., et al., Do methodological differences account for the current controversy 
on tissue factor expression in platelets? Platelets, 2018. 29(4): p. 406-414. 
123. Evans, J.H., et al., Intracellular calcium signals regulating cytosolic phospholipase A2 
translocation to internal membranes. Journal of Biological Chemistry, 2001. 276(32): p. 
30150-30160. 
124. Dennis, E.A., et al., Phospholipase A2 enzymes: physical structure, biological function, 
disease implication, chemical inhibition, and therapeutic intervention. Chemical 
reviews, 2011. 111(10): p. 6130-6185. 
125. Morita, I., Distinct functions of COX-1 and COX-2. Prostaglandins & other lipid 
mediators, 2002. 68: p. 165-175. 
126. Huang, J.-S., et al., Cell signalling through thromboxane A2 receptors. Cellular 
signalling, 2004. 16(5): p. 521-533. 
127. Funk, C.D., Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology. Science, 
2001. 294(5548): p. 1871-1875. 
128. Vliegenthart, J. and G. Veldink, Lipoxygenases, nonheme iron-containing enzymes. 
Advances in inorganic biochemistry, 1984. 6: p. 139-161. 
129. Hammond, V.J. and V.B. O'Donnell, Esterified eicosanoids: generation, characterization 
and function. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2012. 1818(10): p. 
2403-2412. 
130. Brash, A.R., Lipoxygenases: occurrence, functions, catalysis, and acquisition of 
substrate. Journal of Biological Chemistry, 1999. 274(34): p. 23679-23682. 
131. Dobrian, A.D., et al., Functional and pathological roles of the 12-and 15-lipoxygenases. 
Progress in lipid research, 2011. 50(1): p. 115-131. 
132. Kuhn, H., M. Walther, and R.J. Kuban, Mammalian arachidonate 15-lipoxygenases: 
structure, function, and biological implications. Prostaglandins & other lipid mediators, 
2002. 68: p. 263-290. 
133. Rai, G., et al., Potent and Selective Inhibitors of Human Reticulocyte 12/15-
Lipoxygenase as Anti-Stroke Therapies. Journal of Medicinal Chemistry, 2014. 57(10): 
p. 4035-4048. 
134. Thomas, C.P., et al., Phospholipid-esterified eicosanoids are generated in agonist-
activated human platelets, and enhance tissue factor-dependent thrombin generation. 
Journal of Biological Chemistry, 2010: p. jbc. M109. 078428. 
135. Hsi, L.C., L.C. Wilson, and T.E. Eling, Opposing effects of 15-lipoxygenase-1 and-2 
metabolites on MAPK signaling in prostate: alteration in PPARγ. Journal of Biological 
Chemistry, 2002. 
 126 
 
136. Conrad, D.J., et al., Specific inflammatory cytokines regulate the expression of human 
monocyte 15-lipoxygenase. Proceedings of the National Academy of Sciences, 1992. 
89(1): p. 217-221. 
137. Bochkov, V.N., et al., Generation and biological activities of oxidized phospholipids. 
Antioxidants & redox signaling, 2010. 12(8): p. 1009-1059. 
138. Subbanagounder, G., et al., Determinants of bioactivity of oxidized phospholipids: 
specific oxidized fatty acyl groups at the sn-2 position. Arteriosclerosis, thrombosis, 
and vascular biology, 2000. 20(10): p. 2248-2254. 
139. Berliner, J.A., et al., Evidence for a role of phospholipid oxidation products in 
atherogenesis. Trends in cardiovascular medicine, 2001. 11(3-4): p. 142-147. 
140. Serbulea, V., D. DeWeese, and N. Leitinger, The effect of oxidized phospholipids on 
phenotypic polarization and function of macrophages. Free radical biology & medicine, 
2017. 111: p. 156-168. 
141. O’Donnell, V.B., et al., Enzymatically oxidized phospholipids assume center stage as 
essential regulators of innate immunity and cell death. Science Signaling, 2019. 
12(574): p. eaau2293. 
142. Maskrey, B.H., et al., Activated platelets and monocytes generate four 
hydroxyphosphatidylethanolamines via lipoxygenase. Journal of Biological Chemistry, 
2007. 282(28): p. 20151-20163. 
143. Clark, S.R., et al., Esterified eicosanoids are acutely generated by 5-lipoxygenase in 
primary human neutrophils and in human and murine infection. Blood, 2011. 117(6): p. 
2033-2043. 
144. Coffey, M.J., et al., Platelet 12-lipoxygenase activation via glycoprotein VI: involvement 
of multiple signaling pathways in agonist control of H (P) ETE synthesis. Circulation 
research, 2004. 94(12): p. 1598-1605. 
145. Porro, B., et al., Analysis, physiological and clinical significance of 12-HETE: a neglected 
platelet-derived 12-lipoxygenase product. Journal of Chromatography B, 2014. 964: p. 
26-40. 
146. Lauder, S.N., et al., Networks of enzymatically oxidized membrane lipids support 
calcium-dependent coagulation factor binding to maintain hemostasis. Sci. Signal., 
2017. 10(507): p. eaan2787. 
147. O'Donnell, V.B., R.C. Murphy, and S.P. Watson, Platelet lipidomics: modern day 
perspective on lipid discovery and characterization in platelets. Circulation research, 
2014. 114(7): p. 1185-1203. 
148. O'Donnell, V.B. and R.C. Murphy, New families of bioactive oxidized phospholipids 
generated by immune cells: identification and signaling actions. Blood, 2012. 120(10): 
p. 1985-1992. 
149. Slatter, D.A., et al., Enzymatically oxidized phospholipids restore thrombin generation 
in coagulation factor deficiencies. JCI insight, 2018. 3(6). 
150. Shi, J., et al., Lactadherin detects early phosphatidylserine exposure on immortalized 
leukemia cells undergoing programmed cell death. Cytometry Part A: The Journal of 
the International Society for Analytical Cytology, 2006. 69(12): p. 1193-1201. 
151. Hou, J., et al., Lactadherin functions as a probe for phosphatidylserine exposure and as 
an anticoagulant in the study of stored platelets. Vox sanguinis, 2011. 100(2): p. 187-
195. 
152. Tait, J.F., C. Smith, and B.L. Wood, Measurement of phosphatidylserine exposure in 
leukocytes and platelets by whole-blood flow cytometry with annexin V. Blood Cells, 
Molecules, and Diseases, 1999. 25(5): p. 271-278. 
153. Thomas, C.P., et al., Identification and quantification of aminophospholipid molecular 
species on the surface of apoptotic and activated cells. Nature protocols, 2014. 9(1): p. 
51. 
154. Suzuki, J., et al., Calcium-dependent phospholipid scrambling by TMEM16F. Nature, 
2010. 468(7325): p. 834. 
 127 
 
155. van Kruchten, R., et al., Both TMEM16F-dependent and TMEM16F-independent 
pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet 
activation. Blood, 2013. 121(10): p. 1850-1857. 
156. Vanags, D.M., S. Orrenius, and M. Aguilar‐Santelises, Alterations in Bcl‐2/Bax protein 
levels in platelets form part of an ionomycin‐induced process that resembles apoptosis. 
British journal of haematology, 1997. 99(4): p. 824-831. 
157. Shcherbina, A. and E. Remold-O’Donnell, Role of caspase in a subset of human platelet 
activation responses. Blood, 1999. 93(12): p. 4222-4231. 
158. Wolf, B.B., et al., Calpain functions in a caspase-independent manner to promote 
apoptosis-like events during platelet activation. Blood, 1999. 94(5): p. 1683-1692. 
159. Schoenwaelder, S.M., et al., Two distinct pathways regulate platelet 
phosphatidylserine exposure and procoagulant function. Blood, 2009. 114(3): p. 663-
666. 
160. Zhang, H., et al., Bcl-2 family proteins are essential for platelet survival. Cell death and 
differentiation, 2007. 14(5): p. 943. 
161. Kile, B., The role of the intrinsic apoptosis pathway in platelet life and death. Journal of 
Thrombosis and Haemostasis, 2009. 7: p. 214-217. 
162. Allen-Redpath, K., et al., Phospholipid membranes drive abdominal aortic aneurysm 
development through stimulating coagulation factor activity. Proceedings of the 
National Academy of Sciences, 2019. 116(16): p. 8038-8047. 
163. Hishikawa, D., et al., Diversity and function of membrane glycerophospholipids 
generated by the remodeling pathway in mammalian cells. Journal of lipid research, 
2014: p. jlr. R046094. 
164. Soupene, E. and F.A. Kuypers, Mammalian long-chain acyl-CoA synthetases. 
Experimental biology and medicine (Maywood, N.J.), 2008. 233(5): p. 507-521. 
165. Hermansson, M., K. Hokynar, and P. Somerharju, Mechanisms of glycerophospholipid 
homeostasis in mammalian cells. Progress in lipid research, 2011. 50(3): p. 240-257. 
166. Yamashita, A., et al., Coenzyme-A-independent transacylation system; possible 
involvement of phospholipase A2 in transacylation. Biology, 2017. 6(2): p. 23. 
167. Shindou, H., et al., Recent progress on acyl CoA: lysophospholipid acyltransferase 
research. Journal of lipid research, 2009. 50(Supplement): p. S46-S51. 
168. Shindou, H., et al., Generation of membrane diversity by lysophospholipid 
acyltransferases. The Journal of Biochemistry, 2013. 154(1): p. 21-28. 
169. Zarini, S., et al., Effect of arachidonic acid reacylation on leukotriene biosynthesis in 
human neutrophils stimulated with GM-CSF and fMLP. Journal of Biological Chemistry, 
2006. 
170. Gijón, M.A., et al., Lysophospholipid acyltransferases and arachidonate recycling in 
human neutrophils. Journal of Biological Chemistry, 2008. 
171. Boender, J., M. Kruip, and F. Leebeek, A diagnostic approach to mild bleeding 
disorders. Journal of Thrombosis and Haemostasis, 2016. 14(8): p. 1507-1516. 
172. D'Andrea, G., M. Chetta, and M. Margaglione, Inherited platelet disorders: 
thrombocytopenias and thrombocytopathies. Blood transfusion = Trasfusione del 
sangue, 2009. 7(4): p. 278-292. 
173. Balduini, C., A. Savoia, and M. Seri, Inherited thrombocytopenias frequently diagnosed 
in adults. Journal of Thrombosis and Haemostasis, 2013. 11(6): p. 1006-1019. 
174. Rao, A., Inherited defects in platelet signaling mechanisms. Journal of Thrombosis and 
Haemostasis, 2003. 1(4): p. 671-681. 
175. James, P., et al., Rare bleeding disorders–bleeding assessment tools, laboratory aspects 
and phenotype and therapy of FXI deficiency. Haemophilia, 2014. 20: p. 71-75. 
176. Ruiz-Saez, A. Occurrence of thrombosis in rare bleeding disorders. in Seminars in 
thrombosis and hemostasis. 2013. Thieme Medical Publishers. 
 128 
 
177. Faughnan, M., et al., International guidelines for the diagnosis and management of 
hereditary haemorrhagic telangiectasia. Journal of medical genetics, 2011: p. jmg. 
2009.069013. 
178. Malfait, F. and A. De Paepe, Bleeding in the heritable connective tissue disorders: 
mechanisms, diagnosis and treatment. Blood reviews, 2009. 23(5): p. 191-197. 
179. QUICK, A.J. and J.E. FAVRE-GILLY, The prothrombin consumption test: its clinical and 
theoretic implications. Blood, 1949. 4(12): p. 1281-1289. 
180. Organisation, U.K.H.C.D., UKHCDO Annual Report 2018 including bleeding disorder 
statistics for 2017/2018, U.K.H. Database, Editor. 2018, UKHCDO: Manchester, United 
Kingdom. p. 1-124. 
181. Quiroga, T., et al., High prevalence of bleeders of unknown cause among patients with 
inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 
controls. Haematologica, 2007. 92(3): p. 357-365. 
182. Quiroga, T. and D. Mezzano, Is my patient a bleeder? A diagnostic framework for mild 
bleeding disorders. ASH Education Program Book, 2012. 2012(1): p. 466-474. 
183. Mezzano, D. and T. Quiroga, Diagnostic challenges of inherited mild bleeding disorders: 
a bait for poorly explored clinical and basic research. Journal of Thrombosis and 
Haemostasis, 2018. 
184. Obaji, S., et al., Unclassified bleeding disorders: outcome of haemostatic challenges 
following tranexamic acid and/or desmopressin. Haemophilia, 2016. 22(2): p. 285-291. 
185. MacDonald, S., et al., Characterization of a large cohort of patients with unclassified 
bleeding disorder; clinical features, management of haemostatic challenges and use of 
global haemostatic assessment with proposed recommendations for diagnosis and 
treatment. International journal of laboratory hematology, 2019. 
186. Lolait, S.J., et al., Cloning and characterization of a vasopressin V2 receptor and 
possible link to nephrogenic diabetes insipidus. Nature, 1992. 357(6376): p. 336-339. 
187. Kaufmann, J. and U. Vischer, Cellular mechanisms of the hemostatic effects of 
desmopressin (DDAVP). Journal of Thrombosis and Haemostasis, 2003. 1(4): p. 682-
689. 
188. Mannucci, P.M., Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 
20 years. Blood, 1997. 90(7): p. 2515-2521. 
189. Cushman, M., Epidemiology and risk factors for venous thrombosis. Seminars in 
hematology, 2007. 44(2): p. 62-69. 
190. Raskob, G.E., et al., Thrombosis: a major contributor to global disease burden. 
Arteriosclerosis, thrombosis, and vascular biology, 2014. 34(11): p. 2363-2371. 
191. Wendelboe, A.M. and G.E. Raskob, Global burden of thrombosis: epidemiologic 
aspects. Circulation research, 2016. 118(9): p. 1340-1347. 
192. Cohen, A., et al., The number of VTE events and associated morbidity and mortality. 
Thromb Haemost, 2007. 98(4): p. 756-764. 
193. Cushman, M., et al., Deep vein thrombosis and pulmonary embolism in two cohorts: 
the longitudinal investigation of thromboembolism etiology. The American journal of 
medicine, 2004. 117(1): p. 19-25. 
194. Anderson Jr, F.A. and F.A. Spencer, Risk factors for venous thromboembolism. 
Circulation, 2003. 107(23_suppl_1): p. I-9-I-16. 
195. Montoro-García, S., et al. The role of platelets in venous thromboembolism. in 
Seminars in thrombosis and hemostasis. 2016. Thieme Medical Publishers. 
196. Kyrle, P.A. and S. Eichinger, Is Virchow's triad complete? Blood, 2009. 114(6): p. 1138-
1139. 
197. Sevitt, S., The structure and growth of valve-pocket thrombi in femoral veins. Journal of 
clinical pathology, 1974. 27(7): p. 517-528. 
198. Esmon, C.T., Basic mechanisms and pathogenesis of venous thrombosis. Blood reviews, 
2009. 23(5): p. 225-229. 
 129 
 
199. Aleman, M.M., et al., Fibrinogen and red blood cells in venous thrombosis. Thrombosis 
research, 2014. 133: p. S38-S40. 
200. Ivanov, P., et al., Impact of Thrombophilic Genetic Factors on Pulmonary Embolism: 
Early Onset and Recurrent Incidences. Lung, 2008. 186(1): p. 27-36. 
201. Antonioli, E., et al., Influence of JAK2V617F allele burden on phenotype in essential 
thrombocythemia. Haematologica, 2008. 93(1): p. 41-48. 
202. Tefferi, A. and T. Barbui, Polycythemia vera and essential thrombocythemia: 2015 
update on diagnosis, risk‐stratification and management. American Journal of 
Hematology, 2015. 90(2): p. 162-173. 
203. Arellano-Rodrigo, E., et al., Increased platelet and leukocyte activation as contributing 
mechanisms for thrombosis in essential thrombocythemia and correlation with the 
JAK2 mutational status. Haematologica, 2006. 91(2): p. 169-175. 
204. Tong, D., et al., Phosphatidylserine-exposing blood and endothelial cells contribute to 
the hypercoagulable state in essential thrombocythemia patients. Annals of 
hematology, 2018. 97(4): p. 605-616. 
205. Zwicker, J.I., et al., Tumor-derived tissue factor–bearing microparticles are associated 
with venous thromboembolic events in malignancy. Clinical Cancer Research, 2009. 
15(22): p. 6830-6840. 
206. Tripodi, A., Thrombin generation assay and its application in the clinical laboratory. 
Clinical chemistry, 2016. 62(5): p. 699-707. 
207. Baglin, T., The measurement and application of thrombin generation. British journal of 
haematology, 2005. 130(5): p. 653-661. 
208. Fischer, A., et al., Respective roles of antithrombin III and alpha 2 macroglobulin in 
thrombin inactivation. Thrombosis and haemostasis, 1981. 45(01): p. 051-054. 
209. Hemker, H., et al., The calibrated automated thrombogram (CAT): a universal routine 
test for hyper-and hypocoagulability. Pathophysiology of haemostasis and thrombosis, 
2002. 32(5-6): p. 249-253. 
210. Hemker, H.C., et al., Calibrated automated thrombin generation measurement in 
clotting plasma. Pathophysiology of haemostasis and thrombosis, 2003. 33(1): p. 4-15. 
211. Hemker, C.H., et al., The thrombogram: monitoring thrombin generation in platelet 
rich plasma. Thrombosis and haemostasis, 2000. 83(04): p. 589-591. 
212. Castoldi, E. and J. Rosing, Thrombin generation tests. Thrombosis research, 2011. 127: 
p. S21-S25. 
213. Baumgartner, C., et al., Comparison of platelet‐derived and plasma factor VIII efficacy 
using a novel native whole blood thrombin generation assay. Journal of Thrombosis 
and Haemostasis, 2015. 13(12): p. 2210-2219. 
214. Gerotziafas, G.T., et al., Towards a standardization of thrombin generation assessment: 
the influence of tissue factor, platelets and phospholipids concentration on the normal 
values of Thrombogram-Thrombinoscope assay. Thrombosis journal, 2005. 3(1): p. 16. 
215. Duarte, R.C.F., et al., Thrombin generation assays for global evaluation of the 
hemostatic system: perspectives and limitations. Revista brasileira de hematologia e 
hemoterapia, 2017. 39(3): p. 259-265. 
216. Keularts, I.M., et al., The role of factor XI in thrombin generation induced by low 
concentrations of tissue factor. Thrombosis and haemostasis, 2001. 85(06): p. 1060-
1065. 
217. Dargaud, Y., et al., Evaluation of thrombin generating capacity in plasma from patients 
with haemophilia A and B. Thrombosis and haemostasis, 2005. 93(03): p. 475-480. 
218. Lewis, S., et al., Measurement of global haemostasis in severe haemophilia A following 
factor VIII infusion. British journal of haematology, 2007. 138(6): p. 775-782. 
219. Rugeri, L., et al., Thrombin generation in patients with factor XI deficiency and clinical 
bleeding risk. Haemophilia, 2010. 16(5): p. 771-777. 
 130 
 
220. Dargaud, Y., et al., Proposal for standardized preanalytical and analytical conditions for 
measuring thrombin generation in hemophilia: communication from the SSC of the 
ISTH. Journal of thrombosis and haemostasis: JTH, 2017. 15(8): p. 1704-1707. 
221. Pike, G.N., et al., Sample conditions determine the ability of thrombin generation 
parameters to identify bleeding phenotype in FXI deficiency. Blood, 2015. 126(3): p. 
397-405. 
222. Luddington, R. and T. Baglin, Clinical measurement of thrombin generation by 
calibrated automated thrombography requires contact factor inhibition. Journal of 
Thrombosis and Haemostasis, 2004. 2(11): p. 1954-1959. 
223. Spronk, H.M., et al., Monitoring thrombin generation: is addition of corn trypsin 
inhibitor needed? Thrombosis and haemostasis, 2009. 101(06): p. 1156-1162. 
224. Mohammed, B., et al., Failure of corn trypsin inhibitor to affect the thrombin 
generation assay in plasma from severe hemophiliacs. Journal of Thrombosis and 
Haemostasis, 2014. 12(9): p. 1558-1561. 
225. Murphy, R.C., et al., Electrospray ionization and tandem mass spectrometry of 
eicosanoids. Analytical biochemistry, 2005. 346(1): p. 1-42. 
226. Fenn, J.B., et al., Electrospray ionization for mass spectrometry of large biomolecules. 
Science, 1989. 246(4926): p. 64-71. 
227. Maskrey, B.H. and V.B. O'Donnell, Analysis of eicosanoids and related lipid mediators 
using mass spectrometry. 2008, Portland Press Limited. 
228. Pleines, I., et al., Mutations in tropomyosin 4 underlie a rare form of human 
macrothrombocytopenia. The Journal of Clinical Investigation, 2017. 127(3): p. 814-
829. 
229. Castoldi, E., et al., Compound heterozygosity for 2 novel TMEM16F mutations in a 
patient with Scott syndrome. Blood, 2011. 117(16): p. 4399-4400. 
230. Lipets, E.N. and F.I. Ataullakhanov, Global assays of hemostasis in the diagnostics of 
hypercoagulation and evaluation of thrombosis risk. Thrombosis Journal, 2015. 13(1): 
p. 4. 
231. Lacroix, R., et al., Standardization of pre-analytical variables in plasma microparticle 
determination: results of the International Society on Thrombosis and Haemostasis SSC 
Collaborative workshop. Journal of Thrombosis and Haemostasis, 2013. 11(6): p. 1190-
1193. 
232. Böing, A.N., et al., Single-step isolation of extracellular vesicles by size-exclusion 
chromatography. Journal of extracellular vesicles, 2014. 3: p. 10.3402/jev.v3.23430. 
233. Kodigepalli, K.M., et al., Roles and regulation of phospholipid scramblases. FEBS letters, 
2015. 589(1): p. 3-14. 
234. Bernal-Mizrachi, L., et al., High levels of circulating endothelial microparticles in 
patients with acute coronary syndromes. American heart journal, 2003. 145(6): p. 962-
970. 
235. Chapman-Smith, A. and J.E. Cronan Jr, Molecular Biology of Biotin Attachment to 
Proteins. The Journal of Nutrition, 1999. 129(2): p. 477S-484S. 
236. Cronan, J.E., Biotination of proteins in vivo. A post-translational modification to label, 
purify, and study proteins. Journal of Biological Chemistry, 1990. 265(18): p. 10327-
10333. 
237. Zhao, L., et al., Phosphatidylserine exposing-platelets and microparticles promote 
procoagulant activity in colon cancer patients. Journal of experimental & clinical cancer 
research : CR, 2016. 35: p. 54-54. 
238. Uderhardt, S., et al., Enzymatic lipid oxidation by eosinophils propagates coagulation, 
hemostasis, and thrombotic disease. Journal of Experimental Medicine, 2017. 214(7): 
p. 2121-2138. 
239. Klatt, C., et al., Platelet-RBC interaction mediated by FasL/FasR induces procoagulant 
activity important for thrombosis. The Journal of Clinical Investigation, 2018. 128(9): p. 
3906-3925. 
 131 
 
240. Protty, M., et al., BS23 Gender and aspirin impact generation of procoagulant oxidized 
phospholipids by platelets in a healthy human cohort. Heart, 2019. 105(Suppl 6): p. 
A156-A156. 
241. O'Donnell, J.S., J.M. O'Sullivan, and R.J.S. Preston, Advances in understanding the 
molecular mechanisms that maintain normal haemostasis. British Journal of 
Haematology, 2019. 186(1): p. 24-36. 
242. Murphy, G.J., et al., Increased Mortality, Postoperative Morbidity, and Cost After Red 
Blood Cell Transfusion in Patients Having Cardiac Surgery. Circulation, 2007. 116(22): p. 
2544-2552. 
243. Bolton‐Maggs, P.H. and H. Cohen, Serious H azards of T ransfusion (SHOT) 
haemovigilance and progress is improving transfusion safety. British journal of 
haematology, 2013. 163(3): p. 303-314. 
244. Shakur, H., et al., CRASH-2 trial collaborators. Effects of tranexamic acid on death, 
vascular occlusive events, and blood transfusion in trauma patients with significant 
haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010. 
376(9734): p. 23-32. 
245. Shakur, H., et al., Effect of early tranexamic acid administration on mortality, 
hysterectomy, and other morbidities in women with post-partum haemorrhage 
(WOMAN): an international, randomised, double-blind, placebo-controlled trial. The 
Lancet, 2017. 389(10084): p. 2105-2116. 
246. Desborough, M.J.R., et al., Desmopressin for treatment of platelet dysfunction and 
reversal of antiplatelet agents: a systematic review and meta-analysis of randomized 
controlled trials. Journal of Thrombosis and Haemostasis, 2017. 15(2): p. 263-272. 
247. Apfelbaum, J., et al., Practice guidelines for perioperative blood management: an 
updated report by the American Society of Anesthesiologists Task Force on 
Perioperative Blood Management. Anesthesiology, 2015. 122(2): p. 241. 
248. Alves Martins, D., et al., Effects of dietary arachidonic acid on cortisol production and 
gene expression in stress response of Senegaleses ole (Solea senegalensis) post-larvae. 
Fish Physiology and Biochemistry, 2013. 39: p. 1223-1236. 
249. Mocking, R., et al., Fatty acid metabolism and its longitudinal relationship with the 
hypothalamic–pituitary–adrenal axis in major depression: Associations with 
prospective antidepressant response. Psychoneuroendocrinology, 2015. 59. 
250. Garay, S.M., et al., Seasonal variation in salivary cortisol but not symptoms of 
depression and trait anxiety in pregnant women undergoing an elective caesarean 
section. Psychoneuroendocrinology, 2019. 108: p. 14-19. 
251. Harper, M.T., et al., Transient Receptor Potential Channels Function as a Coincidence 
Signal Detector Mediating Phosphatidylserine Exposure. Science Signaling, 2013. 
6(281): p. ra50-ra50. 
 
 
 
 
 
 
 
 
 
 132 
 
 
 
Appendix 
Unclassified Bleeding Disorder proforma 
 
Study number: 
 
Age:                        Gender: 
 
Details of Family history:  
 
Bleeding symptom up until diagnosis ISTH BAT score 
Epistaxis Details: 
Cautery □     Packing □  
Antifibrinolytic □  
Blood Tx □    
Replacement therapy □   ……………       
Bruising Details: 
Consultation □    
Replacement therapy □   …………… 
Bleeding from minor wounds Details: 
Consultation □  
Surgical haemostasis □ 
Blood Tx □    
Replacement therapy □   ………….   
Oral cavity Details: 
Consultation □  
Surgical haemostasis □  
Blood Tx □    
Replacement therapy □   ………….. 
Gastrointestinal bleeding Details: 
Consultation □  
Surgical haemostasis □ 
Blood Tx □    
Replacement therapy □   …………. 
Haematuria Details: 
Consultation □  
Surgical haemostasis □   
Blood Tx □    
Replacement therapy □ …………..  
Tooth extraction Details: 
Resuturing or packing □ 
Surgical haemostasis □ 
Blood Tx □    
Replacement therapy □ ………….. 
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Surgery Details: 
Surgical haemostasis □ 
Blood Tx □        
Replacement therapy □ ……………  
Menorrhagia Details: 
Antifibrinolytics □ 
Hormonal therapy □ 
Iron therapy □ 
Replacement therapy □ ……………. 
Post-partum haemorrhage Details: 
Antifibrinolytics □ 
Hormonal therapy □ 
Iron therapy □ 
Replacement therapy □ ……………. 
Muscle haematoma Details: 
Surgical haemostasis □ 
Blood Tx □        
Replacement therapy □ …………… 
Other bleeding  
 Sum:-  
 
 
Details of previous haemostatic challenges: 
Number:  
Antifibrinolytic □ 
Desmopressin □ 
Platelets □ 
Fresh frozen plasma □ 
Blood transfusion □ 
Other:  
Outcome: 
 
FBC  
MCV  
Platelets  
Relevant blood film findings  
APTT/PT/fibrinogen  
VWF Ag/Ricof/CBA/FVIII  
Blood group  
Platelet aggregation  
Platelet nucleotides  
FIX (males)  
FXI  
FXIII  
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Deep vein thrombosis proforma 
Study number: 
 
Age:                     Gender:  
Height:  
Weight: 
Body mass index: 
Left calf:                Right calf:  
Presenting complaint: 
 
RISK FACTORS 
Surgery in 12/52   □ Trauma lower limb □ Medical inpatient 12/52 □ 
Malignancy □ Previous DVT/PE □ Family Hx DVT/PE □ 
Varicose veins □ Childbirth 12/52 □ Pregnant □ 
Travel > 4 hrs □ BMI > 30 □ Immobile >3/7 □ 
 Inherited thrombophilia □ Contraceptive pill/HRT □ 
 Specify………….. IVDU □ 
 
Past medical history: 
 
Alcohol:  
Smoking:  
 
Drug Dose 
  
  
  
  
 
Clinical examination findings: 
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Investigations and Results 
Hb  Na  Albumin  
Platelets  K  Alk phos  
WBC  Urea  ALT  
APTT  Creatinine  Bilirubin  
PT  eGFR  Protein  
MCV  CRP  Globulin  
Ferritin  D-dimer  Calcium  
 
 
Chest X-Ray (All patients with idiopathic DVT): 
 
Ultrasound result 
Right/Left 
Above knee (Distal):  
Peroneal vein □ 
Tibial vein □ 
Gastrocnemius □ 
Soleal □ 
 
Above knee (Proximal): 
Popliteal vein □ 
Common femoral vein □ 
Femoral vein □ 
Superficial femoral vein □ 
Ileo-femoral □ 
 
Management plan:  
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Basal concentrations of APL in UBD and DVT patients 
 
Basal APL Healthy controls 
ng/4 x 10 7 platelets 
mean values (+/- SE) 
UBD patients 
ng/4 x 10 7 platelets 
mean values (+/-SE) 
 
DOPS 0.31 (0.05) 0.18 (0.05) P=0.07 
SOPS 2.45 (0.31) 2.50 (0.26) P=0.72 
SAPS 2.01 (0.31) 2.08 (0.41) P=0.99 
SOPE 0.95 (0.17) 0.77 (0.20) P=0.39 
OpAPE 1.99 (0.33) 1.99 (0.37) P=0.98 
PpAPE 5.52 (0.68) 4.04 (0.81) P=0.20 
SpAPE 11.46 (2.76) 9.95 (2.00) P=0.76 
SAPE 7.13 (0.99) 8.84 (1.36) P=0.28 
 
Basal APL Healthy controls 
ng/4 x 10 7 platelets 
mean values (+/- SE) 
DVT patients 
ng/4 x 10 7 platelets 
mean values (+/-SE) 
 
DOPS 0.31 (0.05) 0.36 (0.04) P=0.39 
SOPS 2.45 (0.31) 2.48 (0.25) P=0.76 
SAPS 2.01 (0.31) 2.04 (0.39) P=0.89 
SOPE 0.95 (0.17) 0.60 (0.09) P=0.42 
OpAPE 1.99 (0.33) 1.67 (0.23) P=0.66 
PpAPE 5.52 (0.68) 6.30 (0.47) P=0.45 
SpAPE 11.46 (2.76) 11.23 (2.33) P=0.85 
SAPE 7.13 (0.99) 4.55 (0.57) P=0.08 
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Patient Age/gender Diagnosis Family 
history 
Bleeding score at diagnosis Details of haemostatic 
challenges after diagnosis 
Bleeding outcome 
PL009 75 F 
 
UBD No • Bleeding post dental 
extraction (3) 
• Post-surgical: (4) 
➢ Tonsillectomy 
(blood Tx) 
➢ Anterior vaginal wall 
repair 
• Bruising (1) 
BS=8 
Dental extraction (TXA)  
2 x Colonoscopy and biopsies 
(DDAVP & TXA) 
Colonic endoscopic mucosal 
resection (DDAVP & TXA) 
No bleeding 
PL010 82F 
 
 
UBD Yes • Epistaxis (3) 
• Bleeding post dental 
extraction (sutures) (3) 
• Post-surgical: 
➢ Hysterectomy (FFP 
& cryoprecipitate) 
(4) 
• PPH X 2 (FFP & 
cryoprecipitate) (3) 
• Menorrhagia (4)                                                                     
BS=17 
3 x Dental extraction (TXA)  
2 x Cataract surgery (TXA) 
No bleeding 
PL011 82 M 
 
UBD No • Bleeding from minor 
wounds (1) 
• Post-surgical: 
➢ Total knee 
replacement (blood 
Tx) (4) 
BS =5 
Orthopaedic hand surgery 
(DDAVP & TXA) 
No bleeding 
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PL012 66F 
 
UBD No  • Bleeding post dental 
extraction x 2 (sutures) (3) 
• Post-surgical: (4) 
➢ Hysterectomy 
➢ Tonsillectomy 
(blood Tx) 
• PPH X 1 (2) 
• Menorrhagia (4) 
BS=13 
4 x Orthopaedic hand 
procedures (TXA) 
Laparoscopic ventral rectopexy 
(DDAVP & TXA) 
No bleeding 
PL013 67F 
 
UBD No • Bleeding post dental 
extraction (3)  
• Menorrhagia (4) 
BS= 7 
Laparoscopic cholecystectomy 
(no cover) 
Colonoscopy & biopsies (TXA) 
Postop haematoma and 
bruising around port entry 
with no cover 
PL014 58F UBD Yes • Bleeding post dental 
extraction (2) 
• Post-surgical: (4) 
➢ Caesarean section 
(blood Tx) 
• Menorrhagia (4) 
• Easy bruising (1) 
BS=11 
Endometrial ablation and 
insertion of miraena coil 
(DDAVP & TXA) 
No bleeding 
PL015 76F 
 
UBD No • Easy bruising (2) 
• Bleeding post dental 
extraction (3) 
• Post-surgical: (2) 
➢ Lumpectomy 
➢ Haemorrhoidectomy 
• Bleeding from minor 
wounds (1) 
• Menorrhagia (2) 
3 x Dental extraction (TXA) 
Cystoscopy (TXA) 
Laparoscopic hernia repair 
(TXA) 
No bleeding 
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BS =10 
PL016 62F 
 
UBD Yes • Bleeding post dental 
extraction (3)  
• Post-surgical: 
➢ Hysterectomy 
(blood Tx) (4) 
• PPH X 1 (1) 
• Menorrhagia (4)   
BS=12                                             
No procedures   
PL019 60F 
 
UBD Yes • Bleeding post dental 
extraction (sutures) (3) 
• PPH X 1 (blood Tx) (3) 
• Easy bruising (1) 
• Menorrhagia (3) 
 BS=10 
2 x Septoplasty (DDAVP & TXA) 
  
No bleeding 
PL020 78F 
 
UBD No • Epistaxis (3) 
• Post-surgical: (4) 
➢ Tonsillectomy 
(blood Tx) 
• PPH (blood Tx) (3) 
• Menorrhagia (4)                                                               
BS=14 
Removal of a skin lesion (TXA) No bleeding 
PL021 56F 
 
 
UBD Yes •  Bleeding post dental 
extraction (3) 
• Post-surgical: (4)  
• Bladder repair (blood Tx) 
• Knee arthroscopy 
• Menorrhagia (4)  
BS=11                                                             
Endometrial ablation (DDAVP 
& TXA) 
3 x Knee arthroscopy (DDAVP 
& TXA) 
Breast biopsy (DDAVP & TXA) 
Dental extraction (DDAVP & 
TXA) 
No bleeding 
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PL022 31F 
 
UBD No • Menorrhagia (2) 
• Bleeding post dental 
extraction x 2 (3) 
• PPH X 1 (3) 
• Easy bruising (1)    
BS=9                                                               
Surgical stripping of varicose 
veins (DDAVP & TXA)  
Endometrial ablation & 
insertion of mirena coil 
(DDAVP & TXA) 
No bleeding 
PL027 47F 
 
UBD Yes • Easy bruising (2) 
• Menorrhagia (4) 
• Post-surgical:(2) 
➢ Hysterectomy         
 BS=8                     
No procedures  
PL029 66F UBD Yes • Bleeding post dental 
extraction x 2 (sutures) (3) 
• Post- surgical: (4) 
➢ Cholecystectomy 
(blood Tx) 
➢ Tonsillectomy  
• Menorrhagia (2) 
BS=9 
Sebaceous cyst x 3 (TXA) 
Dental extraction (TXA)  
 
 
No bleeding 
PL031 76F UBD Yes • Epistaxis (cautery) (3) 
• Bleeding post dental 
extraction (2) 
• Post-surgical: (4) 
➢ Hysterectomy 
(blood Tx) 
➢ Orthopaedic 
surgery 
• PPH (blood Tx) (3) 
• Menorrhagia (4)  
BS=16                                                              
Corrective foot surgery (TXA)  
Orthopaedic revision surgery 
(TXA & DDAVP)  
Laparoscopic pelvic floor repair 
(TXA & DDAVP) 
No bleeding 
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PL032 61F 
 
UBD No • Post-surgical: (2) 
➢ Tonsillectomy  
• Bleeding post dental 
extraction (2) 
• Menorrhagia (3) 
• PPH (4) 
• Easy bruising (1) 
BS=12                                                                 
5 X Dental extraction (TXA) No bleeding 
PL033 68F UBD Yes • Bleeding post dental 
extraction (sutures) (3) 
• Post-surgical: (2) 
➢ Tonsillectomy 
➢ Lumpectomy  
• Easy bruising (2) 
  BS = 7 
Parathyroidectomy (TXA and 
DDAVP) 
No bleeding 
PL034 45F UBD No • Bleeding post dental 
extraction (2) 
• Post-surgical: (4) 
➢ Caesarean section 
• Menorrhagia (2) 
• Easy bruising (2) 
BS=10 
Lumbar puncture (TXA & 
DDAVP) 
No bleeding 
PL035 56F 
 
UBD No • Bleeding post dental 
extraction (3) 
• Easy bruising (1) 
• Post-surgical: (2) 
➢ Lumpectomy 
➢ Tonsillectomy 
• Menorrhagia (4) 
BS = 10 
Discectomy (TXA & DDAVP) 
Bunion removal (TXA & 
DDAVP) 
Nissan fundoplication & 
banding of haemorrhoids (TXA 
& DDAVP) 
No bleeding 
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PL036 58M 
 
UBD No • Post-surgical: (2) 
➢ Endoscopic 
polypectomy  
• Easy bruising (3)    
BS=5                                                            
Intranasal ethmoidectomy 
(DDAVP & TXA)  
Nasal polypectomy x 3 (DDAVP 
& TXA; platelets for 3rd 
procedure) 
Platelets for 3rd procedure 
(bleeding with DDAVP & 
TXA alone) 
PL037 76F 
 
Scott 
syndrome 
Yes • Bleeding post-dental 
extraction (3) 
• PPH (3) 
• Intraocular bleed (retinal 
haemorrhage related to 
retinal vein thrombosis) (4)  
BS=10                                                       
Acute vitreal haemorrhage 
(TXA & platelets) 
Colonoscopy & biopsies x 2 
(TXA & platelets) 
 
No bleeding 
PL039 53M Abnormal PCI Yes  
•  Muscle haematoma (3)  
• Ruptured ACL – 
haemarthrosis (3)                                                                 
BS=6 
Dental extraction x 4 (TXA) 
Orthopaedic repair wrist (TXA) 
Arthroscopy (Platelets & FFP) 
Oozing following 1 dental 
extraction (4 teeth 
removed), needed sutures  
PL060 54F PFD No • Easy bruising (2) 
• Minor wounds (1)  
BS=3                                                                   
3 x Dental extraction (TXA) No bleeding 
PL061 67F UBD No • Easy bruising (2) 
• Epistaxis (3) 
BS=5 
Shoulder arthroscopy x 3 
(DDAVP & TXA) 
Bunion removal (DDAVP &TXA) 
No bleeding 
 
 F=Female; M=Male; UBD=Unclassified bleeding disorder; PCI=Prothrombin consumption index; PFD=Platelet function defect; BS=Bleeding score; 
DDAVP=Desmopressin; TXA=Tranexamic acid; Tx=Transfusion 
 
Demographics of UBD patients and details of previous haemostatic challenges 
